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The System I and System III Holocytochrome c Synthases  
in Cytochrome c Biogenesis 
by 
Brian San Francisco 
Doctor of Philosophy in Plant and Microbial Biosciences 
Washington University in St. Louis, 2013 
Professor Robert G. Kranz, Chair 
 
Cytochromes c are proteins that are involved in important redox reactions in organisms 
from every kingdom of life.  C-type cytochromes, uniquely, possess a covalently bound heme.  
Since cytochromes c are assembled at their site(s) of function (outside of the cytoplasmic 
membrane in bacteria, in the chloroplast lumen, or in the mitochrondrial intermembrane space), 
their assembly poses unique challenges to heme trafficking and post translational modification.  
Three major systems exist in nature for cytochrome c assembly, termed systems I, II, and III.  
Using recombinant Escherichia coli, aspects of systems I and III were analyzed, with an 
emphasis on the synthase protein(s) and protein complexes that carry out the covalent attachment 
of heme to apocytochrome.  Studies on system I focused on the integral membrane protein 
CcmF, the putative cytochrome c synthetase, which was shown to contain a stable and 
stoichiometric heme b.  The ligands to the b-heme were identified (TM-His1 and TM-His2), and 
the midpoint potential of the heme b was determined and found to be consistent with its 
involvement in a critical redox reaction underlying the synthetase reaction.  Additionally, a long-
 xi 
suspected interaction between CcmF and the periplasmic heme chaperone, holoCcmE, was 
characterized, with the discovery that heme from holoCcmE is coordinated by two conserved 
periplasmic histidines in CcmF (P-His1 and P-His2) that flank the conserved WWD domain.  It 
was also shown that CcmF, in complex with CcmH, is the holocytochrome c synthase for system 
I, able to synthesize cytochromes c in the absence of other Ccm components.  Studies on system 
III, the human HCCS, constituted the first purification and biochemical characterization of an 
HCCS protein.  It was discovered that HCCS purifies with a heme b and forms a stable complex 
with the human cytochrome c.  Using a combination of mutagenesis (of both the apocytochrome 
and HCCS), functional analysis, and biochemical characterization (of HCCS, alone and in 
complex with cytochrome c), these studies facilitated an elaboration of the molecular 
mechanisms for holocytochrome c formation by HCCS. 
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Chapter 1: Introduction, Significance, Summary, and Scope of Thesis  
 2 
Introduction 
Heme type and structure, and cytochrome classifications 
Cytochromes are an important class of heme proteins that facilitate electron transfer 
reactions in a wide range of biologically critical reactions.  Cytochromes are broadly classified 
according to the type of heme they possess.  Hemes (b, o, a, and c) are distinguished from one 
another by the type of covalent modification(s) to the heme.  In heme biosynthesis, reduced iron 
(Fe
2+
) is inserted into a porphyrin ring (known as protoporphyrin IX) by the ferrochelatase 
enzyme [1].  Within the heme macrocyle, each of the four pyrrole ring nitrogens supplies a 
planar ligand to the iron atom.  Extending out from the heme macrocycle are vinyl groups at the 
2- and 4-positions, and propionate groups at positions 6 and 7.  Heme, thus synthesized, is 
known as heme b (or protoheme) and is incorporated (non-covalently) into many proteins, 
including cytochromes b (hence their nomenclature) and the globins (e.g., myoglobin).  
Typically, the side chains of certain amino acids (usually histidine, methionine, cysteine, or 
tyrosine) provide the 5
th
 and 6
th
 axial (i.e., non-planar) ligands to the heme iron.  Alternatively, 
heme b may undergo subsequent covalent modification to form hemes a, o, or c (see Fig 1) 
[1,2,3].  The synthesis of heme a and heme o is carried out by single dedicated integral 
membrane proteins, respectively, and involves the addition of a 17-carbon hydroxyethylfarnesyl 
group to the heme 2-vinyl [3].  Heme a has an additional formyl group at the 8-position.  
Although both hemes a and o undergo covalent modifications to the porphyrin structure, these 
hemes are associated with their respective proteins non-covalently.  Heme c (Fig 1) is unique in 
this regard; the vinyls of heme are covalently attached (via thioether linkages) to the target 
protein (usually, at the thiols of two cysteines in a conserved Cys-Xxx-Xxx-Cys-His motif) 
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[2,4,5].  Thus, synthesis of heme c is fundamentally the same as cytochrome c assembly, with 
protein folding occurring after covalent attachment.   
 The unique covalent attachment of heme in the c-type cytochromes is thought to confer 
additional stability to the holo-protein (i.e., to prevent heme loss) [6].  This theory is consistent 
with the fact that cytochromes c function outside of the cytoplasmic membrane.  In fact, in some 
prokaryotes, cytochromes c operate at a great distance from the cytoplasmic membrane [7] (for 
example, in the reduction of insoluble metal oxides in the environment by the multiheme 
cytochromes c that comprise the Shewanella nanowire [8,9]).  There are a few examples of other 
proteins that contain covalent heme.  For example, the heme chaperone protein of system I, 
holoCcmE (discussed below), binds heme covalently through a histidine residue [10,11,12,13].  
However, since this particular protein is not a cytochrome, per se (i.e., its primary function is not 
electron transfer), synthesis of holoCcmE is not formally considered cytochrome c biogenesis.  A 
globin from cyanobacteria also has a covalent link to a histidine side chain [14,15,16].   
The various heme types discussed above can be distinguished from one another by 
spectrophotometric techniques.  Hemes, and heme proteins, exhibit three characteristic 
absorption maxima (“peaks”) in the visible range, termed the α (550-560 nm), β (520-530 nm), 
and Soret (400-430 nm) [17].  Changes in the positions of these peaks are reflective of changes 
in the heme binding environment within a protein.  A particularly sensitive method using UV-
Vis absorption spectroscopy, known as the pyridine hemochrome, can further distinguish 
between hemes with zero, one, or two covalent modifications to the vinyls [18].  In this assay, 
the heme protein is denatured by sodium hydroxide and the native axial ligands are replaced by 
pyridine.  Chemical reduction (typically, with the strong reducing agent sodium dithionite) of the 
pyridine hemochrome yields characteristic α maxima that can be used to discern the number of 
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covalent attachments to the heme vinyls: a 550 nm α absorption indicates covalent modification 
at both the 2- and 4-vinyls of heme, 553 nm is indicative of a single covalent modification, and 
556 indicates no covalent attachments.   
General requirements for formation of cytochrome c 
 Cytochromes c are assembled at their site of function.  In prokaryotes, this is outside of 
the cytoplasmic membrane (i.e., in the periplasm of gram negative bacteria, and extra-cellularly 
in the gram positives).  In eukaryotes, cytochromes c are matured in the intermembrane space of 
mitochondria or in the lumen of chloroplasts.  In all cases, the site of cytochrome c assembly is 
separated from biosynthesis of heme and translation of the apoprotein by a lipid bilayer, thus 
posing unique challenges to heme trafficking, apocytochrome secretion, and the covalent 
attachment reaction.  Cytochrome c synthesis, therefore, requires dedicated mechanisms to 
traffick heme and apocytochrome to the site of thioether formation [2,4,5].  Prokaryotic 
apocytochromes contain signal sequences that direct the unfolded polypeptide from the site of 
translation across a lipid bilayer (via the general Sec pathway) to the site of cytochrome c 
assembly [19,20].  In mitochondria, this is accomplished by components of the TOM complex 
[21].   
 Apocytochromes are defined by the conserved Cys-Xxx-Xxx-Cys-His motif.  In 
holocytochrome formation, the thiol groups of the N- and C-terminal cysteines attack the 2- and 
4- heme vinyls, respectively, to form thioether linkages, and the imidazole group of the histidine 
serves as an axial ligand to the iron of heme [22,23].  Thioether formation is a spontaneous 
(energy-independent) Markovnikov addition, where each of the reduced thiols attacks the more 
substituted α carbon of the heme vinyl, with addition of hydrogen to the less substituted β carbon 
(Fig 1).  Rare, variant cytochrome c attachment motifs (including Cys-Xxx-Xxx-Cys-Lys, Cys-
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Xxx15-Cys-His, and even Ala-Xxx-Xxx-Cys-His, with a single covalent link to heme) have been 
identified [24,25], but the requirements for cytochrome c assembly are the same.  For covalent 
attachment to occur, the heme of iron must be in the reduced (Fe
2+
) state, and the thiols of the 
cysteines must be reduced [22,26].  Unlike other cytochromes, the c-type cytochromes fold into 
their functional conformations only after covalent attachment of heme [27]; in the absence of 
heme, the unfolded polypeptide is often rapidly degraded.   
Systems for cytochrome c formation in nature 
Three major systems have evolved for cytochrome c biosynthesis, termed systems I, II 
and III (Fig 2) [2,4,5].  System III is found in the mitochondria of animals and some protozoa; 
system II is found in most gram positive bacteria, the cyanobacteria and the chloroplasts of 
plants and algae; system I is found in most gram negative bacteria, the archaea, and the 
mitochondria of plants and certain protozoa.  Although the three systems differ in terms of 
complexity, mechanism, and phylogenetic distribution, each accomplishes covalent ligation of 
heme to the apocytochrome (usually, at Cys-Xxx-Xxx-Cys-His).   
System I  
 Genetic analyses in Rhodobacter capsulatus [28,29,30,31] (and, subsequently, 
Paracoccus denitrificans [32,33,34], Bradyrhizobium japonicum [35,36], and E. coli [37]) in the 
late 1980s and early 1990s revealed a pathway for bacterial cytochrome c assembly.  Called 
system I, this pathway consists of between 8 or 9 dedicated proteins (CcmABCDEFGH, in E. 
coli), most of which are integral membrane proteins (Fig 2).  In some organisms, such as R. 
capsulatus, ccmH is split into two ORFs, encoded by ccmH and ccmI [28].  In bacteria, the ccm 
genes are usually found as an intact operon, but, sometimes, are split into several gene clusters 
[38].  In plants, some of the ccm genes are present in the mitochondrial genome and others are 
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nuclear-encoded [39,40].  The general Sec and Dsb pathways are required for apocytochrome 
secretion and (indirectly) reduction of the apocytochrome thiols, respectively [20,41].  The 
import of the nuclear-encoded apocytochrome into plant mitochondria is less well-understood.  
However, unlike apocytochrome secretion, heme translocation for cytochrome c maturation 
occurs exclusively as a function of the system I proteins [42].     
Heme trafficking in system I proceeds in two steps (Fig 2): (i) formation and release of 
the heme chaperone protein, called holo (+ heme) CcmE, (from CcmABCD) and (ii) heme 
transfer from holoCcmE to the apocytochrome (putatively, via the CcmFH complex) to yield a 
holocytochrome c.  Formation of holoCcmE occurs in the CcmCDE complex [43,44], where a 
unique covalent attachment is formed between the β carbon of the heme 2-vinyl and a conserved 
histidine residue (His130) in CcmE [10,11,12,13,45].  CcmC is a member of a heme-handling 
protein (HHP) superfamily [46] that also includes CcmF and the system II cytochrome c 
synthetase, CcsBA.  The defining feature of these proteins is the conserved WWD domain [29], a 
hydrophobic, extra-cytoplasmic feature (for interaction with heme) that is flanked by two 
conserved histidines that serve as heme axial ligands.  In the absence of CcmAB, CcmCDE form 
a stable holo (+ heme) complex, where heme, covalently attached to His130 of CcmE, is bound 
in the CcmC WWD domain with axial ligands from CcmC His60 and His184 [43].   
Expression of CcmAB leads to formation of an ABC transporter complex (CcmABCD) 
that uses ATP hydrolysis to release covalent holoCcmE [47,48,49].  These studies were initially 
carried out in R. capsulatus, where the CcmABCD complex was first identified [49].  CcmA, 
CcmB, and CcmC each have homology to individual subunits of components of ABC-transporter 
complexes, with the classic Walker domain found in CcmA [50].  Hydrolysis of ATP by 
CcmABCD leads to the release of oxidized (Fe
3+
) holoCcmE, which is proposed to chaperone its 
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heme to the site of cytochrome c formation, CcmFH, (see below) [44,51,52].  It has been 
established that formation of covalent holoCcmE occurs independent of ATP-hydrolysis (and in 
the absence of CcmAB altogether); thus, CcmABCD functions a holoCcmE release complex 
[48].     
CcmG and CcmH are thioredox-active proteins that maintain the apocytochrome thiols 
(in the Cys-Xxx-Xxx-Cys-His motif) in the reduced state [28,39,53,54].  CcmG and CcmH each 
contain a conserved pair of cysteine residues (in the classical thioredoxin Cys-Xxx-Xxx-Cys 
motif) that are involved in reduction of the disulfide bond between the two cysteines in the 
apoctychrome (at Cys-Xxx-Xxx-Cys-His). The three-dimensional structures of the soluble 
domains of both CcmG [55,56] and CcmH [57,58] have been determined.  There is significant 
evidence that CcmH interacts directly with the apocytochrome [39,57,59,60] and with CcmF 
[44,52,61,62].  CcmH is proposed to orient the thiols of the apocytochrome for thioether 
formation with the heme bound in the CcmF WWD domain.  CcmG does not associate directly 
with the CcmFH complex (see below).  Rather, the cysteines in CcmG are reduced by DsdD 
[63]; reduced CcmG, in turn, likely reduces the cysteines in CcmH, which is then thought to 
reduce the disulfide bond in the apocytochrome [54,64] (initially formed by the action of DsbA 
[65], or an environmental oxidant).   
CcmF is a 13-transmembrane domain (TMD) integral membrane protein that contains 
four conserved histidines: two in transmembrane domains (TM-His1 and TM-His2) and two in 
periplasmic loops (P-His1 and P-His2) that flank the conserved WWD domain [44].  In the 
absence of other Ccm proteins, purified CcmF contains a stoichiometric and stable non-covalent 
heme b [44,66], which we have hypothesized plays a role in reducing the incoming heme from 
holoCcmE [42,66] (see Fig 2).  Reduced heme (Fe
2+
) is required for thioether formation [22,26], 
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and reduction would also favor the release of heme from CcmE His130 [42,43,66].  CcmF forms 
an integral membrane complex with CcmH, which has been purified [44] or co-
immunoprecipitated [52,61,62].  CcmF (in complex with CcmH) is believed to be the site of 
thioether formation between the heme vinyls and the apocytochrome; thus, it has been termed the 
“cytochrome c heme lyase” or “cytochrome c synthetase” [42,67,68,69,70].   
System II 
 Genetic analyses in Chlamydomonas [71,72,73,74] and some bacterial species (including 
Bacillus [75,76,77] and Bordetella [78,79,80]) in the mid-1990s revealed the presence of a 
pathway for cytochrome c assembly distinct from system I (Fig 2).   These studies defined four 
proteins required for this pathway, termed system II: CcsA, CcsB, DsbD (or a related protein, 
CcdA, in some species), and CcsX (a thioredoxin involved in reduction of the apocytochrome 
Cys-Xxx-Xxx-Cys-His motif).  The activities of DsbD and CcsX can be complemented by 
addition of thiol-reducing agents (e.g., dithiothreitol); therefore, DsbD and CcsX are thiol-
reducing components of the system II pathway.   
 CcsA and CcsB consist of six and four TMDs, respectively.  CcsA, a member of the 
heme handling protein (HHP) family, contains the conserved WWD domain flanked by two 
conserved histidines, and an additional conserved histidine in a transmembrane domain [50,81].  
CcsB also contains a conserved transmembrane histidine and a large (up to 500 residues) poorly-
conserved extra-cytoplasmic domain that is thought to be involved in apocytochrome handling 
[78].  Studies in Bordetella [79], and subsequent studies in heterologous E. coli [82], showed that 
CcsA and CcsB form a complex for cytochrome c assembly.  The CcsBA protein complex, 
together, thus contains four conserved histidines (TM-His1 and 2, and P-His1 and 2) and the 
WWD domain, in a remarkably similar orientation to that of CcmF.  In some species (such as 
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Helicobacter and Wolinella) system II is encoded as a single fused ORF, called ccsBA.  
Expression of CcsBA (from Wolinella [83] or Helicobacter [51]) heterologously in E. coli is 
sufficient to facilitate robust cytochrome c assembly; thus, CcsBA is the system II cytochrome c 
synthetase.  The CcsBA complex is proposed to carry out the processes of heme translocation, 
apocytochrome binding, and thioether formation [42,82,84].   
The CcsBA complex from Helicobacter hepaticus (expressed in E. coli as an N-terminal 
fusion to glutathione S-transferase) has been purified and characterized.  Similar to CcmF, 
CcsBA purifies with a bound heme b.  Mutation of either TM-His1 or TM-His2 abolishes or 
significantly impairs heme binding, while mutation of either P-His1 or P-His2 does not affect 
levels of the bound heme b.  Each of the four histidines is required for cytochrome c assembly: 
substitution with alanine or glycine abolishes holocytochrome formation.  Substitutions can be 
complemented chemically by adding imidazole directly to culture, thus confirming a heme 
ligand-type function for each His residue.  Interestingly, imidazole complements only weakly 
under aerobic conditions, while anaerobically, imidazole restores function to near-WT levels.  
This suggests that the His residues in CcsBA may function to protect heme from oxidation as it 
is being channeled from its transmembrane binding site to the external WWD.   
System III 
 The gene product responsible for cytochrome c formation in Saccharomyces cerevisiae 
was identified in 1987 by Dumont and colleagues [85].  Termed the holocytochrome c synthase 
(HCCS) or cytochrome c heme lyase (CCHL), this enzyme, when expressed in the E. coli 
cytoplasm (along with its cognate apocytochrome), is sufficient for holoctyochrome c formation 
(Fig 2) [86].  HCCS, which comprises system III, functions in the intermembrane space of the 
mitochondria of most eukaryotes (including humans).  In some species, there is a dedicated heme 
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lyase (CC1HL) for covalent heme attachment to cytochrome c1 [85,87], while in others a single 
HCCS is active towards both cytochrome c and cytochrome c1 [67,88].  CC1HL is highly related 
to CCHL.   
HCCS is required for the import of the nuclear-encoded apocytochrome into 
mitochondria [89,90].  Mitochondrial import of the unfolded apocytochrome is initially mediated 
by components of the TOM complex [21], and, subsequently, depends on recognition of the 
incoming N-terminus of the apocytochrome by HCCS.  Covalent heme attachment by HCCS 
(and subsequent folding of the holocytochrome c) prevents the holocytochrome from re-exiting 
the intermembrane space [89,90,91,92].  Import of the membrane-bound cytochrome c1 occurs 
via a separate mechanism [93] that does not involve a cytochrome c heme lyase.  A number of 
studies (all using the HCCS from S. cerevisiae) in yeast and E. coli have identified residues in 
the apocytochrome N-terminus (including the Cys-Xxx-Xxx-Cys-His motif) that are required for 
mitochondrial import and/or covalent heme attachment [86,94,95,96,97,98].  Cyc2p, a FAD-
binding protein, is an accessory protein that is important, but not required, for maturation 
[99,100,101].  This protein is present only in S. cerevisiae and may play a role in reducing heme, 
but more work is needed to determine its precise function.  An earlier report suggested that Cys-
Pro-Xxx motifs in HCCS might be heme-binding sites [102] (Fig 2), but since these motifs are 
absent in some HCCSs [67], this is unlikely.   
Other systems for cytochrome c assembly 
 Greater than 99 % of organisms rely on systems I, II, or III for cytochrome c biogenesis.  
However, some rare, alternative pathways exist for holocytochrome c formation.  System IV, 
also called the ccb pathway, is a dedicated pathway for covalent heme attachment to a single 
cysteine in cytochrome b6 of the cytochrome b6f complex [103,104], present in the chloroplasts 
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of the oxygenic phototrophs [105].  Some archaea and a very few bacteria contain an abbreviated 
ccm pathway (which some have termed system I’) that lacks a clear homolog of CcmH, and in 
which the covalent heme-binding histidine of CcmE has been replaced with a cysteine [106].  
Finally, certain protozoa, which produce a unique cytochrome c with covalent attachment to a 
single Cys (i.e., Ala-Xxx-Xxx-Cys-His), do not appear to encode the genes for system I, II, or III 
[107,108,109].  The cytochrome c assembly pathway present in these organisms has been 
designated System V, although this nomenclature may be premature since the genes that 
comprise this apparent system have yet to be identified.   
Evolutionary history of the three systems 
 Why are there three separate systems for cytochrome c assembly, and what, if any, are 
the advantages conferred?  All mitochondria contain either system I or system III.  Since the 
ancestor of the modern mitochondrion (an alpha-proteobacterium) contains system I, it is clear 
that system III evolved in mitochondria after the mitochondrial endosymbiosis [110,111,112].  
We hypothesize that at some point after endosymbiosis, the complicated, ATP-dependent system 
I may have become “obsolete” and was replaced by the simpler system III.  The protozoa are 
especially useful to consider in this regard, since some protozoal mitochondria contain system I 
and some contain system III.  The protozoa that contain system I may be evolutionary 
“holdovers” stuck in the transition from system I to system III, and future studies may reveal 
some species that contain both systems.  We speculate that the mitochondria of plants (all of 
which contain system I) and those protozoa that contain system I, may face more challenging 
environments for cytochrome c synthesis (possibly iron- or heme-poor, and certainly highly 
oxidizing) such that the advantages of the system I pathway are required (see below).  Note that 
system I, as well as system II, has evolved to maintain heme in (or reduce heme to) the Fe
2+
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state; thus, plants may have retained system I (in mitochondria) and system II (in chloroplasts) to 
protect heme from oxidation.   
 Dissecting the evolutionary history of systems I and II is complicated by the significant 
lateral gene transfer that has occurred with these two systems [38].  One would expect that 
system II (with its lower energetic requirement) should predominate unless system I confers 
some selection advantage.  We showed previously that system I can synthesize cytochromes at 5-
fold lower heme levels than can system II [113], and that holoCcmE of system I can function as 
a heme reservoir [51].  Thus, we speculate that the holoCcmE heme reservoir and high heme 
affinity of system I may have evolved (and was retained) to meet the challenges of synthesizing 
cytochromes in iron- or heme-poor environments.  Attempts to correlate the occurrence of a 
given system (I or II) with a specific bacterial microhabitat (e.g., iron-poor or iron-rich) have 
been difficult, owing primarily to the lack of information about the microhabitats of 
microorganisms.  Interestingly, some species (e.g., Bordetella parapertussis) encode the genes 
for both systems I and II.  Whether both systems are actively expressed, or expressed 
differentially as a function of environmental conditions, has not been examined, but organisms 
such as these may offer clues as to the evolutionary advantages of a system I versus a system II 
cytochrome c assembly pathway.   
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Significance, Summary, and Scope of the Thesis 
Early studies in the field of cytochrome c assembly were directed at identifying the gene 
products required for assembly.  Reconstitution of each of the three major pathways 
heterologously in E. coli (∆ccm, deleted for the endogeneous cytochrome c maturation genes) 
was a major advance in this regard.  More recent approaches have been designed to elucidate the 
molecular mechanisms underlying cytochrome c assembly, including heme trafficking, control of 
redox state, and protein-protein interactions.  Of particular interest to this thesis are the structural 
and mechanistic aspects of the synthase proteins and protein complexes of systems I (CcmFH) 
and III (HCCS), and the molecular details of their function (Fig 2).   
At the beginning of this research, some limited biochemical progress had been made with 
several system I proteins: high-resolution three-dimensional structures had become available for 
the soluble domains of apoCcmE [114], CcmG [56] and CcmH [57].  Excitingly, the first 
biochemical and spectroscopic characterization of the putative system I synthetase, CcmF (from 
E. coli), had just been reported from the Kranz lab, with the discovery that CcmF (purified in the 
absence of other Ccm proteins) contained a stable and stoichiometric heme b [44].  A possible 
heme ligand (TM-His1) to the heme b had been identified, and, crucially, a revised topology for 
CcmF had been reported.  The updated topology revealed that CcmF contained two additional 
TMDs, which repositioned the WWD domain adjacent to the outer leaflet of the cytoplasmic 
membrane, where it is flanked by two conserved His residues (P-His1 and P-His2).  Importantly, 
the new topology illustrated the marked structural similarities between CcmF and the other 
WWD-domain containing proteins, CcsBA (the cytochrome c synthetase of system II) and 
CcmC.   
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Building off of these findings, the first aim of this research was to define and 
spectroscopically characterize the b-heme binding site within CcmF, with the ultimate goal of 
understanding the role of this heme in cytochrome c biogenesis.  This research, discussed in 
chapter 2, identified the second axial ligand to the b-heme (TM-His2), and piloted the used of 
exogeneous imidazole to chemically complement the cytochrome c assembly defects of 
substitutions at either TM-His1 or TM-His2 in CcmF, thus solidifying the heme-binding function 
of these residues.  The role of these histidines as axial ligands to the heme b was confirmed by 
resonance Raman spectroscopy, in collaboration with Dr. Kenton Rodgers (NDSU).  A reliable 
and tractable assay for the determination of redox potentials was adapted (from the laboratory of 
Dr. Emma Raven, Leicester University) for use with membrane proteins, and was employed to 
determine the midpoint potential of the heme b in CcmF.  This constituted the first functionally-
relevant data pertaining to the heme b: since the midpoint potential was below (more negative 
than) that of the heme in holoCcmE, our hypothesis that the heme b may be involved in 
reduction of the incoming heme from holoCcmE (thus preparing it for attachment to the 
apocytochrome) is indeed feasible.   
Another significant thrust of this research was devoted to understanding interactions 
between CcmF and other Ccm proteins.  Formation of a complex between CcmF and CcmH had 
been well-documented [44,52,61,62], although the specific sites of interaction in each protein 
were (and are) still unknown.  Less-well understood, however, was the interaction of CcmF with 
the periplasmic heme chaperone protein, holoCcmE.  Although nearly every review on 
cytochrome c biosynthesis in the last decade had proposed formation of a holoCcmE-CcmF 
complex as an intermediate required for holocytochrome formation [42,67,68,69,70], data 
directly demonstrating this interaction had not been reported.  Another similarly conspicuous gap 
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in our understanding of system I was the absence of direct experimental evidence that CcmF (in 
complex with CcmH) is the synthetase for system I.  Unlike systems II and system III (which are 
single proteins or protein complexes whose expression in E. coli ∆ccm is sufficient for robust 
holocytochrome c formation), CcmF had never been shown to be capable of synthesizing 
cytochrome c in the absence of other Ccm proteins.  The assignment of the synthetase activity 
was largely circumstantial in that it was based primarily on interactions with other Ccm proteins, 
some of which were experimentally-supported (e.g., with CcmH, which has a demonstrated 
apocytochrome binding function) and others that were more hypothetical (i.e., with holoCcmE).   
Research in this thesis showed, directly, that CcmFH (along with CcmG) is the 
cytochrome c synthetase of system I: expression of CcmFGH (in the absence of other Ccm 
components) in E. coli ∆ccm is sufficient for robust covalent heme attachment to bacterial 
cytochromes c2 and c4.  The synthetase activity required three conserved histidines in CcmF 
(TM-His1 and 2, and P-His1) as well as the conserved cysteine pairs in the thioredoxins CcmG 
and CcmH, and led to production of holocytochrome c with biochemical and spectroscopic 
properties indistinguishable from that produced by the full system I.  These studies are discussed 
in chapter 4.  Chapter 3 of this thesis discusses characterization of the CcmF-holoCcmE 
complex, trapped only in the absence of CcmH, with the discovery that complex formation 
depends on all four conserved His residues in CcmF.  HoloCcmE must be released from complex 
with CcmABCD in order to interact with CcmF, and heme in holoCcmE was required for 
complex formation with CcmF: apoCcmE interacted at 20-fold lower levels than holoCcmE.  
Together, these results address two important remaining questions in cytochrome c biogenesis, 
and fill some of the larger gaps in the field.    
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For system III, progress in understanding the mechanisms underlying HCCS function had 
been severely impeded by difficulties in expression and purification [24].  In fact, despite the 
identification of HCCS as the gene product responsible for heme attachment to cytochrome c in 
Saccharomyces cerevisiae over twenty-five years ago [85], the enzyme had never been purified 
or characterized, and the mechanism by which HCCS mediates covalent heme attachment to the 
apocytochrome was poorly understood.  Every review on mitochondrial cytochrome c assembly 
states this deficiency (e.g., [24,42,67,68]).  Chapter 5 of this work discusses successful 
purification and characterization of the human HCCS from recombinant E. coli.  The human 
HCCS was found to be membrane-associated (despite the absence of predicted TMDs) and was 
purified with endogenous heme coordinated by a conserved histidine (His154).  The amino acids 
in the human apocytochrome required for covalent attachment were identified, and the non-
substrate cytochrome c2 from the alpha-proteobacterium Rhodobacter capsulatus was converted 
into a robust substrate for the human HCCS by engineering three sequence alterations.  Trapped, 
intermediate complexes between HCCS, heme, and cytochrome c, with a conserved histidine in 
each protein serving as a heme axial ligand, were purified and characterized.  These findings 
suggest mechanisms for heme binding, interaction with apocytochrome c, thioether formation, 
and release of mature holocytochrome c from HCCS.   
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Figures 
Figure 1. Structure of heme c and genes required for heme c formation.   
Porphyrin ring carbon atoms are numbered according to the Fischer system.  Diagram is 
modified from [42].   
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Figure 2. Systems I, II, and III for cytochrome c biogenesis.   
Models depict subpathways for trafficking of heme and apocytochrome during holocytochrome c 
formation.  Representative organisms possessing each system are listed.  Diagram is modified 
from [42].   
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Abstract 
Cytochrome c maturation in many bacteria, archaea, and plant mitochondria involves the 
integral membrane protein CcmF, which is thought to function as a cytochrome c synthetase by 
facilitating the final covalent attachment of heme to the apocytochrome c.  We previously 
reported that the E. coli CcmF protein contains a b-type heme that is stably and 
stoichiometrically associated with the protein and is not the heme attached to apocytochrome c.  
Here, we show that mutation of either of two conserved transmembrane histidines (His261 or 
His491) impairs stoichiometric b-heme binding in CcmF and results in spectral perturbations in 
the remaining heme.  Exogeneous imidazole is able to correct cytochrome c maturation for 
His261 and His491 substitutions with small side chains (Ala or Gly), suggesting that a “cavity” 
is formed in these CcmF mutants in which imidazole binds and acts as a functional ligand to the 
b-heme.  The results of resonance Raman spectroscopy on wild-type CcmF are consistent with a 
hexacoordinate low spin b-heme with at least one endogeneous axial His ligand.  Analysis of 
purified recombinant CcmF proteins from diverse prokaryotes reveals that the b-heme in CcmF 
is widely conserved.  We have also determined the reduction potential of the CcmF b-heme (Em,7 
= -147 mV).  We discuss these results in the context of CcmF structure and functions as a heme 
reductase and cytochrome c synthetase.      
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Introduction 
The c-type cytochromes are heme proteins present in nearly all organisms that participate 
in electron transfer, typically for the generation of an electrochemical proton gradient.  C-type 
cytochromes function outside of the cytoplasmic membrane in prokaryotes, in the intermembrane 
space of the mitochondrion, and in the lumen of the chloroplast.  Cytochromes c are commonly 
distinguished by covalent attachment of the two vinyl groups (α-carbons) of heme to the thiols of 
a conserved Cys-Xxx-Xxx-Cys-His motif in the apocytochrome.  For thioether formation 
between heme and apocytochrome, the heme iron and the cysteine thiols must be in the reduced 
state (1, 2).  In many prokaryotes, nearly all plant mitochondria and some protozoan 
mitochondria, cytochromes c are assembled by the cytochrome c maturation (ccm) pathway 
called system I (Figure 1A), which typically comprises eight or nine integral membrane proteins 
(In E. coli, CcmABCDEFGH) (3-6).   
In system I, heme is initially bound at a site in CcmC (Figure 1A) (7-9).  Here, a unique 
covalent attachment is formed between His130 of CcmE and the β-carbon of the 2-vinyl of heme 
(10-12).  CcmE with covalent heme is released from CcmC by the action of CcmAB (an ABC 
transporter) (13-15).  CcmE is believed to traffic heme to the site of cytochrome c assembly, 
putatively the CcmF/H synthetase complex, where the heme from holoCcmE is attached to 
apocytochrome c (8, 16, 17).  Although studies have shown that CcmF and CcmH form an 
integral membrane complex (8, 16, 18), the function of this complex, including its role as a 
synthetase, is poorly understood.   
We have proposed that formation of the covalent bond between CcmE and heme (within 
the holoCcmCDE complex) is favored by heme oxidation (to Fe
3+
) (5, 7, 8).  Consistent with 
this, the purified holoCcmCDE complex (7, 8) and purified holoCcmE (8, 11, 12) contain 
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covalent heme in the oxidized (Fe
3+
) state.  However, heme attachment to the apocytochrome 
requires that the heme from holoCcmE is reduced (Fe
2+
) prior to ligation (1, 2, 5).  A possible 
mechanism for reducing heme in holoCcmE before heme attachment to apocytochrome c has 
recently emerged: we discovered that CcmF contains a b-type heme, independent of all other 
Ccm proteins, that exists in 1:1 stoichiometry with the protein (8).  We proposed that reduction 
of the heme in holoCcmE by the CcmF b-heme would facilitate release of the CcmE His130 
covalent bond and prepare the heme for attachment to the apocytochrome (5, 7).   
It is important to establish the spectral and redox properties of the b-heme in CcmF to 
understand the function(s) of CcmF in the maturation of cytochromes c.  Topological studies 
have revealed that CcmF contains 13 transmembrane domains (TMDs; Figure 1B) (8, 19).  There 
are four completely conserved histidines that might serve as axial ligands to the b-heme: two are 
predicted to be in periplasmic loops (His173 and His303 in CcmF from E. coli) and two are 
predicted to reside in TMDs (His261 and His491) (see stars in Figure 1B).  Alanine substitutions 
at each of these histidines show severe defects in cytochrome c assembly (16).  To identify the 
axial ligands to the b-heme in CcmF, we use spectroscopic and site-directed mutagenesis 
approaches as well as chemical complementation with exogeneous imidazole.  We show that the 
b-heme is present in recombinant CcmF proteins from diverse organisms and determine the 
reduction potential of the CcmF b-heme.  Our findings address the location of the b-heme in 
CcmF and allow us to propose redox control mechanisms in the CcmF synthetase reactions.   
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Experimental Procedures 
Bacterial Growth Conditions.  Escherichia coli strains (Table S1) were grown at 37
o
C by 
shaking at 240 rpm in Luria-Bertani broth (LB; Difco) supplemented with the appropriate 
antibiotics (Sigma-Aldrich) and other media additives at the following concentrations, unless 
otherwise noted: carbenicillin, 50 µg ml
-1
; chloramphenicol, 20 µg ml
-1
; gentamicin, 10 µg ml
-1
; 
kanamycin, 100 µg ml
-1
; isopropyl-β-D-thiogalactopyranoside (IPTG, Gold Biotechnology), 1 
mM; arabinose (Gold Biotechnology), 0.1 % (wt/vol).   
Protein Expression and Purification.  For expression, E. coli strains RK103 (17) or 
RK113 (this work, see Table S1) were used.   Starter cultures were initiated from a single colony 
and grown overnight at 37
o
C in 10 mL of LB with the appropriate antibiotics.  1 L of LB was 
inoculated to 1 % and was grown to an OD600 of 1.8, at which point the culture was induced with 
1 mM IPTG for pGEX-based expression or 0.1 % arabinose (wt/vol) for pBAD-based expression 
for 14-16 hr.  Cells were harvested at 5,000 x g for 12 min and frozen at -80
o
C.  Cell pellets were 
thawed and resuspended in 10 mL/gram wet wt of a modified 1 x TALON (Clontech) buffer (20 
mM Tris-HCl, pH 8; 100 mM NaCl) and treated with 4-(2-aminoethyl) bezenesulfonyl fluoride 
hydrochloride (AEBSF, Gold Biotechnology; 1 mM) and egg white lysozyme (Sigma-Aldrich; 
100 µg ml
-1
) for 30 min while shaking on ice.  Cells were disrupted by repeated sonication for 30 
sec bursts on a Branson 250 sonicator (50 % duty, 60 % output) until clearing of the suspension 
was observed.  Crude sonicate was centrifuged at 24,000 x g for 12 min to remove unbroken 
cells and cell debris, and membranes were isolated by centrifugation at 100,000 x g for 45 min.  
Membrane pellets were solubilized in 1 x modified TALON buffer with 1 % (wt/vol) Anatrace 
n-Dodecyl-β-D-Maltopyranoside (DDM, Affymetrix).  Solubilized membranes (called “L” or 
load in Figures) were passed over TALON resin per the manufacturer’s recommendations and 
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bound protein was washed in 1 x modified TALON buffer with 0.1 % DDM with increasing 
concentrations of imidazole (in Figures, denoted as wash 1 “W1”, 0 mM imidazole; wash 2 
“W2”, 2 mM imidazole; or wash 3 “W3”, 5 mM imidazole).  Bound hexahistidine-tagged protein 
was eluted in 1 x modified TALON buffer containing 0.1 % DDM and 75 mM imidazole (called 
“E” or elution in Figures).  The purified protein was concentrated and subjected to buffer 
exchange in an Amicon Ultra Centrifugal Filter 30,000 MWCO (Millipore) after purification 
(called “EC” or concentrated elution in Figures) to reduce imidazole to less than 100 µM, unless 
otherwise noted.  To address the accumulation of DDM, purification of CcmF was alternately 
carried out using 0.02 % DDM instead of 0.1 %.  For these purifications, imidazole was removed 
by successive dialysis using Pierce SnakeSkin Pleated Dialysis Tubing 7,000 MWCO (Thermo 
Scientific) against 20 mM Tris, pH 8, 100 mM NaCl, 0.02 % DDM, and the protein was 
concentrated in an Amicon Ultra Centrifugal Filter 100,000 MWCO (Millipore).  Using this 
method, the concentration of DDM was maintained at 0.02 % throughout purification and 
concentration.   
Resonance Raman spectroscopy.  Resonance Raman (rR) spectra were obtained using 30 
to 40 µM CcmF protein from E. coli, purified with the endogeneous b-heme.  Sample solutions 
contained 20 mM Tris, pH 8.0, 100 mM NaCl, and dodecyl maltoside at 0.02 %, 0.48 %, or 3.2 
%.  Heme carbonyl complexes of CcmF were prepared in 5 mm NMR tubes by exhaustive 
equilibration of the CcmF solution with water-saturated N2 followed by titration of the sample 
with sodium dithionite to reduce the heme.  The inert atmosphere in the tube was then displaced 
with either natural isotopic abundance CO or 
13
CO (95 atom % 
13
C).  Raman scattering was 
excited using 413.1 nm emission from a Kr
+
 laser.  Sample tubes were spun at ~20 Hz and 
spectra were recorded at ambient temperature.  Scattered light was collected in the 135
o
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backscattering geometry, passed through a holographic notch filter to remove Rayleigh scattered 
light and depolarized.  The Raman spectrum was recorded using a 0.6 m spectrograph equipped 
with a 2400 g/mm holographic grating and a LN2 cooled CCD detector.  Spectra were calibrated 
versus toluene, DMSO d
6
, and dibromomethane.  Vibrational frequencies reported here are 
reproducible to ±1 cm
−1
. 
Heme stains and other methods.  Heme stains and immunoblots were performed as 
described in (17, 20).  Proteins were separated by 12.5 % SDS-PAGE and transferred to Hybond 
C nitrocellulose membranes (GE Healthcare).  Anti-His antibodies (Santa Cruz technologies) 
were used at a dilution of 1:5000.  Protein A peroxidase (Sigma-Aldrich) was used as the 
secondary label.  The chemiluminescent signal for heme stains and anti-His westerns was 
developed using the Pierce SuperSignal Femto kit (Thermo Scientific), and detected with an 
LAS-1000 Plus detection system (Fujifilm-GE Healthcare).  Protein concentrations were 
determined using the Pierce BCA Protein Assay Kit (Thermo Scientific) using BSA as a 
standard.  The concentration of heme in the CcmF protein preparations was determined by UV-
visible absorption spectroscopy, pyridine extraction as described in (21) or heme stain as 
described in (22).  Protein purity was assessed by Coomassie Blue staining of SDS-PAGE. 
UV/Vis absorption spectroscopy.  UV-visible absorption spectra were recorded with a 
Shimadzu UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described in 
(23).  Chemically reduced spectra were generated by addition of sodium dithionite (sodium 
hydrosulfite) to the purified sample.  Unless otherwise indicated, all spectra were recorded in 20 
mM Tris-HCl (pH 8), 100 mM NaCl, 0.1 % DDM.  To analyze the effect of imidazole on the 
electronic spectrum, small quantities of a concentrated imidazole solution (1 M, pH 7) were 
added to purified protein and spectra were recorded. 
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Cytochrome Reporter and Imidazole Complementation Assays. Cytochrome c4:His6 
production was assayed by the following methods using two different strains.  (Method 1) Strain 
RK111 (∆ccm carrying the arabinose-inducible chromosomal integrate of the cyt c4:His6 gene) 
harboring pRGK406 (pGEX ∆ccmF) and one of the following pBAD ccmF plasmids (pRGK408, 
409, 410, 411, 412, 413, 414, 415, 416, 417, or 418; see Table S1 in Supporting Information) 
was grown aerobically in 5 mLs of LB with appropriate antibiotics for 3 hr and induced for an 
additional 3 hr with 0.8 % arabinose (wt/vol).  (Method 2) Strain RK103 ((17); ∆ccm) harboring 
pRGK332 ((17); carrying the arabinose-inducible cyt c4:His6 gene) and one of the following 
pGEX system I-based plasmids (pRGK386 (17), pRGK403, pRGK404, pRGK405, or pRGK407; 
see Table S1 in Supporting Information) was grown aerobically in 5 mL LB with appropriate 
antibiotics for 3 hr and induced for an additional 3 hr with 0.2 % arabinose (wt/vol) and 1 mM 
IPTG.  For both methods, cells were harvested by centrifugation at 10,000 x g for 5 min and the 
cell pellet was resuspended in 200 µL of Bacterial Protein Extraction Reagent (BPER, Thermo 
Scientific) to lyse cells and extract protein.  Total protein concentration was determined using the 
Nanodrop 1000 spectrophotometer (Thermo Scientific) and 100 µg was analyzed by SDS-PAGE 
followed by heme stain.  Imidazole complementation assays were performed in the same way 
with 10 mM imidazole (pH 7) added to the media prior to inoculation. 
Determination of the Reduction Potential of CcmF.  The reduction potential for the b-
heme in CcmF was determined by reduction of a dye of known potential (24), using a 
modification of the Massey method (25).  The assay contained 20 mM Tris-HCl, pH 7, 100 mM 
NaCl, DDM at 0.02 % or 1.2 %, 500 µM xanthine (Sigma-Aldrich), 20 µM CcmF and one of the 
following redox dyes: nile blue chloride (Em = -116 mV) (26), resorufin (Em = -50 mV) (26), or 
safranin O (Em = -280 mV) (26).  50 to 100 nM of xanthine oxidase enzyme (Sigma-Aldrich) 
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was added to initiate the reaction.  The reaction was performed at 25
o
C in a Coy Anaerobic 
Airlock Chamber after all solutions were allowed to equilibrate with N2 overnight.  Visible 
spectra were recorded every 2 min using a Shimadzu UV-1800 spectrophotometer until reduction 
was complete (typically between 1 and 2 hrs).  The absorbance change for the b-heme peak was 
measured at 426 nm, where the change in absorbance of the dye is negligible, and the absorbance 
change for the dye was measured at 632 nm, where there is little contribution from heme 
absorbance.  The changes in absorbance were analyzed by the Nernst equation terms: [25 mV ln 
(b-hemered/b-hemeox)] for the one-electron reduction of heme and [12.5 mV ln (dyered/dyeox)] for 
the two-electron reduction of dye, where b-hemered/b-hemeox and dyered/dyeox represent ratios of 
the molar concentrations of the reduced and oxidized forms of the b-heme and the dye, 
respectively.  Values corresponding to the Nernst equation terms for the b-heme and the dye at 
each time point during the titration were plotted against each other on the x- and y-axes, 
respectively, yielding a straight line with a slope of 1.  The y-intercept of this line represents the 
difference in potential between the b-heme and the known potential of the reference dye.  Using 
this method, the reduction potential for the b-heme was calculated to within ± 2 mV based on 
four independent titrations.  To establish the accuracy of this method, two heme proteins of 
known potential (cytochrome c and myoglobin) were titrated using the above method and their 
respective reduction potentials were found to be within 2 mV of published values.  Potentials are 
given versus the standard hydrogen electrode.   
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Results 
Resonance Raman Spectroscopy   
Resonance Raman (rR) spectroscopy of heme proteins can yield considerable insight into 
structural, conformational and electronic properties of the heme cofactor.  Specifically, it is 
possible to determine coordination number, oxidation number, and spin state of the iron, as well 
as heme conformation, axial ligand identity, the nature of axial ligand bonding, and nonbonded 
interactions with the protein (27-30).   To gain some of this insight into the heme b that purifies 
with CcmF, we recorded Soret-excited rR spectra of ferric and ferrous WT CcmF.  We also 
recorded spectra of the CcmF-CO complex to further probe the heme pocket. 
Figure 2 shows the high- and low-frequency Soret excited rR spectra of ferric (top, red) 
and ferrous (bottom, violet) CcmF in 0.02 % DDM.  The bands in the high frequency regions of 
these spectra report oxidation and spin states of the heme iron as well as the coordination number 
(29, 30).  The v3 regions of the these spectra exhibit two bands (1491 and 1504 cm
-1
 for ferric 
CcmF; 1469 and 1491 cm
-1
 for ferrous CcmF) typical of pentacoordinate high-spin (5cHS) and 
hexacoordinate low-spin (6cLS) heme complexes in both oxidation states.  Thus, the heme b in 
ferric and ferrous CcmF exists as an equilibrium mixture of 5cHS and 6cLS states.  Note that for 
ferrous CcmF, the 1469 cm
−1
 v3 band corresponding to the 5cHS fraction (Figure 2, bottom) is 
considerably more intense than its 6cLS counterpart.  However, this intensity ratio does not 
reflect the relative populations of the two states of the ferrous heme because the relative rR 
scattering cross sections are not the same.  In an effort to estimate the population ratio, the UV-
visible spectrum was fit so that the Soret band intensities from the HS and LS populations could 
be compared (Figure S1).  Based on this analysis, ferrous CcmF contains approximately 20 % 
5cHS heme. 
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To assess whether the heme heterogeneity is intrinsic to CcmF or induced by solubilizing 
the protein in detergent, Soret-excited rR spectra of ferric and ferrous CcmF were recorded from 
solutions containing 0.02 % (Figure 2), 0.48 %, and 3.2 % DDM.  The high-frequency spectra of 
ferric CcmF are compared in Figure 2 (partial traces, red).  The rR spectra clearly show that 
higher DDM concentrations correspond to greater HS heme populations.  Thus, although 
heterogeneity was apparent in all of the preparations, low DDM concentrations clearly favor the 
6cLS heme population of ferric CcmF.  Two possible explanations for this detergent dependence 
are envisioned at this time.  First, the two states of the heme could be reporting conformational 
states of the protein that are accessed as part of its native function.  For example, these could be 
states whose populations are modulated by in vivo interaction with CcmH, holoCcmE, or 
apocytochrome c.  Alternatively, the population of two ferric heme states may arise from a non-
physiological CcmF conformer whose formation is induced by solubilizing the protein in DDM 
detergent.  It is important to note that the relative populations of 5cHS and 6cLS ferrous CcmF 
were only slightly sensitive to detergent concentration (data not shown).   
Raman scattering by νFe-His modes of 5cHS ferrous hemes is typically well enhanced with 
blue excitation and usually occurs within the range of 200 to 245 cm
-1
 (32).  Thus, if the axial 
ligand is an imidazole side chain of a histidine residue, we would expect to see a strong band in 
that frequency range.  The second spectrum from the bottom (blue) in the low frequency range of 
Figure 2 shows the 441.6-nm excited rR spectrum of ferrous CcmF(WT).  This spectrum exhibits 
an intense band at 210 cm
−1
, within the frequency range of Fe-His stretching modes.  Such bands 
are typical for a Fe−His unit wherein the proximal histidine ligand is the donor to a weak H-bond 
within the proximal heme pocket (28, 31, 32).  Such H-bonds can involve water in a H-bond 
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network or O atoms from backbone carbonyl groups.  Thus, in the 5cHS ferrous form, the 
proximal ligand is almost certainly the imidazole side chain of a histidine residue. 
Vibrational frequencies of the FeCO group in heme—CO complexes are useful probes of 
the distal heme pocket.  To further investigate the proximal ligand properties of CcmF with 
respect to the heme b, we recorded spectra of the CcmF—CO complex.  By virtue of the π 
backbonding that typifies FeCO moieties, there is an inverse relationship between the sensitivity 
of the Fe—C and C—O bond strengths to the bonded and nonbonded interactions of the FeCO 
unit (34-36).  This inverse relationship is clearly revealed on a heme FeCO backbonding 
correlation plot by the negative slope of the Fe—C stretching frequency versus the C—O 
stretching frequency for a large number of iron porphyrinates, including carbonyl complexes of 
heme proteins.  Because the donor strength of the proximal ligand modulates the vertical position 
of a heme carbonyl complex on the correlation plot, the nature of the proximal ligand can be 
discerned from the position of the heme carbonyl complex relative to the positions of other heme 
carbonyls with known proximal ligands.   
In order to place a particular complex on the correlation plot, the frequencies must be 
identified in the rR spectrum by isotope editing of the vibrational frequencies with 
13
CO.  By this 
method, the frequencies of modes involving distortions of the FeCO unit can be unambiguously 
identified.  Figure 3A shows the regions of the rR spectrum of the CcmF—CO (green) and 
CcmF—13CO (blue) complexes where bands arising from FeCO vibrations occur (33).  Bands 
were assigned based on their 
13
C sensitivity, which is apparent from the difference spectra shown 
in red.  The bands at 494 and 572 cm
-1
 are assigned to the vFe—C and the δFeCO modes, 
respectively.  The band at 1962 cm
-1
 was assigned to the vC—O mode.  Interestingly, the low 
frequency region of the CcmF—CO spectrum recorded in 3.2 % DDM (bottom, violet) reveals 
 39 
two Fe—C stretching bands: one at 495 cm−1 (the same Raman shift observed at low DDM 
concentrations) and the other at 525 cm
−1
.  Thus, high DDM concentrations induce formation of 
a second CcmF—CO complex. 
Figure 3B shows the FeCO backbonding correlation plot described above, with three 
inverse correlations between vFe−C and vC−O frequencies for a wide selection of heme carbonyl 
complexes.  The bottom (green) line in Figure 3B correlates Fe—C and C—O bond strengths for 
proximal ligands having anionic character, such as the strongly H-bond donating proximal 
imidazoles of the heme peroxidases and the proximal thiolates of the cytochromes P450.  The 
middle (black) line correlates the analogous bond strengths in proteins that have charge neutral 
proximal ligands that are bound to the heme iron through an N atom.  Nearly all of these 
complexes have proximal imidazole ligands from histidine residues.  The top (blue) line 
correlates heme—CO complexes that are either pentacoordinate or have proximal O-atom donor 
ligands.  The position of CcmF—CO in 0.48 % DDM is indicated by the half-filled red diamond 
in Figure 3B.  This point falls on the proximal histidine correlation line, consistent with at least 
one endogenous axial histidine ligand for the heme b of CcmF.  Note that this analysis does not 
facilitate identification of the specific coordinating histidine residue.  The heme carbonyl that 
was only observed in 3.2 % DDM falls on the top line in Figure 3B, as shown by the half-filled 
red triangle.  This position constitutes compelling evidence that the heme—CO complex in high 
DDM is either pentacoordinate or has a sixth axial ligand coordinated to iron through an oxygen 
atom.  This result shows that in high DDM solutions, the second protein-based axial ligand that 
gives rise to 6cLS heme is unavailable to the heme in a significant fraction of these ferrous 
heme—CO complexes.  This behavior is consistent with the correlation between the HS ferric 
heme population and DDM concentration illustrated in Figure 2. 
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Heme content of Ala substitutions   
To identify the ligands to b-heme iron in CcmF, we focused on the four conserved 
histidines (His173 and His303 in periplasmic loops, and His261 and His491 in TMDs).  
Previously, we showed that purified CcmF with a His173Ala substitution contained wild-type 
(WT) levels of b-heme, while CcmF with a His261Ala substitution had approximately four-fold 
less heme (8).  Here, we analyze heme levels in purified CcmF with alanine substitutions at 
His303 or His491.  Figure 4A shows that CcmF His303Ala and CcmF His491Ala were each 
purified as full-length proteins with minimal degradation.  Comparison of the Soret maxima in 
the electronic spectra indicates that CcmF His303Ala purified with heme levels similar to WT 
CcmF while CcmF His491Ala purified with less than 20 % of WT levels (note the differences in 
absorbance in Figures 4B, 4C, and 4D).  This was confirmed by semi-quantitative heme stain to 
detect the b-heme, which runs at the dye front during SDS-PAGE (Figures 4E, 4F, and 4G).  The 
purified concentrated preparations (lane 8 of Figures 4E, 4F, and 4G) show much less heme for 
CcmF His491Ala.  The same concentration of purified CcmF was analyzed for each of the 
proteins; thus, the fractional heme loading in each protein can be directly compared.  These data 
and previous findings in ref. (8), suggest that periplasmic His173 and His303 are not b-heme 
ligands, while transmembrane His261 and His491 are good candidates for ligands to the b-heme.  
In agreement with this, CcmF with glycine substitutions at His261 and His491 also contained 
approximately 20 % heme content relative to WT CcmF (data not shown).   
Spectral perturbations in His261Cys   
In making substitutions to His261 and His491, we observed that a His261Cys substitution 
in CcmF retained a high level of function relative to WT (see below) and that purified CcmF 
His261Cys (Figure 5A) contained approximately 50 % of the b-heme as WT (Figure 5B).  
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Cysteine has been shown to function as a ligand in place of the natural histidine ligand in many 
heme proteins, including myoglobin (37-39), cytochrome b5 (40), and flavocytochrome b2 (41).  
The UV/Vis absorption spectrum of CcmF His261Cys has several distinct features in comparison 
to the spectrum of WT CcmF (compare Figures 5C and 5D).  Oxidized (“as purified”) WT CcmF 
exhibits a sharp Soret maximum at 412 nm, whereas the Soret band for CcmF His261Cys is 
broad with a maximum at 406 nm.  Additionally, the α and β absorptions in the visible region are 
much less pronounced for CcmF His261Cys than for WT CcmF.  The position of the Soret at 
406 nm is indicative of high-spin heme (40), but the breadth of the Soret band and the α and β 
absorptions suggest that ferric CcmF His261Cys may also contain a population of 6cLS heme 
(42, 43).  Thus, while the UV/Vis absorption spectrum of ferric WT CcmF is dominated by 
features characteristic of 6cLS heme (40), the spectrum of ferric CcmF His261Cys is consistent 
with a mixture of 5cHS and 6cLS heme.  The dithionite-reduced spectrum for CcmF His261Cys 
shows a Soret of 423 nm and exhibits clear α and β absorptions, although the α:β peak ratio is 
different than for WT CcmF.  Based on the position of the Soret band and the clearly resolvable 
α and β maxima, ferrous CcmF His261Cys appears to contain predominantly low-spin heme 
(40).  The presence of 6cLS heme in CcmF His261Cys suggests possible coordination by His491 
and Cys261.  While low-spin hemes with cysteine ligands typically exhibit Soret bands near 450 
nm (44), Soret absorptions near 425 nm have been observed when the sulfur-iron bond is 
weakened or displaced (39, 42, 43, 45).  These spectral perturbations observed in ferric and 
ferrous CcmF His261Cys (relative to the spectrum of WT CcmF) suggest that in the WT protein, 
His261 is an axial ligand to the b-heme.     
Imidazole, the side chain of histidine, has been used as a surrogate proximal ligand to 
probe heme binding sites in proteins in vitro (e.g., 40, 42, 46).  To investigate the effect of 
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imidazole on heme in the His261Cys CcmF protein, UV/Vis spectra of purified CcmF 
His261Cys were recorded in the presence of imidazole.  At a concentration of 30 mM imidazole, 
the spectrum of the oxidized His261Cys mutant shifts to resemble that of WT CcmF (compare 
solid lines in Figures 5C and 5E).  The Soret band occurs at 414 nm (compared to 406 nm in the 
absence of imidazole) and pronounced α and β absorptions similar to WT CcmF can be 
observed.  Upon reduction with sodium dithionite, the His261Cys (+ 30 mM imidazole) exhibits 
a Soret band at 423 nm and an α to β peak ratio similar to that of reduced WT CcmF.  Addition 
of 30 mM imidazole to WT CcmF preparations did not change the UV/Vis spectrum (not 
shown).   These data suggest that in the presence of imidazole, heme in His261Cys is 
predominantly 6cLS in both the oxidized and reduced states.  The similarities in the spectra of 
CcmF His261Cys in the presence of imidazole and WT CcmF suggest that, in the WT protein, 
the b-heme may be liganded by the imidazole side chains of two His residues.   
Functional restoration of CcmF His261 and His491 mutants by imidazole 
Alanine substitutions at each of the four conserved histidine residues (His173, His261, 
His303, and His491) abolished in vivo function (cytochrome c assembly) in E. coli under aerobic 
conditions (Figure S2).  Initially, we analyzed whether these alanine substitutions could be 
corrected for in vivo function by adding imidazole to E. coli cultures (Figure S1).  In vivo 
chemical complementation by exogeneous imidazole is conceptually similar to the correction of 
heme binding by imidazole in the recombinant myoglobin His93Gly “cavity” mutant, for which 
10 mM imidazole was optimal (47).  This approach has also been used to correct the function of 
histidine mutants in the hydrogenase cytochrome b of Azotobacter vinelandii (48) and the 
CcsBA system II cytochrome c synthetases from Helicobacter hepaticus (23) and Wolinella 
succinogenes (49).  The His491Ala mutant of CcmF was corrected for cytochrome c4 assembly 
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at 10 mM imidazole (Figure S2, lane 12).  To determine if glycine substitutions in CcmF could 
be corrected for function, we replaced transmembrane His491 or His261 with glycine and 
assayed for cytochrome c4 assembly in the absence and presence of imidazole.  Substitution of 
either His261 or His491 with glycine abolished or severely impaired cytochrome c4 assembly in 
vivo (quantified in Figure 6A and 6B; representative heme stains for cytochrome c4 are in Figure 
S3).  Addition of 10 mM imidazole restored function to CcmF His261Gly and to His491Gly 
(Figure 6A and 6B).  We propose that the CcmF His261Gly and His491Ala/Gly proteins form 
“cavities” in which imidazole can bind and serve as a ligand to the b-heme in CcmF.  Based on 
these results, we predicted that amino acids with bulkier side chains (that are unable to function 
as b-heme ligands) would not accommodate imidazole binding in the “cavity”, and thus would 
not permit functional correction.  We tested this by engineering additional substitutions at 
His261 and His491.  As mentioned above, His261Cys was roughly 70 % functional relative to 
wild-type in the absence of imidazole (Figure 6A).  However, neither His261Tyr nor His261Met 
were functional above background levels, nor were these substitutions corrected substantially by 
imidazole (Figure 6A).  The same was true for Cys and Tyr substitutions at His491 (Figure 6B).  
His491Arg showed a low level of function relative to WT (approximately 18 %), but imidazole 
did not improve the function of this mutant (Figure 6B).  These results are consistent with 
His261 and His491 acting as heme ligands, such that when these His residues are substituted 
with amino acids containing small side chains (Gly or Ala), a cavity is formed in which 
imidazole can bind and serve as a surrogate heme axial ligand.  The inability of imidazole to 
correct the cytochrome c assembly defect of CcmF His261Ala could be the result of the methyl 
group of Ala occluding the “cavity” such that imidazole is unable to bind.  We have not 
investigated this further.   
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Conservation of the b-heme in CcmF 
To determine if the b-heme in CcmF is conserved, we engineered CcmF proteins from a 
phylogenetically diverse group of prokaryotes (Figure 7A; gamma proteobacteria- Escherichia 
coli and Shewanella oneidensis; delta proteobacteria-Desulfovibrio vulgaris, alpha 
proteobacteria-Roseobacter denitrificans; deinococci-Thermus thermophilus).  CcmF proteins 
from E. coli (NrfE, here called CcmF2) and Shewanella (here called CcmF3) that recognize and 
mature cytochromes c with alternate heme binding sites (Cys-Xxx-Xxx-Cys-Lys in E. coli; and, 
putatively, Cys-Xxx15-Cys-His in Shewanella) were also engineered with hexahistidine tags and 
purified (Figure S4).  Each of these CcmF homologs possesses the four conserved histidine 
residues studied above in the E. coli CcmF.  Heme analysis by UV/Vis absorption spectroscopy 
(Figure 7B) and heme stain (Figure S4) revealed that each purified CcmF protein contained b-
heme in approximately equimolar stoichiometry.   
Reduction potential of the b-heme in CcmF 
We determined the reduction potential for the CcmF b-heme using the purified CcmF 
from E. coli (Figure 8).  Using a modification of the method of Massey (with xanthine/xanthine 
oxidase to generate reductant) (25), values for the midpoint potential of the CcmF b-heme 
(Fe
3+
/Fe
2+
) were determined against nile blue chloride (Em= -116 mV) at pH 7 (26).  The spectral 
results obtained from a typical reduction run with CcmF and nile blue chloride are shown in 
Figure 8A.  The decreases in absorbance at 412 nm and 480 nm and the increase in absorbance at 
426 nm are indicative of reduction of the CcmF b-heme.  The decrease in absorbance at 632 nm 
is due to reduction of nile blue chloride.  The linear Nernst plot for reduction of the b-heme and 
nile blue chloride produced the expected slope of 1 (Figure 8B), indicating that the  reduced and 
oxidized forms of the dye and the heme were at their equilibrium concentrations at the time each 
 45 
spectrum was recorded.  This behavior ensures that there is no overpotential contribution to the 
midpoint potentials determined from these measurements.  The reduction potential of the b-heme 
in CcmF was found to be -147 ± 2 mV.  This value was confirmed using resorufin (Em = -50 
mV) (26) or safranin O (Em = -280 mV) (26) as alternate redox dyes (Figure S5).  It has been 
observed previously that the type of detergent (50, 51) and detergent concentration (50) can alter 
reduction potentials of b-type hemes in membrane proteins.  To assess the effects of DDM, we 
determined the reduction potential of the CcmF b-heme in solutions containing 0.02 % (Figure 8) 
or 1.2 % DDM.  The reduction potential in 1.2 % DDM was found to be substantially more 
positive (Em = -110 ± 4 mV) than in 0.02 % DDM (Figure S6).  This is likely attributable to the 
same DDM-dependent speciation of the ferric heme-b between HS and LS states that was 
revealed by the rR spectra (vide supra).   
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Discusssion 
Here, we present several lines of evidence that TMD His261 and His491 are the ligands 
to the CcmF b-heme: (i) Gly or Ala substitutions at either His result in approximately 80 % less 
heme as compared to WT CcmF (Figure 4), (ii) substitution of His261 with Cys, a known heme 
ligand, yields a functional CcmF that shows improved heme binding relative to substitutions with 
non-ligand residues (Ala or Gly) and shows a perturbed UV/Vis spectrum (Figure 5), and (iii) 
exogeneous imidazole chemically corrects the in vivo cytochrome c synthetase function of small 
residue substitutions at CcmF His261 and His491, but not substitutions with bulkier residues 
(Figure 6).  The results of rR spectroscopy confirm the presence of hexacoordinate, low-spin b-
heme (Figure 2), and rR analysis of the heme-carbonyl complex suggests axial His coordination 
of the b-heme (Figure 3).  Additionally, we show that the CcmF b-heme is widely conserved by 
analyzing recombinant CcmF proteins from diverse bacteria (Figure 7). 
Implications of His261 and His491 as the b-heme axial ligands in CcmF 
His261 in CcmF is located in TMD5, and His491 is located near the C-terminus in 
TMD12 (see Figure 1B).  In order for these residues to coordinate the iron of the b-heme, we 
propose that TMD5 and TMD12 are positioned close to each other in the three-dimensional 
structure of CcmF.  These findings suggest that the most likely position for the b-heme is directly 
below the periplasmic WWD domain in CcmF (refer to Figure 1B).  The WWD domain is a 
highly conserved tryptophan-rich motif that is located at the outer leaflet of the inner membrane 
and has been shown to interact directly with heme in the WWD family member CcmC (7).  In 
CcmC, heme axial ligands are provided by two His residues located in periplasmic loops that 
flank the WWD domain (7, 8).  Similar to CcmC, we predict that the WWD domain of CcmF 
forms a heme binding site for heme from holoCcmE, with periplasmic His173 and His303 of 
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CcmF serving as heme axial ligands (Figure 1B).  Thus, the positioning of the b-heme directly 
below the CcmF WWD domain is consistent with our hypothesized role for CcmF in reducing 
heme from holoCcmE prior to attachment to the apocytochrome (see below).   
The function of CcmF b-heme as a holoCcmE reductase 
Reduction of the heme in holoCcmE is required for covalent attachment of this heme to 
the apocytochrome c.  We have previously discussed that reduction of the holoCcmE heme could 
also favor ejection of the CcmE His130 covalent linkage (5).  To address our hypothesis that the 
b-heme in CcmF may be involved in electron transfer to holoCcmE (5, 8), we determined the 
reduction potential of the CcmF b-heme.  We report here that the CcmF b-heme has a midpoint 
potential of -147 mV at pH 7 (Figure 8).  Harvat et al. have reported a redox potential of -121 
mV at pH 7.3 for holoCcmE´, a soluble version of CcmE without the single TMD (52).  Despite 
the differences in the buffer conditions used in determining the reduction potentials for 
holoCcmE´ and here for CcmF (e.g., the presence of DDM), it is certainly feasible that CcmF 
functions as a holoCcmE reductase.  However, the reduction potential of isolated, purified 
holoCcmE´ may not reflect the physiological potential of this heme prior to attachment to the 
apocytochrome c.  Recall that, en route to attachment to apocytochrome c, the holoCcmE heme 
likely enters the WWD domain of CcmF, where heme axial ligands are provided by His173 and 
His303 of CcmF (see Figure 1B).  In purified holoCcmE, Tyr134 of CcmE has been shown to 
serve as an axial ligand to the heme (12, 53).  It is well-established that heme reduction potential 
is sensitive to changes in axial ligation (38, 41, 54), and tyrosine axial ligation is typically 
associated with a lowering of the reduction potential (i.e., more negative) relative to ligation by 
histidine (38, 55, 56).  Thus, the heme ligand “switch” from CcmE Tyr134 to CcmF 
His173/His303 upon binding of holoCcmE in the CcmF WWD domain could result in an 
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increase in the reduction potential (i.e., more positive) of the heme in holoCcmE.  Although the 
identity of the physiological electron donor to the CcmF b-heme is unknown, we previously 
showed that CcmF could be reduced by select quinone species in vitro in the presence of 
dithiothreitol (8).  Further studies are needed to investigate these features of cytochrome c 
assembly.   
Interaction between CcmF and holoCcmE 
Although it is widely believed that the heme from holoCcmE moves onto the 
apocytochrome c via CcmF, to our knowledge, an interaction between CcmF and holoCcmE has 
never been detected.  Thony-Meyer and colleagues have suggested that apoCcmE and CcmF 
interact (16).  However, in that study, because the genes encoding CcmABCD were absent, all of 
the CcmE was in the apo- form, so the physiological relevance of this finding is unclear.  
Furthermore, while Ren et al. (16) showed that antisera to CcmF co-immunoprecipitated 
apoCcmE, the reverse co-immunoprecipitation with anti-sera to CcmE yielded “non-specific 
signals” (16).  In our hands, the only protein that co-purifies with CcmF is CcmH (for example, 
see Figure 4 in ref. (8)).  We have been unable to detect apo- or holoCcmE above background 
levels in purifications of hexahistidine-tagged CcmF.  We suggest that holoCcmE may not co-
purify with CcmF (or the CcmF/H complex) unless the apocytochrome c acceptor (Cys-Xxx-
Xxx-Cys-His) is bound.  This proposal is in part based on our recent findings on the “acceptor-
dependent” nature of the CcmC-heme-CcmE complex of system I (7).  CcmC does not bind 
detectable levels of heme in its WWD domain in the absence of CcmE (Figure 1A), indicating 
that heme binding in CcmC requires the presence of the heme acceptor, CcmE.  By analogy, 
heme in holoCcmE may not enter the WWD domain of CcmF unless the heme acceptor protein, 
apocytochrome c, is present.  Future work will be dedicated to better understanding the 
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interaction of holoCcmE with CcmF; specifically, investigating if the docking of holoCcmE in 
the CcmF WWD domain requires the presence of the apocytochrome c acceptor, and, if the 
holoCcmE/CcmF/CcmH complex can be “trapped,” determining the reduction potential of the 
heme in holoCcmE when (and if) it is bound in the CcmF WWD domain.   
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Figures 
Figure 1. Model for stystem I and membrane topology of CcmF 
Adapted from reference (5).  (A) Current working model of the system I cytochrome c 
biogenesis pathway.  Model includes trafficking and oxidation states of heme as well as the 
subpathways for apocytochrome translocation and reduction.  (B) Topology of the CcmF integral 
membrane protein from E. coli.  Possible histidine axial ligands to heme are starred.  The highly 
conserved WWD domain is shaded as are the hydrophobic patches.  Completely conserved 
amino acids (red) were identified by individual protein alignments using CcmF ORFs from the 
following organisms: the alpha proteobacteria, Agrobacterium tumefaciens C58, R. capsulatus, 
Caulobacter crescentus CB15, and Bradyrhizobium japonicum; the beta proteobacteria, 
Nitrospira mutliformis ATCC 25196 and Nitrosomonas europaea ATCC 19718; the gamma 
proteobacteria, E. coli K-12 MG1655, Pseudomonas fluorescens Pf01, Shewanella oneidensis 
MR-1 and Vibrio parahaemolyticus RIMD 2210633; the delta proteobacteria, Myxococcus 
xanthus and Desulfovibrio desulfuricans; and the deinococci, Deinococcus geothermalis and 
Thermus thermophilus.   
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Figure 2.  Resonance Raman spectral analysis of the CcmF b-heme 
Soret-excited resonance Raman spectra of the heme b in ferric (red) and ferrous (violet, blue) 
CcmF.  Sample solutions were 88 µM in holoCcmF, 20 mM in Tris, pH 8, 100mM in NaCl, 0.02 
% in dodecyl maltoside, ~2 nm in imidazole.  HoloCcmF concentrations in the 3.2 % and 0.48 % 
DDM samples were 23 and 25 µM, respectively.  The red and violet spectra were recorded using 
10 mW of laser light at 413.1 nm (line focus of emission from Kr
+
 laser).  The low-frequency 
blue spectrum was recorded with 2 mW of 441.6-nm emission from a HeCd laser to identify the 
Fe−His stretching band. 
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Figure 3.  Resonance Raman spectral analysis of CcmF-CO complexes 
(A) Soret(413.1 nm)-excited rR spectra of natural abundance CcmF−CO (green) and 
CcmF−13CO (blue) in the vFe-C and vC-O frequency regions.  The red traces are the difference 
spectra, whose amplitudes have been multiplied by a factor of two for ease of viewing.  The 
difference features reveal the bands whose frequencies are 
13
C dependent, thereby facilitating 
their assignments to FeCO modes, which are indicated in the labels above the bands.  The violet 
trace shows the spectrum of natural abundance CcmF−CO in 3.2 % DDM.  Note that this 
spectrum exhibits two Fe−C stretching bands.  This heterogeneity is attributed to protein 
conformational changes driven by the high detergent concentration.  (B) Heme FeCO 
backbonding correlation plot showing the positions of the two CcmF−CO conformers.  The 
CcmF−CO complex that falls on the middle line (0.48 % DDM) most likely contains a proximal 
imidazole ligand from a His residue.  Its position low and to the right on the imidazole line 
shows that the CO ligand interacts only weakly with the heme pocket.  The CcmF−CO complex 
that falls on the top line (3.2 % DDM) is either pentacoordinate or has a proximal ligand that is 
bound through an oxygen atom. 
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Figure 4. Heme levels in CcmF (WT), His303Ala, and His491Ala proteins.   
Coomassie stain (A) of CcmF(WT), CcmF(H303A), and CcmF(H491A) showing purified full-
length 54 kDa proteins (indicated by arrow).  UV/Vis absorption spectra of CcmF(WT) (B), 
CcmF(H303A) (C), and CcmF(H491A) (D) as purified (oxidized; solid lines) and dithionite-
reduced (dotted lines).  Absorption maxima are indicated with arrows.  Heme stains of 
CcmF(WT) (E), CcmF(H303A) (F), and CcmF(H491A) (G); free heme is indicated with arrows; 
M, molecular weight standards; L, load; FT, flow-through; W1-W3, washes 1-3; E, elution; EC, 
concentrated elution, as described in Experimental Procedures.  20 µM purified CcmF protein 
was analyzed by UV/Vis absorption spectroscopy (B, C, D) and 30 µg was analyzed by heme 
stain or Coomassie stain (A; E, F, G, lane 8).   
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Figure 5. Spectral analysis of CcmF His261Cys and wild-type CcmF (WT) proteins.   
Coomassie stain (A) and heme stain (B) of CcmF(WT) and CcmF(H261C) proteins.  UV/Vis 
absorption spectra of CcmF(WT) (C), CcmF(H261C) (D), and CcmF(H261C) in the presence of 
30 mM imidazole (E), oxidized (solid lines) and dithionite-reduced (dotted lines).  Absorption 
maxima are indicated with arrows.  Absorbance values between 500 nm and 700 nm have been 
multiplied by a factor of 3.  30 µg of purified protein was analyzed by Coomassie and heme stain 
(A, B).  For UV/Vis absorption spectra approximately 20 µM purified protein was analyzed for 
wild-type, and approximately 40 µM purified protein was analyzed for His261Cys in the 
presence and absence of 30 mM imidazole.   
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Figure 6.  Imidazole correction of CcmF His261 and His491 mutants.   
The function of each of the indicated substitutions at CcmF His261 (A) or His491 (B) is reported 
as a percentage of wild-type CcmF (WT) function.  Holocytochrome c4 was quantified by 
measuring the chemiluminescent heme stain signal of 100 µg of BPER-isolated proteins from 
three independent experiments.  Representative heme stains are provided in Supporting 
Information (Figure S3).  Error bars denote standard deviation.  “C” denotes control, which 
represents chemiluminescent signal in the absence of CcmF (any signal lower than the control is 
considered background).   
  
 66 
  
 67 
Figure 7. Phylogenetic distribution and spectral analysis of diverse CcmF proteins.   
(A) Adapted from reference (23).  Representative distribution of systems I, II and III among the 
bacteria and archaea.  The system number is noted in parentheses after each group name, and 
stars indicate groups containing organisms from which recombinant hexahistidine-tagged CcmF 
was analyzed in the present study.  (B) Reduced UV/Vis absorption spectra of CcmF from E. coli 
(Ec), Thermus thermophilus (Tt; Deinococcus group), Desulfovibrio vulgaris (Dv), Roseobacter 
denitrificans (Rd), and Shewanella oneidensis (So); Shewanella oneidensis CcmF-3 (So-F3), and 
E. coli CcmF-2 (Ec-F2).  Absorption maxima are indicated with arrows.  Spectra have been 
offset for clarity.  Approximately 20 µM of each purified CcmF protein was analyzed for which 
Coomassie and heme stains are provided in Supporting Information (Figure S4).   
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Figure 8.  Redox titration of the CcmF b-heme.   
Spectra collected during a typical reductive titration of CcmF b-heme with nile blue chloride (A) 
and the corresponding linear Nernst plot (B).  Arrows in (A) indicate the direction of changes in 
absorption during the course of the titration.  In (B), [25 mV ln (b-hemered/b-hemeox)] was used 
for the one-electron reduction of heme and [12.5 mV ln (dyered/dyeox)] was used for the two-
electron reduction of dye, where b-hemered/b-hemeox and dyered/dyeox represent ratios of the 
molar concentrations of the reduced and oxidized forms of the b-heme and the dye, respectively.  
Conditions: 20 mM Tris-HCl, pH 7, 100 mM NaCl, 0.02 % DDM.   
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Supporting Information 
Construction of strains and plasmids.  All oligonucleotide primer sequences, plasmids, and 
strains are given in Table S1.  To create RK113, we deleted the endogeneous ccm operon in E. 
coli BW25113 by P1 transduction.  Briefly, P1 phage were grown first in LB media containing 5 
mM CaCl2 and 0.2 % glucose (wt/vol) with the donor strain (RK103 (1)).  Donor cells were 
killed by addition of chloroform and phage were isolated.  Dilutions of isolated phage (100 µL) 
were incubated with 100 µL of the recipient strain (BW25113) in LB containing 5 mM CaCl2 
and 100 mM MgSO4 at 37
o
C for 30 min.  Physical interaction between the phage and cells was 
disrupted by addition of 66.7 mM sodium citrate (Fisher), pH 5.5, and the culture was added to 1 
mL LB broth and incubated for one hour at 37
o
C while shaking at 300 rpm.  Transductants were 
selected by growth on LB + Kan, and cells were purified from P1 phage by repeated streaking on 
LB + Kan plates containing sodium citrate.  Deletion of the ccm operon in RK113 was confirmed 
by genomic PCR.  To create RK111, we used the pKNOCK system (2).  Briefly, the cyt c4:His6 
gene along with the araC gene were cloned from pRGK332 (1) into pKNOCK-Gm (2).  The 
araC gene was included to serve as the site for homologous recombination with the 
chromosome.  Cloning was done in E. coli S17-1/λpir, and the plasmid was conjugally 
transferred to E. coli RK103 (1).  Putative exconjugants were selected for resistance to 10 ug ml
-1
 
gentamicin, and correct integration of cyt c4:His was verified by genomic PCR.   
E. coli strains TB1 and HB101 were used as host strains for cloning.  pRGK333 (1) 
containing the full system I operon (ccmABCDEFGH) was the template for all PCR 
amplifications unless otherwise indicated.  A plasmid containing ccmABCDE (∆ccmFGH) was 
constructed by PCR amplification of ccmABCDE with Ccm_N-term and Del_CcmF_Left, the 
product of which was digested, and ligated into BamHI and EcoRI digested pGEX-4T-1 (GE 
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Healthcare) to make pRGK402.   To generate the His173Ala, His261Ala, and His303Ala 
mutants, short PCR products were amplified using Del_CcmE_Right and 
CcmF_His173Ala_Rev, CcmF_His261Ala_Rev, or CcmF_His303Ala_Rev.  These products 
were gel purified and used in a second amplification with CcmH_XhoI_Rev using pRGK386 (3) 
as template to generate ccmF(His173Ala):His6GH, ccmF(His261Ala):His6GH, and 
ccmF(His303Ala):His6GH (His6 refers to a hexahistidine tag at the carboxy terminus of CcmF).  
The final, full-length products were ligated into NdeI and XhoI digested pRGK402 to generate 
pRGK403, pRGK404, and pRGK405, respectively.  A plasmid containing ccmABCDEGH 
(∆ccmF) was constructed by PCR amplification of ccmGH with Del_CcmF_Right and Ccm_C-
term primers, the product of which was digested and ligated into EcoRI and NdeI digested 
pRGK402 to make pRGK406.  For the His491Ala mutant, a short PCR product was generated by 
amplifying with CcmF_His491Ala_Fwd and CcmF_ 6xHis_NdeI_Rev.  This product was gel 
purified and then used in a second amplification with Del_CcmE_Right to generate ccmF 
(His491Ala):His6.  The final, full-length product was ligated into the single NdeI site of 
pRGK406 to generate pRGK407.   
To insert ccmF:His6, ccmF(His261Ala):His6, or ccmF(His491Ala):His6 into pRGK330 
(1) for arabinose-inducible expression in the absence of other ccm genes, the corresponding 
ccmF gene was amplified from pRGK386, pRGK404, or pRGK407, respectively, with 
CcmF_NcoI_Fwd and CcmF_6xHis_PstI_Rev, digested, and ligated into NcoI and PstI digested 
pRGK330 to make pRGK408, pRGK409, and pRGK410.  His261Gly, Cys, Tyr, and Met were 
generated by amplifying with the appropriate reverse mismatch primer and CcmF_NcoI_Fwd to 
generate short PCR products.  These products were gel purified and used in a second 
amplification with CcmF_6xHis_PstI_Rev.  His491Gly, Cys, Tyr and Arg were generated by 
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amplifying with the appropriate forward mismatch primer and CcmF_6xHis_PstI_Rev to 
generate short PCR products.  These products were gel purified and used in a second 
amplification with CcmF_NcoI_Fwd.  The final, full-length products for all site-directed mutants 
at His261 and His491 described above were digested with NcoI and PstI and inserted into 
pRGK330 to generate pRGK411-418.  Each of the final constructs was sequenced to confirm the 
mutation.   
The ccmF-3 gene from Shewanella oneidensis (SO_0478) was PCR amplified from 
genomic DNA, digested, and ligated into the NcoI and PstI sites in pRGK330 to generate 
pRGK420.  The ccmF gene from Roseobacter denitrificans (RD1_3223) was amplified from 
genomic DNA, digested, and ligated into the EcoRI and KpnI sites of pRGK330 to make 
pRGK424.  Roseobacter denitrificans genomic DNA was provided generously by the 
Blankenship lab.  The ccmF-2 gene from E. coli (b4074) was amplified from genomic DNA, 
digested, and ligated into the NcoI and XbaI sites of pRGK330 to make pRGK421.  The ccmF 
genes from Shewanella oneidensis (SO-0266), Desulfovibrio vulgaris (DVU_1050), and 
Thermus thermophilus (TTHA1404) were each amplified from genomic DNA with the 
appropriate primers and cloned into pCR-Blunt II-TOPO (Invitrogen).  From pCR-Blunt II-
TOPO, the ccmF gene from Shewanella oneidensis was ligated into the NheI and XhoI sites of 
pRGK330 to make pRGK419, the ccmF gene from Desulfovibrio vulgaris was ligated into the 
NcoI and XbaI sites to make pRGK423, and the ccmF gene from Thermus thermophilus was 
ligated into the KpnI and NheI sites to make pRGK422.  Desulfovibrio vulgaris subsp. vulgaris 
ATCC 29579 and Thermus thermophilus ATCC 27634 strains were obtained from ATCC and 
cultured according to ATCC recommendations, and genomic DNA was prepared using the 
Puregene System Cell and Tissue DNA Isolation Kit (Gentra Systems).     
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Figure S1.  Peak fitting of the ferrous CcmF UV-visible absorbance spectrum.   
The fit peaks reveal speciation between 6cLS (red) and 5cHS (blue) hemes with a significant 
fraction being 5cHS.  Assuming that the extinction coefficients at the HS and LS Soret maxima 
are roughly equal, the samples of ferrous CcmF(WT) used in this study comprise approximately 
20 % 5cHS heme.  Based on similarities among the UV-visible spectra and insensitivity of the 3 
ratios to [DDM] between 0.48 % and 0.02 %, this speciation is essentially independent of DDM 
concentration. 
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Figure S2.  Cytochrome c4:His6 assembly in the presence or absence of 10 mM imidazole.   
Arrow indicates 24 kDa holocytochrome c4:His6 matured by a functional system I.  “pSysI∆F” 
denotes a system I deleted for ccmF; “c4:His only” denotes an absence of all ccm genes; “M” 
denotes molecular weight standards (shown is the 28 kDa standard).  100 µg of BPER-isolated 
proteins was loaded into each lane for SDS-PAGE prior to heme staining.   
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Figure S3.  Cytochrome c assembly in the presence or absence of imidazole. 
Representative heme stains showing cytochrome c4:His6 assembly of mutants at His261 (A) and 
His491 (B) in the presence or absence of 10 mM imidazole (as described in Figure S1).  Arrow 
indicates 24 kDa holocytochrome c4:His6 matured by a functional system I.  Substitutions: A, 
Ala; G, Gly; C, Cys; Y, Tyr; M, Met; R, Arg.  The dash denotes the negative control condition 
(absence of CcmF) and “wt” denotes wild-type CcmF.  “M” denotes molecular weight standards 
(shown is the 28 kDa standard).  100 µg of BPER-isolated proteins was loaded into each lane for 
SDS-PAGE prior to heme staining.   
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Figure S4. Purification of CcmF proteins from diverse bacteria. 
Coomassie stain (A) and corresponding heme stain (B) after SDS-PAGE of CcmF:His6 from E. 
coli (Ec), Thermus thermophilus (Tt; Deinococcus group), Desulfovibrio vulgaris (Dv), 
Roseobacter denitrificans (Rd), Shewanella oneidensis (So), Shewanella oneidensis CcmF-3 (So-
F3), and E. coli CcmF-2 (Ec-F2).  Arrows indicate full-length 54 kDa CcmF:His6 and free heme 
at the SDS-PAGE dye front.  Note that some of the So-CcmF3 and Ec-CcmF2 aggregate at 
approximately 117 kDa, possibly a dimeric form, under the conditions of SDS-PAGE used.  
Additionally, note that for Dv, So-CcmF3 and Ec-F2, some heme is retained in the full length 
protein and/or in the higher molecular weight forms.  For each of the proteins analyzed, heme 
was found to be non-covalent as determined by pyridine hemachromagen (data not shown).  
Thus, Dv, So-CcmF3 and Ec-F2 may bind heme in a partially SDS-resistant, although non-
covalent, manner.  30 µg of purified hexahistidine-tagged protein was analyzed for each.   
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Figure S5. Redox titration of the CcmF b-heme with alternate redox dyes.   
Spectra collected during reduction of CcmF b-heme with resorufin (A) or safranin O (B).  
Arrows indicate the direction of changes in absorption during the course of the titration.  The 
decreases in absorbance at 534 nm and 572 nm in (A) are due to reduction of resorufin.  In (B), 
the decrease in absorbance at 412 nm and the increase in absorbance at 426 nm are indicative of 
reduction of the CcmF b-heme, and the decrease in absorbance at 532 nm is due to reduction of 
safranin O.  Note that the dye resorufin (Em = -50 mV) (4) is completely reduced before 
reduction of the CcmF b-heme, while the CcmF b-heme is completely reduced before reduction 
of safranin O (Em = -280 mV) (4).  This indicates that the relative midpoint potential of the 
CcmF b-heme is in between that of resorufin and safranin O.  Conditions: 20 mM Tris-HCl, pH 
7, 100 mM NaCl, 0.02 % DDM.    
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Figure S6. Redox titration of the CcmF b-heme in high DDM (1.2 %).   
Spectra collected during a reductive titration of CcmF b-heme with nile blue chloride (Em = -116 
mV) (4) (A) and the corresponding linear Nernst plot (B).  Arrows in (A) indicate the direction 
of changes in absorption during the course of the titration.  In (B), [25 mV ln (b-hemered/b-
hemeox)] was used for the one-electron reduction of heme and [12.5 mV ln (dyered/dyeox)] was 
used for the two-electron reduction of dye, where b-hemered/b-hemeox and dyered/dyeox represent 
ratios of the molar concentrations of the reduced and oxidized forms of the b-heme and the dye, 
respectively.  The reduction potential in 1.2 % DDM was substantially more positive (Em = -110 
± 4 mV) than in 0.02 % DDM.  Conditions: 20 mM Tris-HCl, pH 7, 100 mM NaCl, 1.2 % DDM.    
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Abstract 
The periplasmic heme chaperone holoCcmE is essential for heme trafficking in the cytochrome c 
biosynthetic pathway in many bacteria, archaea, and plant mitochondria.  This pathway, called 
system I, involves two steps: i) formation and release of holoCcmE (by CcmABCD), and ii) 
delivery of the heme in holoCcmE to the putative cytochrome c heme lyase complex, CcmFH.  
CcmFH is believed to facilitate the final covalent attachment of heme (from holoCcmE) to the 
apocytochrome c.  Although all models for system I propose that holoCcmE delivers heme 
directly to CcmF, no interaction between holoCcmE and CcmF has been demonstrated.  Here, a 
complex between holoCcmE and CcmF is “trapped”, purified, and characterized.  HoloCcmE 
must be released from the ABC-transporter complex CcmABCD to interact with CcmF, and the 
holo-form of CcmE interacts with CcmF at levels at least 20-fold higher than apoCcmE.  Two 
conserved histidines (here termed P-His1 and P-His2) in separate periplasmic loops in CcmF are 
required for interaction with holoCcmE, and evidence is presented that P-His1 and P-His2 
function as heme-binding ligands.  These results show that heme in holoCcmE is essential for 
complex formation with CcmF, and that the heme of holoCcmE is coordinated by P-His1 and P-
His2 within the WWD domain of CcmF.  These features are strikingly similar to formation of the 
CcmC:heme:CcmE ternary complex (Richard-Fogal and Kranz, JMB 2010), and suggest 
common mechanistic and structural aspects.    
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Introduction 
C-type cytochromes are heme proteins involved in vital electron transfer reactions in the 
cell.  These cytochromes function outside of the cytoplasmic membrane in prokaryotes, in the 
lumen of chloroplasts, and in the intermembrane space of mitochondria.  Cytochromes c are 
unique among heme proteins in that the heme is covalently attached to the protein (via thioether 
linkages between the 2- and 4-vinyls of heme and two thiols of a conserved Cys-Xxx-Xxx-Cys-
His motif in the apoprotein).  For covalent attachment to occur, both the apocytochrome thiols 
and the iron of heme must be reduced 
1; 2
.  In many bacteria, plant and protozoal mitochondria, 
and archaea, holocytochrome c formation requires the cytochrome c maturation (ccm) pathway, 
called system I (see Fig 1), which comprises eight dedicated membrane proteins (in E. coli, 
CcmABCDEFGH) 
3; 4; 5; 6; 7
.   
System I can be conceptually described as two steps (see Fig 1): (i) formation and release 
of the heme chaperone protein, called holo (+ heme) CcmE, (from CcmABCD) and (ii) heme 
transfer from holoCcmE to the apocytochrome (putatively, via CcmFH) to yield a 
holocytochrome c.  Formation of holoCcmE occurs in the CcmCDE complex 
8; 9
, where a unique 
covalent attachment is formed between the β carbon of the heme 2-vinyl and a conserved 
histidine residue (His130) in CcmE 
10; 11; 12
.  Expression of CcmAB leads to formation of an 
ABC transporter complex (CcmABCD) that uses ATP hydrolysis to release covalent holoCcmE 
13; 14; 15
.  Released, oxidized (Fe
3+
) holoCcmE is proposed to chaperone its heme to the site of 
cytochrome c formation, CcmFH, but this has not been proven (see below) 
9; 16; 17
.  CcmF, which 
forms an integral membrane complex with CcmH, is believed to be the site of thioether 
formation between the heme vinyls and the apocytochrome; thus, it has been termed the 
“cytochrome c heme lyase”.  The CcmFH integral membrane complex has been purified 9 or co-
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immunoprecipitated 
17; 18; 19
.  CcmF contains a separate and stable non-covalent heme b 
9; 20
, 
which we have hypothesized plays a role in reducing the incoming heme from holoCcmE 
4; 20
.  
Reduction of heme (to Fe
2+
) is a requirement for thioether formation 
1; 2; 4
, and would also favor 
the release of heme from CcmE His130 
4; 8; 20
.  CcmG 
21; 22; 23
 and CcmH 
24; 25
 are thioredox 
proteins that maintain the apocytochrome thiols (in the Cys-Xxx-Xxx-Cys-His motif) in the 
reduced state 
26; 27; 28
.  In some species, such as Rhodobacter capsulatus, ccmH is split into two 
open reading frames (called ccmH and ccmI).  While there is significant evidence that the 
apocytochrome interacts with the CcmFH cytochrome c heme lyase complex (via CcmH) 
24; 26; 29; 
30
, there has been no data demonstrating that holoCcmE interacts with CcmF (see Discussion for 
details).  Nonetheless, formation of a complex between holoCcmE and CcmF has been proposed 
in nearly every review on cytochrome c biogenesis during the last decade (e.g., 
3; 4; 5; 6; 7
).  Thus, 
the proposal that holoCcmE trafficks heme directly to CcmF (see Fig 1) for holocytochrome c 
formation remains unproven.   
Here, we describe purification and characterization of an intermediate complex between 
holoCcmE and CcmF, achieved by purifying CcmF from detergent-solubilized membranes 
lacking CcmG and CcmH.  We show that holoCcmE must be released from CcmCD in order to 
interact with CcmF, and that holoCcmE forms a complex with CcmF at levels at least 20-fold 
higher than apoCcmE.  We demonstrate that two periplasmic histidines (His173 and His303, 
here called P-His1 and P-His2, respectively) in separate periplasmic loops in CcmF are required 
for interaction with holoCcmE, with evidence that these residues function as heme-binding 
ligands.  We propose that heme in holoCcmE is a critical component for interaction with CcmF 
and we discuss how these results mirror formation of the CcmC:heme:CcmE ternary complex 
8
 
(see Fig 1).    
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Results 
The holoCcmE-CcmF complex 
Although all current in vivo models for the system I pathway presume a holoCcmE—
CcmF intermediate during holocytochrome c biosynthesis, we have been unable to co-purify 
holoCcmE at detectable levels in our preparations of CcmFH 
9
.  Our purifications of CcmF (and 
CcmFH complex) are typically from DDM-solubilized membranes that contain all Ccm proteins 
(CcmABCDEFGH).  The inability to identify a complex between holoCcmE and CcmF could be 
due to a transient, short-lived interaction or current models for system I may be incorrect.  In an 
attempt to detect an interaction between holoCcmE and CcmF, we expressed CcmF along with 
the minimal set of CCM components required for formation and release of holoCcmE from the 
CcmABCD complex (i.e., CcmABCDEF, or pGEX ∆CcmGH; Fig 2 A-D).  Note that the 
proteins CcmG and CcmH are absent in these cells.  Full-length hexahistidine-tagged CcmF (54-
kDa) was TALON-purified as a single polypeptide to greater than 90% purity (Fig 2A, lane 8) 
that reacted with CcmF antisera (Fig 2B, lane 8).  Heme staining revealed that, in addition to the 
CcmF b-type heme (which dissociates from the protein and migrates as free heme during 
denaturing SDS-PAGE) preparations of CcmF from membranes lacking CcmG and CcmH 
contained 20-kDa holoCcmE (Fig 2C, lane 8).  Immunodetection with CcmE antisera confirmed 
that the 20-kDa covalent heme species was holoCcmE (Fig 2D, lane 8).     
UV-Vis absorption spectra of the oxidized (as purified) CcmF-holoCcmE preparation 
showed a Soret maximum at 412 nm and broad α and β absorptions between 500 and 600 nm 
(Fig 2E).  Chemical reduction with sodium dithionite yielded a Soret maximum at 426 nm and 
sharp α and β absorptions at 559 and 530, respectively.  These spectral features, in addition to the 
556 nm absorption in the reduced pyridine hemochrome (Fig 2E, inset) are characteristic of non-
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covalent, b-type hemes 
32
, and are indistinguishable from those of the CcmF b-heme 
9; 20
.  
Because the holoCcmE polypeptide is not readily detectable by Coomassie staining (Fig 2A, lane 
8), it is likely that holoCcmE is less than stoichiometric with CcmF in the CcmF-holoCcmE 
complex.  This result, together with only slight differences in the electronic absorptions of 
holoCcmE and CcmF, make it difficult to discern the spectral contributions of the heme from 
holoCcmE.  We next wanted to analyze the role of other Ccm proteins as well as specific 
residues in CcmF in formation of the holoCcmE-CcmF complex.   
HoloCcmE co-purifies with CcmF in the absence of CcmG and CcmH 
As mentioned above, purifications of CcmF from membranes containing all Ccm proteins 
(CcmABCDEFGH) typically do not yield detectable holoCcmE.  Therefore, we directly 
compared levels of holoCcmE that co-purified with CcmF in the presence of all Ccm proteins 
(expressed from pSysI) to those that co-purified with CcmF in the absence of CcmG and CcmH 
(expressed from pSysI ∆GH).  As controls, we included in this analysis constructs lacking ccmF 
(pSysI ∆FGH, or pGEX ccmABCDE) and ccmE (pSysI ∆EGH, pGEX ccmABCDF:His6).  With 
the exception of ∆FGH, CcmF was purified as a single full-length polypeptide (54-kDa; Fig 3A, 
lanes 2-4) that reacted with CcmF antisera (Fig 3B, lanes 2-4).  Immunoblotting with CcmH 
antisera showed that co-purified 34-kDa CcmH was present only in CcmF purifications from the 
pSysI background, as expected (Fig 3C, lane 4).  Heme staining and anti-CcmE immunoblotting 
of TALON-purified fractions revealed that, in the absence of CcmG and CcmH, CcmF co-
purified with approximately 10-fold more holoCcmE than when CcmG and CcmH were present 
(Fig 3D and E, compare lanes 3 and 4; quantified in Fig 3H).  In the absence of CcmF (pSysI 
∆FGH), no holoCcmE was detected by heme stain or anti-CcmE immunoblot (Fig 3D and E, 
lane 1), showing that there was no detectable retention of holoCcmE on the TALON resin.  
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Similarly, in the absence of CcmE (pSysI ∆EGH), no 20-kDa covalent heme species or reactivity 
with CcmE antisera were observed (Fig 3D and E, lane 2).  Analysis of DDM-solubilized 
membrane fractions by heme staining and immunoblotting with CcmE antisera showed that all 
membranes (with the exception of those from pSysI ∆EGH) contained holoCcmE at levels at 
least as high as that of pSysI ∆GH (Fig 3F and G; quantified in Fig 3I).  Therefore, the 10-fold 
higher levels of holoCcmE that co-purified with CcmF from pSysI ∆GH are not due to increased 
expression of holoCcmE from this construct.  We conclude that CcmH prevents (controls) 
trapping of the holoCcmE/CcmF complex (see Discussion).   
HoloCcmE must be released from CcmCD to interact with CcmF 
The first step in heme translocation in the system I (CCM) pathway involves formation of 
covalent (holo) CcmE, which occurs via complex formation with CcmC and CcmD 
8; 9; 35
.  
Subsequently, CcmA and CcmB form an ABC transporter “release complex” with CcmC and 
CcmD, which uses ATP hydrolysis to release holoCcmE for heme trafficking to (putatively) 
CcmFH 
13; 14; 15.  In the absence of CcmAB, holoCcmE becomes “trapped” with CcmCD in a 
very stable intermediate complex 
8
, and holocytochrome c formation is blocked at this step.  We 
examined whether interaction between CcmF and holoCcmE is dependent on release of 
holoCcmE from CcmABCD.  We engineered an in-frame deletion of ccmAB in pSysI ∆GH to 
yield pSysI ∆GH delAB (pGEX ccmCDEF:His6), with a GST translational fusion to CcmC 
rather than CcmA.     
CcmF was expressed from pSysI ∆GH delAB and purified as a single full-length 
polypeptide (54-kDa; Fig 4A, lane 3) that reacted with CcmF antisera (Fig 4B, lane 3).  Heme 
staining and anti-CcmE immunoblotting revealed that the absence of CcmAB resulted in at least 
a 10-fold decrease in the amount of holoCcmE that co-purified with CcmF (Fig 4C and D, 
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compare lanes 2 and 3; quantified in Fig 4G).  Analysis of DDM-solubilized membrane fractions 
by heme staining and immunoblotting with CcmE antisera showed that membranes from pSysI 
∆GH delAB contained holoCcmE at levels at least as high as that of pSysI ∆GH (Fig 4E and F; 
quantified in Fig 4H).  To confirm that release of holoCcmE from CcmCD was blocked by 
deletion of ccmAB, we purified GST:CcmC from the flow-through fraction of the TALON 
column (Fig 4 I-L).  Purified full-length GST:CcmC (48-kDa) and free GST each reacted with 
GST antisera (Fig 4K, lane 1).  Heme staining (Fig 4J, lane 6) and immunodetection with CcmE 
antisera (Fig 4L, lane 1) revealed that purified GST:CcmC contained high levels of trapped 
(unreleased) holoCcmE.  Thus, in the absence of CcmAB, holoCcmE is trapped on CcmC, which 
effectively abolishes formation of the CcmF-holoCcmE complex.  Only released holoCcmE 
interacts with CcmF, as previous models have hypothesized.  This strongly suggests that the 
interaction we detect between holoCcmE and CcmF is a true intermediate during 
holocytochrome c formation.   
ApoCcmE does not interact with CcmF 
CcmE binds heme through a unique covalent bond between conserved His130 and the 2-
vinyl of the heme 
10; 11; 12
.  Previous work has shown that mutation of His130 to alanine abolishes 
covalent bond formation between heme and CcmE 
36
, although CcmE(His130Ala) still forms a 
complex with CcmCD and is likely released upon ATP hydrolysis by CcmAB 
8
.  Since released 
CcmE(His130Ala) is completely apo- (lacking heme), holocytochrome c formation is blocked at 
this step (i.e., the covalent bond to heme in holoCcmE is necessary for CcmE to chaperone heme 
to, putatively, CcmFH).  To test whether apo-CcmE could interact with CcmF, we engineered the 
His130Ala substitution in ccmE in pSysI ∆GH to yield pSysI ∆GH mutE (pGEX 
ccmABCDE(His130Ala)F:His6).  CcmF was expressed from pSysI ∆GH mutE and purified as a 
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single full-length polypeptide (54-kDa; Fig 5A, lane 3) that reacted with CcmF antisera (Fig 5B, 
lane 3).  As expected, heme staining showed no evidence of holoCcmE in purified CcmF 
fractions (Fig 5C, lane 3; quantified in Fig 5G), since mutation of His130 results in only the apo-
form of CcmE (Fig 5E, lane 3; quantified in Fig 5H).  Immunoblotting with CcmE antisera 
revealed approximately a 20-fold decrease in the amount of apoCcmE that co-purified with 
CcmF (Fig 5D, compare lanes 2 and 3; quantified in Fig 5G), even though DDM-solubilized 
membranes from pSysI ∆GH mutE contained apoCcmE at levels at least as high as those of 
pSysI ∆GH (Fig 5F, compare lanes 2 and 3; quantified in Fig 5H).  Thus, apoCcmE is not 
capable of interaction with CcmF, which suggests that holoCcmE—CcmF complex formation is 
heme-dependent (see Discussion).     
CcmF P-His1 and P-His2 exhibit heme ligand activity  
CcmF contains four conserved His residues (see Fig 6): His261 in TMD5 and His491 in 
TMD12 (here called TM-His1 and TM-His2, respectively); and His173 and His303 in 
periplasmic loops flanking the conserved WWD domain (here called P-His1 and P-His2, 
respectively).  Alanine substitutions at any of the His residues in CcmF abolishes 
holocytochrome c formation 
9; 17; 20
.  TM-His1 and TM-His2 are ligands to the b-heme in CcmF: 
mutation of either of these transmembrane His residues results in a loss of nearly all b-heme in 
the purified protein 
9; 20
.  However, the roles of P-His1 and P-His2 are unknown.  Based on their 
position flanking the WWD domain (which, in CcmC, has been shown to be the site of 
interaction with the holoCcmE heme 
8
), we hypothesize that P-His1 and P-His2 in CcmF may be 
ligands to the incoming heme from holoCcmE (see Fig 6 and Discussion).     
Previously, we showed that the cytochrome c assembly defects of glycine substitutions at 
TM-His1 and TM-His2 could be corrected in vivo by addition of 10 mM imidazole directly to 
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culture 
20
.  Conceptually, this is similar to the correction of heme binding in the myoglobin 
His93Gly “cavity” mutant by imidazole 37.  Thus, functional correction of a histidine mutant by 
imidazole can be suggestive of a heme ligand function.  To test whether P-His1 or P-His2 might 
exhibit a ligand function, we engineered alanine, glycine, cysteine, tyrosine, or methionine 
substitutions at each His residue and assayed for holocytochrome c4 formation in the absence 
and presence of imidazole.  Heme staining of BPER fractions revealed that in the absence of 
imidazole, none of the engineered substitutions at P-His1 or P-His2 supported holocytochrome c 
formation (Fig 7A and B, lanes 1-7; quantified in Fig 7C and D).  However, 10 mM imidazole 
corrected the holocytochrome c assembly defects of glycine substitutions at P-His1 and P-His2 
to approximately 50% levels of WT (Fig 7A and B, lane 10; quantified in Fig 7C and D).  
Substitution of P-His1 with bulkier amino acids did not result in detectable holocytochrome c4 
formation in the presence of imidazole (Fig 7A, lanes 9-15; quantified in Fig 7C).  The tyrosine 
and methionine substitutions at P-His2 were corrected to approximately 10% and 5% levels of 
WT, respectively, suggesting that the P-His2 position may be more flexible than the P-His1 (i.e., 
for imidazole).  We conclude that the glycine substitutions at P-His1 and P-His2 result in the 
formation of a cavity in which imidazole can bind and serve as a ligand to support 
holocytochrome c formation.  However, bulkier amino acids (including perhaps the methyl side 
group of alanine) may present a steric hindrance to imidazole correction.  Since we have 
previously shown that neither P-His1 nor P-His2 were ligands to the CcmF b-heme, we theorize 
that the apparent ligand function of these residues is related to the incoming heme from 
holoCcmE.   
CcmF P-His1 and P-His2 are required for interaction with holoCcmE 
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To directly test if P-His1 and P-His2 are required for interaction with holoCcmE, we 
engineered alanine substitutions at each residue, as well as a double alanine substitution, in the 
pSysI ∆GH background and assayed for holoCcmE in preparations of CcmF.  CcmF was 
expressed from pSysI ∆GH(P-His1Ala), pSysI ∆GH(P-His2Ala), or pSysI ∆GH(P-His1Ala/P-
His2Ala) and purified as a single full-length polypeptide (54-kDa; Fig 8A, lanes 3-5) that reacted 
with CcmF antisera (Fig 8B, lanes 3-5).  Heme staining and immunoblotting with CcmE antisera 
showed approximately a 5-fold decrease in the amount of holoCcmE that co-purified with CcmF 
for each of the single substitutions (Fig 8C and D, compare lane 2 to 3 and 4; quantified in Fig 
8G), and approximately a 10-fold decrease for the double mutant (Fig 8C and D, compare lanes 2 
and 5; quantified in Fig 8G).  DDM-solubilized membranes from all backgrounds contained 
similar levels of holoCcmE (Fig 8E and F; quantified in Fig 8H).  Thus, P-His1 and P-His2 in 
CcmF are essential for interaction with holoCcmE, and are likely the ligands to the heme from 
holoCcmE.    
The CcmF b-heme is required for interaction with holoCcmE 
CcmF contains two conserved histidines in transmembrane domains (TM-His1 and TM-
His2) that are ligands to the CcmF b-heme.  Substitution of either histidine residue with alanine 
abolishes b-heme binding in CcmF to undetectable levels 
20
.  To test if the CcmF b-heme is 
required for interaction with holoCcmE, we engineered alanine substitutions at TM-His1 and 
TM-His2 in the pSysI ∆GH background and assayed for holoCcmE in preparations of CcmF.  
CcmF was expressed from pSysI ∆GH(TM-His1Ala) or pSysI ∆GH(TM-His2Ala) and purified 
as a full-length polypeptide (54-kDa; Fig 9A, lanes 3-4) that reacted with CcmF antisera (Fig 9B, 
lanes 3-4).  Heme staining and immunoblotting with CcmE antisera showed approximately an 8-
fold decrease in the amount of holoCcmE that co-purified with CcmF for each substitution (Fig 
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9C and D, compare lane 2 to 3 and 4; quantified in Fig 9G).  DDM-solubilized membranes from 
all backgrounds contained similar levels of holoCcmE (Fig 9E and F; quantified in Fig 9H).  
Note that purified CcmF (TM-His1Ala) and CcmF (TM-His2Ala) do not contain the b-heme (see 
“free heme” in Fig 9C, compare lane 2 to 3 and 4).  This is in stark contrast to the P-His1 and P-
His2 substitutions, which showed b-heme levels identical to WT CcmF (see “free heme” in Fig 
8C).  Thus, the b-heme in CcmF (with ligands from TM-His1 and TM-His2) is essential for 
interaction with holoCcmE.    
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Discussion 
Requirements for formation of the holoCcmE—CcmF complex 
Here, we report isolation of an integral membrane protein complex between the system I 
heme chaperone, holoCcmE, and the putative cytochrome c synthetase, CcmF.  Interaction 
between these two essential CCM proteins has long been suspected, but never shown directly.  
Ren and colleagues (2002) previously reported that CcmE could be immunoprecipitated from 
cell extracts using CcmF antisera (see Fig 4 of 
17
).  However, since only the apo-form of CcmE 
was analyzed in that study (the strain utilized lacked the genes for ccmABCD altogether), the 
relevance of that finding to holocytochrome c formation is unclear.  Despite the fact that only 
apoCcmE was analyzed, many CCM models have cited the findings of Ren and colleagues as 
evidence of interaction between holoCcmE and CcmF.  In our study, using a strain expressing 
CcmABCDE and CcmF, we showed that covalent, released holoCcmE interacts with CcmF at 
levels at least 20-fold higher than the apo-form of CcmE (see Fig 5).  Given that the predicted 
function of CcmF is to facilitate heme transfer from holoCcmE to the apocytochrome, it is not 
surprising that the holo-form of CcmE preferentially binds.  Ren and colleagues also reported 
that point mutants in CcmF (including alanine substitutions at P-His1 and P-His2) showed 
unaltered interactions with (apo) CcmE, relative to WT CcmF.  In contrast, we found that 
substitution of either P-His1 or P-His2 caused a 5-fold decrease in the levels of holoCcmE that 
co-purified with CcmF (relative to WT CcmF), and that the double mutant showed a 10-fold 
decrease (see Fig 8).  The critical roles of P-His1 and P-His2 (which are in periplasmic loops 
adjacent to the CcmF WWD domain; see Fig 6) in binding holoCcmE had been proposed 
previously, and is further elaborated upon below.  We suggest that the apoCcmE detected in 
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preparations of CcmF represents a low background level (likely non-physiological), and that the 
holoCcmE “trapped” in complex with CcmF is the true physiological intermediate in system I.   
Implications of P-His1 and P-His2 binding heme from holoCcmE 
CcmF is a member of the heme-handling superfamily of proteins 
38
, which also includes 
CcmC and the system II cytochrome c synthetase, CcsBA.  The hallmark of the heme-handling 
proteins is the “WWD domain” 39; 40; 41; 42, a conserved tryptophan-rich periplasmic loop that is 
flanked by two conserved histidine residues in adjacent periplasmic loops.  CcmC, which is 
sometimes referred to as the holoCcmE synthase (due to its well-described role in formation of 
holoCcmE) 
14; 35
 forms a stable intermediate complex with holoCcmE (in the absence of 
CcmAB) 
8.  In the “trapped” holoCcmCDE complex, heme from holoCcmE is bound in the 
WWD domain of CcmC, and the two flanking histidines (CcmC His60 and His184) supply the 
5
th
 and 6
th
 axial ligands to heme.  Richard-Fogal and Kranz (2010) showed that substitution of 
either histidine, as well as certain tryptophans in the WWD domain of CcmC, caused 
perturbations in the absorption spectrum of the CcmCDE complex 
8
.  In the absence of heme, 
there was no detectable interaction between (apo) CcmE and CcmC, indicating that the WWD 
domain of CcmC is a platform for interaction with heme rather than for the CcmE polypeptide.  
Thus, we proposed that heme, CcmC, and CcmE are each essential to form the stable “ternary” 
complex 
8
.   
By analogy to the CcmCDE complex, we have hypothesized that the WWD domain of 
CcmF is the site of interaction for heme from holoCcmE, after it is released from CcmCD.  
Several of our findings here are in agreement with this hypothesis: i) CcmF P-His1 and P-His2 
(which flank the WWD domain) exhibited ligand-type activity (Gly substitutions at these 
residues were functionally restored by adding exogeneous imidazole), ii) P-His1 and P-His2 
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were required for interaction with holoCcmE, iii) only the holo-form of CcmE (i.e., with heme), 
and not apoCcmE, interacted with CcmF, and iv) only holoCcmE released from CcmCD 
interacted with CcmF.  The requirement for both heme (i.e., “holo” CcmE) and the WWD 
domain-flanking histidines for formation of the holoCcmE—CcmF complex is remarkably 
similar to formation of the holoCcmCDE complex.     
Identifying the CcmF WWD domain as the binding site for holoCcmE also has 
implications for understanding the cytochrome c heme lyase function of CcmF.   Experimentally 
established models for the membrane topology of CcmF 
9
 suggest that the b-heme (with ligands 
from TM-His1 and TM-His2) is positioned spatially below the WWD domain (see Fig 6).  Given 
this transmembrane “architecture,” a mechanism for reduction of the incoming heme from 
holoCcmE (in the WWD domain) by electron transfer directly from the b-heme can be readily 
envisioned.  Further studies will be needed to test this.  In particular, since the holoCcmE that co-
purifies with CcmF is sub-stoichiometric, it will be necessary to further enrich for holoCcmE in 
the complex to begin these and other spectroscopic studies. 
Absence of CcmGH is critical to formation of the holoCcmE—CcmF complex 
Surprisingly, we found that levels of the “trapped” holoCcmE—CcmF complex increased 
10-fold when CcmGH were absent (see Fig 3).  In fact, purification of CcmF from this particular 
background (pSysI ∆GH) initially enabled us to detect the holoCcmE—CcmF complex. CcmG is 
a periplasmic thioredoxin that has been shown to reduce the cysteines of CcmH (in vitro) (e.g., 
28
), but it does not co-purify with the CcmFH complex 
9; 19
.  By contrast, interaction between 
CcmF and CcmH is well established 
9; 17; 18; 19
.  CcmH is a polytopic membrane protein with two 
transmembrane α helices and a large C-terminal periplasmic domain (see Fig 6).  Apart from the 
two conserved cysteine residues in the N-terminal periplasmic domain, which have been shown 
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to reduce the apocytochrome thiols (in the Cys-Xxx-Xxx-Cys-His motif) 
24; 28; 43
, discrete 
functional domains within CcmH have not been well defined.  Recently, Verissimo and 
colleagues (2011) and Di Silvio and colleagues (2013) have shown that CcmI, which is 
analogous to the C-terminus of E. coli CcmH, interacts with the C-terminus of apocytochrome c 
(not at Cys-Xxx-Xxx-Cys-His), but not holocytochrome c 
29; 30
.  Given our results here, it is 
likely that CcmH may also modulate the interaction between CcmF and holoCcmE.  For 
example, in the absence of apocytochrome, CcmH may occlude the CcmF WWD domain from 
interaction with holoCcmE, thus only “permitting” holoCcmE reduction (to Fe2+) when the 
apocytochrome c “acceptor” is present.  Alternatively, but not mutually exclusively, CcmH may 
facilitate the rapid release of CcmE from the CcmF WWD domain.  We have proposed that 
reduction of heme in holoCcmE accomplishes two reactions (see Fig 10).  First, reduction of 
heme (to Fe
2+) would favor the ejection of His130 imidazole from the β carbon of the heme 2-
vinyl (see Fig 10A, reverse blue arrow).  Second, reduced heme is required for the 2- and 4-
vinyls of heme to form thioether linkages with the apocytochrome c thiols (at Cys-Xxx-Xxx-
Cys-His; see Fig 10B).  It makes ‘sense’ to only allow the first reaction to occur (ejection of 
CcmE His130) when the acceptor is properly positioned (by CcmH) for the second reaction.  
Thus, the synthetase reactions are elegantly orchestrated by the holoCcmE:CcmF:CcmH 
complex.    
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Materials and Methods 
Bacterial Growth Conditions.  Escherichia coli strains (Supplemental Table 1) were grown at 
37
o
C by shaking at 230 rpm in Luria-Bertani broth (LB; Difco) supplemented with the 
appropriate antibiotics (Sigma-Aldrich) and other media additives at the following 
concentrations, unless otherwise noted: carbenicillin, 50 ug ml
-1
; chloramphenicol, 20 ug ml
-1
; 
gentamicin, 10 ug ml
-1
; IPTG (Gold Biotechnology), 1 mM; arabinose (Gold Biotechnology), 0.2 
% (wt/vol).   
Protein Expression and Purification.  E. coli ∆ccm strain RK103 (Table S1) 16 was used for 
expression.  Starter cultures were initiated from a single colony and grown overnight in 10 mL of 
LB with the appropriate antibiotics.  1 L of LB and was inoculated with the 10 mL starter culture 
and grown to an OD600 of 1.8, then induced with 1 mM IPTG for 14-16 hr.  Cells were harvested 
at 5,000 x g and frozen at -80
o
C.  Cell pellets were thawed and resuspended in PBS (100 mM 
NaCl, 7.5 mM Na2HPO4, 2 mM NaH2PO4) and treated with 1 mM PMSF (Sigma-Aldrich) and 
100 µg ml
-1
 egg white lysozyme (Sigma-Aldrich) for 30 min while shaking on ice.  Cells were 
disrupted by repeated sonication for 30 sec bursts on a Branson 250 sonicator (50% duty, 8 
output) until clearing of the suspension was observed.  Crude sonicate was centrifuged at 24,000 
x g for 20 min to clear cell debris, and membranes were isolated by centrifugation at 100,000 x g 
for 45 min.  Membrane pellets were solubilized in a modified 1x TALON (Clontech) buffer (50 
mM Tris-HCL, pH 7; 300 mM NaCl) with 1 % (wt/vol) dodecyl maltoside (DDM, Anatrace) on 
ice for 1 hr.  DDM-solubilized membranes were centrifuged at 24,000 x g for 20 min to remove 
unsolubilized material.  Solubilized membranes (L; load) were passed over TALON resin per the 
manufacturer’s recommendations and washed in 1 x modified TALON buffer with 0.02 % DDM 
with increasing concentrations of imidazole (wash 1 (W1), 0 mM imidazole; wash 2 (W2), 2 mM 
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imidazole; wash 3 (W3), 5 mM imidazole).  Bound hexahistidine-tagged protein was eluted in 1 
x modified TALON buffer containing 0.02 % dodecyl maltoside and 150 mM imidazole (E; 
elution).  Total protein concentration was determined using the Nanodrop 1000 
spectrophotometer (Thermo Scientific).   
Cytochrome Reporter and Imidazole Complementation Assays. Cytochrome c4:His6 production 
was assayed in RK111 (∆ccm carrying the arabinose-inducible chromosomal integrate of the cyt 
c4:His6 gene 
20
) harboring pRGK402 (pGEX ABCDE 
20
) and one of the following pBAD 
ccmF:His6GH plasmids (pRGK434, 435, 436, 437, 438, 439, 440, 441, 442, or 443; see 
Supplemental Table 1).  Starter cultures were initiated from a single colony and grown overnight 
in LB with the appropriate antibiotics.  5 mL of LB was inoculated using 800 mL of starter 
culture and grown for 3 hr, then induced for 3 hr with 0.8 % (wt/vol) arabinose.  Cells were 
harvested by centrifugation at 10,000 x g and the cell pellet was resuspended in 200 µL of BPER 
(Thermo Scientific) to lyse cells and extract protein.  Total protein concentration was determined 
using the Nanodrop 1000 spectrophotometer (Thermo Scientific) and 100 µg was analyzed by 
SDS-PAGE followed by heme stain.  Imidazole complementation assays were performed in the 
same way, with 10 mM imidazole (pH 7) added to the media prior to inoculation.   
Production of antibodies to CcmF.  E. coli CcmF was engineered with a hexahistidine tag as 
described in 
9
, and was expressed from pRGK386 in E. coli strain RK103 
16
.  Cell growth, 
protein expression, and purification were carried out as described above.  Eluted hexahistidine-
tagged CcmF was analyzed by 12.5 % SDS-PAGE and electroeluted from gel fragments over 4-5 
hr at 25 mV into 1x SDS-PAGE buffer (3.5 mM SDS, 50 mM Tris, 384 mM glycine).  Purity of 
the preparations (assessed by Coomassie Blue staining) was greater than 95 %.  Antiserum was 
generated in rabbits at a commercial facility (Cocalico Biologicals).  Antibodies were purified 
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from serum by ammonium sulfate precipitation and adsorbed against crude E. coli extract 
containing all other Ccm proteins.   
Heme stains and other methods.  Heme stains and immunoblots were performed as described 
previously 
16; 31
.  Proteins were separated by 12.5 % SDS-PAGE and transferred to Hybond C 
nitrocellulose membranes (GE Healthcare).  Anti-CcmF antibodies were used at a dilution of 
1:10000, anti-CcmE antibodies at 1:10000, anti-GST antibodies at 1:10000, and anti-CcmH 
antibodies at 1:5000.  Protein A peroxidase (Sigma-Aldrich) was used as the secondary label.  
The chemiluminescent signal for heme stains was developed using the SuperSignal Femto kit 
(Thermo Scientific) or, for immunoblots, the Immobilon Western kit (Millipore), and detected 
with an LAS-1000 Plus detection system (Fujifilm-GE Healthcare).  The abundance of 
holoCcmE was determined by densitometry analysis of the chemiluminescent signal from heme 
stains and anti-CcmE immunoblots using the Science Lab 99-Image Gauge version 3.4 software 
(Fujifilm-GE Healthcare).  Heme concentration in protein preparations was determined by 
pyridine extraction as described in 
32
 or heme staining as described in 
33
.  Protein purity was 
assessed by Coomassie Blue staining of SDS-PAGE.   
UV/Vis absorption spectroscopy.  UV-visible absorption spectra were recorded with a Shimadzu 
UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described previously 
34
.  All spectra were recorded in the same buffer (modified 1x TALON buffer) in which the 
proteins were purified.  Chemically reduced spectra were generated by addition of sodium 
dithionite (sodium hydrosulfite).   
Construction of plasmids.  All oligonucleotide primer sequences, plasmids, and strains are given 
in Table S1.  All oligonucleotides were synthesized by Sigma-Aldrich.  To delete ccmAB from 
pRGK385 (pGEX ∆GH), primers “delABloop_BglII_Fwd” and “delABloop_BglII_Rev” were 
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used to PCR amplify around pRGK385, excluding ccmAB. The resulting PCR product was gel 
purified, digested and re-circularized by ligation at the resulting BglII sites to yield pRGK427 
(pGEX ∆GH delAB).  All nucleotide substitutions were generated using the QuikChange I Site-
Directed Mutagenesis Kit (Agilent Technologies) per the manufacturer’s recommendations.  
Substitutions were engineered into pBAD-based pRGK388 for cytochrome reporter assays, or 
into pGEX-based pRGK385 (pGEX ∆GH) for protein expression and purification.  To engineer 
the double P-His1Ala/P-His2Ala mutation, primers “ccmF_H303A_Fwd” and 
“ccmF_H303A_Rev” were used to introduce the P-His2Ala substitution into pRGK429 (pGEX 
∆GH P-His1Ala).  Each of the final constructs was sequenced to verify the mutation(s).    
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Figures 
Fig 1. Current working model of the system I cytochrome c biogenesis pathway.   
Model includes trafficking and oxidation states of heme as well as apocytochrome translocation 
and reduction. Adapted from (Kranz, Richard-Fogal et al. 2009). 
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Fig 2. The CcmF-holoCcmE complex.  
(A) Coomassie blue staining of purified CcmF:His6 showing 54-kDa CcmF.  (B) Anti-CcmF 
immunoblot of purified CcmF:His6 showing 54-kDa CcmF.  (C) Heme staining of purified 
CcmF showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE.  (D) Anti-CcmE 
immunoblot showing co-purified 20-kDa CcmE.  For (A)-(D), abbreviations are CS, crude 
sonicate; S, soluble fraction; L, load (DDM-solubilized membranes); W1, wash 1; W2, wash 2; 
W3, wash 3; E1, elution 1; E2, elution 2; E3, elution 3; E4, elution 4; M, molecular weight 
standards.  (E) UV-Vis absorption spectra of CcmF-holoCcmE complex as purified (dotted line) 
or reduced with sodium dithionite (solid line). The region from 500-700 nm has been multiplied 
by a factor of 3. (Inset) Sodium dithionite-reduced pyridine hemochrome spectrum of purified 
CcmF-holoCcmE complex from 500-600 nm. Absorption maxima are indicated.  
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Fig 3. HoloCcmE co-purifies with CcmF in the absence of CcmGH.   
(A) Coomassie blue staining of TALON-purified proteins from ∆FGH, ∆EGH, ∆GH, and pSysI 
backgrounds showing purified 54-kDa CcmF.  (B) Anti-CcmF immunoblot of TALON-purified 
proteins showing 54-kDa CcmF.  (C) Anti-CcmH immunoblot of TALON-purified proteins 
showing 34 kDa CcmH.  (D) Heme staining of TALON-purified proteins showing free heme 
(CcmF b-heme) and co-purified 20-kDa holoCcmE.  (E) Anti-CcmE immunoblot of TALON-
purified proteins showing co-purified 20-kDa CcmE.  For (A)-(E), 6 ug purified protein was 
analyzed.  (F) Heme staining of DDM-solubilized membrane fractions from ∆FGH, ∆EGH, 
∆GH, and pSysI backgrounds showing 20 kDa holoCcmE.  (G) Anti-CcmE immunoblot of 
DDM-solubilized membrane fractions showing 20 kDa CcmE.  For (F) and (G), 70 ug total 
protein was analyzed. (H) Quantification of the results of heme staining (holoCcmE) and anti-
CcmE immunoreactivity (total CcmE) from TALON-purified fractions from three independent 
experiments.  (I) Quantification of the results of heme staining and anti-CcmE immunoreactivity 
from DDM-solubilized membrane fractions from three independent experiments.  For (H) and 
(I), percent holoCcmE and total CcmE is relative to ∆GH, which has been set at 100%.  Error 
bars denote SD.  
  
 115 
  
 116 
Fig 4. HoloCcmE must be released from CcmABCD to interact with CcmF.   
(A) Coomassie blue staining of TALON-purified proteins from ∆GH and ∆GH delAB 
backgrounds showing purified 54-kDa full-length CcmF.  (B) Anti-CcmF immunoblot of 
purified CcmF proteins showing 54-kDa full-length CcmF.  (C) Heme staining of purified CcmF 
proteins showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE.  (D) Anti-CcmE 
immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE.  For (A)-(D), 5 ug 
purified protein was analyzed.  (E) Heme staining of DDM-solubilized membrane fractions from 
∆GH and ∆GH delAB backgrounds showing 20 kDa holoCcmE.  (F) Anti-CcmE immunoblot of 
DDM-solubilized membrane fractions showing 20 kDa CcmE.  For (E) and (F), 70 ug total 
protein was analyzed.  (G) Quantification of the results of heme staining (holoCcmE) and anti-
CcmE immunoreactivity (total CcmE) from purified fractions from three independent 
experiments. (H) Quantification of the results of heme staining and anti-CcmE immunoreactivity 
from DDM-solubilized membrane fractions from three independent experiments. For (G) and 
(H), percent holoCcmE and total CcmE is relative to ∆GH, which has been set at 100%.  Error 
bars denote SD.  (I) Coomassie blue staining of purified GST-tagged CcmC from ∆GH delAB 
showing 48-kDa full-length GST-CcmC, 26-kDa GST, and 20 kDa CcmE.  (J) Heme staining of 
purified GST-tagged CcmC showing co-purified 20-kDa holoCcmE.  (K) Anti-GST immunoblot 
of purified GST-tagged CcmC showing 48-kDa full-length GST-CcmC and 26-kDa GST.  (L) 
Anti-CcmE immunoblot of purified GST-tagged CcmC showing co-purified 20-kDa CcmE.  
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Fig 5. ApoCcmE does not co-purify with CcmF.   
(A) Coomassie blue staining of TALON-purified proteins from ∆GH and ∆GH mutE (CcmE 
His130Ala) backgrounds showing purified 54-kDa CcmF.  (B) Anti-CcmF immunoblot of 
purified CcmF proteins showing 54-kDa CcmF.  (C) Heme staining of purified CcmF proteins 
showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE.  (D) Anti-CcmE 
immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE.  For (A)-(D), 5 ug 
purified protein was analyzed.  (E) Heme staining of DDM-solubilized membrane fractions from 
∆GH and ∆GH mutE backgrounds showing 20 kDa holoCcmE.  (F) Anti-CcmE immunoblot of 
DDM-solubilized membrane fractions showing 20 kDa CcmE.  For (E) and (F), 70 ug total 
protein was analyzed.  (G) Quantification of the results of heme staining (holoCcmE) and anti-
CcmE immunoreactivity (total CcmE) from purified fractions from three independent 
experiments.  (H) Quantification of the results of heme staining and anti-CcmE 
immunoreactivity from DDM-solubilized membrane fractions from three independent 
experiments.  For (G) and (H), percent holoCcmE and total CcmE is relative to ∆GH, which has 
been set at 100%.  Error bars denote SD.   
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Fig 6. Topology of the CcmF and CcmH integral membrane proteins from E. coli.   
Possible histidine axial ligands to heme are starred (His173=P-His1; His303=P-His2; 
His261=TM-His1; His491=TM-His2).  The highly conserved WWD domain is shaded as are the 
hydrophobic patches.  Completely conserved amino acids (red) were identified by individual 
protein alignments using CcmF ORFs from selected organisms, as described in (Kranz, Richard-
Fogal et al. 2009).  Diagram is from (Kranz, Richard-Fogal et al. 2009).  
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Fig 7. Maturation of cytochrome c4 in the presence or absence of imidazole.   
Heme staining of B-PER cell extracts showing 24-kDa holocytochrome c4 matured by full 
system I with the indicated substitutions at CcmF P-His1 (A) or P-His2 (B) in the presence or 
absence of 10 mM imidazole added to culture.  P-His1 and P-His2 were each changed to the 
indicated residues.  M, molecular weight standards; C, vector control.  100 ug total protein was 
analyzed.  Quantification of chemiluminescent signal from heme staining of B-PER isolated 
proteins from three independent experiments for P-His1 substitutions (C) or P-His2 substitutions 
(D).  Holocytochrome c4 signal is relative to WT, which has been set at 100%.  Error bars denote 
SD.  ND, no signal detected.   
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Fig 8. CcmF P-His1 and P-His2 are required for co-purification of holoCcmE.   
(A) Coomassie blue staining of TALON-purified proteins from ∆GH, ∆GH (P-His1Ala), ∆GH 
(P-His2Ala), and ∆GH (P-His1Ala/P-His2Ala) backgrounds showing 54-kDa CcmF.  (B) Anti-
CcmF immunoblot of purified CcmF proteins showing 54-kDa CcmF.  (C) Heme staining of 
purified CcmF proteins showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE.  
(D) Anti-CcmE immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE.  For 
(A)-(D), 6 ug purified protein was analyzed.  (E) Heme staining of DDM-solubilized membrane 
fractions from ∆GH and each ∆GH mutant background showing 20 kDa holoCcmE.  (F) Anti-
CcmE immunoblot of DDM-solubilized membrane fractions showing 20 kDa CcmE.  For (E) 
and (F), 70 ug total protein was analyzed.  (G) Quantification of the results of heme staining 
(holoCcmE) and anti-CcmE immunoreactivity (total CcmE) from purified fractions from three 
independent experiments.  (H) Quantification of the results of heme staining and anti-CcmE 
immunoreactivity from DDM-solubilized membrane fractions from three independent 
experiments.  For (G) and (H), percent holoCcmE and total CcmE is relative to ∆GH, which has 
been set at 100%.  Error bars denote SD.   
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Fig 9. CcmF b-heme is required for co-purification of holoCcmE.   
(A) Coomassie blue staining of TALON-purified proteins from ∆GH, ∆GH (TM-His1Ala), and 
∆GH (TM-His2Ala) backgrounds showing 54-kDa CcmF.  (B) Anti-CcmF immunoblot of 
purified CcmF proteins showing 54-kDa CcmF.  (C) Heme staining of purified CcmF proteins 
showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE.  (D) Anti-CcmE 
immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE.  For (A)-(D), 5 ug 
purified protein was analyzed.  (E) Heme staining of DDM-solubilized membrane fractions from 
∆GH and each ∆GH mutant background showing 20 kDa holoCcmE.  (F) Anti-CcmE 
immunoblot of DDM-solubilized membrane fractions showing 20 kDa CcmE.  For (E) and (F), 
70 ug total protein was analyzed. (G) Quantification of the results of heme staining (holoCcmE) 
and anti-CcmE immunoreactivity (total CcmE) from purified fractions from three independent 
experiments.  (H) Quantification of the results of heme staining and anti-CcmE 
immunoreactivity from DDM-solubilized membrane fractions from three independent 
experiments.  For (G) and (H), percent holoCcmE and total CcmE is relative to ∆GH, which has 
been set at 100%.  Error bars denote SD.  
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Fig 10. Mechanisms for formation of holoCcmE and cytochrome c.   
Proposed reaction mechanisms for formation of holoCcmE (His130) (A) and holocytochrome c 
(B).  Noted are the oxidation states of iron (Fe
3+ 
or Fe
2+
); red half arrows are one-electron 
transfers, and full red arrows are two-electron transfers.  Transfer of the proton from the 
imidazolium to the alpha carbon in (A) is probably solvent- or protein-mediated (i.e., the proton 
may be abstracted at an early step, with a solvent- or protein-mediated protonation of the alpha 
carbon occurring at a later step).  Reduction of heme (from Fe
3+
 to Fe
2+
) could favor ejection of 
the CcmE His130 imidazole adduct (reverse blue arrow) and is required for holocytochrome c 
formation.  For simplicity, only a single vinyl of heme is shown.  Adapted from (Kranz, Richard-
Fogal et al. 2009).   
  
 129 
 
 130 
Chapter 4: The CcmFH complex is the system I holocytochrome c synthetase: engineering 
cytochrome c maturation independent of CcmABCDE 
Brian San Francisco and Robert G. Kranz 
Department of Biology, Washington University in St. Louis, St. Louis, MO 63130 
 
 
Submitted for publication to Mol Microbiol (2013) 
 
 
For correspondence: E-mail: kranz@biology.wustl.edu; Tel. (+1) 314 935 4278; Fax (+1) 314 
935 4432.   
Running title: CcmFH is the sytem I holocytochrome c synthetase 
Keywords: cytochrome c maturation, synthetase, heme trafficking, biosynthesis, pathway  
 131 
Summary 
Cytochrome c maturation (ccm) in many bacteria, archaea, and plant mitochondria requires eight 
membrane proteins, CcmABCDEFGH, called system I.  This pathway delivers and attaches 
heme covalently to two cysteines (of Cys-Xxx-Xxx-Cys-His) in the cytochrome c.  All models 
propose that CcmFH facilitates covalent attachment of heme to the apocytochrome; namely, that 
it is the synthetase.  However, holocytochrome c synthetase activity has not been directly 
demonstrated for CcmFH.  We report formation of holocytochromes c by CcmFH and CcmG, a 
periplasmic thioredoxin, independent of CcmABCDE (we term this activity CcmFGH-ind).  
Cytochrome c produced in the absence of CcmABCDE is indistinguishable from cytochrome c 
produced by the full system I, with a cleaved signal sequence and two covalent bonds to heme.  
We engineer increased cytochrome c production by CcmFGH-ind, with yields approaching those 
from the full system I.  Three conserved histidines in CcmF (TM-His1, TM-His2, and P-His1) 
are required for activity, as are the conserved cysteine pairs in CcmG and CcmH.  These findings 
establish that CcmFH is the system I holocytochrome c synthetase, and provide unique 
mechanistic and evolutionary insights into cytochrome c biosynthesis.    
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Introduction 
C-type cytochromes are heme proteins that carry out essential electron transfer reactions 
in organisms from every kingdom of life.  These cytochromes function outside of the 
cytoplasmic membrane in prokaryotes, in the lumen of chloroplasts, and in the intermembrane 
space of mitochondria.  Cytochromes c are characterized by covalent attachment between the 
heme and the apoprotein (via thioether linkages between the 2- and 4-vinyls of heme and two 
thiols of a conserved Cys-Xxx-Xxx-Cys-His motif in the apoprotein).  Because c-type 
cytochromes are assembled at their site of action (separated from heme biosynthesis by a lipid 
bilayer), holocytochrome c formation poses unique challenges to heme trafficking and post-
translational modification.  Three major pathways (called systems I, II, and III) exist in nature to 
direct the covalent attachment of heme to cytochrome c.  In many bacteria, plant and protozoal 
mitochondria, and archaea, holocytochrome c formation is carried out by the cytochrome c 
maturation (ccm) pathway, called system I, which comprises eight membrane proteins (in E. coli, 
CcmABCDEFGH) (Hamel et al., 2009; Kranz et al., 2009; Mavridou et al., 2013; Sanders et al., 
2010; Sawyer and Barker, 2012).   
At the center of heme trafficking in system I is the periplasmic heme chaperone protein, 
CcmE.  CcmE forms a unique and well-studied covalent intermediate with heme, between a 
conserved histidine (His130, in E. coli CcmE) and the β carbon of the heme 2-vinyl (Lee et al., 
2005; Stevens et al., 2003; Uchida et al., 2004).  Heme in “holo” (heme bound) CcmE is 
transferred to the apocytochrome (putatively, by the action of CcmFH), but details of this aspect 
of system I are just emerging.  CcmABCD (an ABC transporter complex) are involved in 
formation and ATP-dependent release of holoCcmE, presumably now free to associate with 
CcmF (Christensen et al., 2007; Feissner et al., 2006a; Goldman et al., 1997; Schulz et al., 
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1999).  CcmF forms an integral membrane complex with CcmH (Rayapuram et al., 2008; Ren et 
al., 2002; Richard-Fogal et al., 2009; Sanders et al., 2008), and is believed to be the site of 
thioether formation between the heme and the apocytochrome.  CcmF contains a separate, stably 
bound non-covalent heme b (Richard-Fogal et al., 2009; San Francisco et al., 2011), which we 
have proposed is involved in reducing the incoming heme from holoCcmE (Kranz et al., 2009; 
Richard-Fogal et al., 2009; San Francisco et al., 2011).  Reduced heme (Fe
2+
) is required for 
thioether formation with the apocytochrome (Barker et al., 1993; Nicholson and Neupert, 1989), 
and reduction of the heme in holoCcmE would also favor discharge of heme from the covalent 
His130 intermediate (Kranz et al., 2009; Richard-Fogal and Kranz, 2010; San Francisco et al., 
2011).  CcmG (Beckman and Kranz, 1993; Di Matteo et al., 2010; Ouyang et al., 2006) and 
CcmH (Di Matteo et al., 2007; Zheng et al., 2012) are membrane-tethered thioredox-active 
proteins that likely maintain the thiol groups of the apocytochrome (in the conserved Cys-Xxx-
Xxx-Cys-His motif) in the reduced state (Meyer et al., 2005; Monika et al., 1997; Setterdahl et 
al., 2000; Turkarslan et al., 2008).     
CcmF (in complex with CcmH) has been referred to extensively as the “cytochrome c 
heme lyase” or “cytochrome c synthetase” of system I, although the assignment of this function 
to CcmF is largely circumstantial.  It is well-established that CcmF forms a complex with CcmH 
(Rayapuram et al., 2008; Ren et al., 2002; Richard-Fogal et al., 2009; Sanders et al., 2008), and 
there is evidence that CcmH interacts directly with the apocytochrome (Di Matteo et al., 2007; 
Di Silvio et al., 2013; Meyer et al., 2005; Verissimo et al., 2011).  However, interaction(s) 
between holoCcmE (the protein assumed to deliver heme to site of thioether formation with the 
apocytochrome) and CcmFH have not been demonstrated (an earlier report only studied 
interaction of apoCcmE with CcmF (Ren et al., 2002), so the physiological significance of this 
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result is unclear).  The absence of direct experimental evidence demonstrating that CcmFH is the 
cytochrome c synthetase thus constitutes a major gap in our understanding of the system I 
pathway.   
Here, we report maturation of holocytochrome c by CcmFH and CcmG, in the absence of 
CcmABCDE.  The cytochrome c produced by the CcmABCDE-independent pathway (here 
termed “CcmFGH-ind”) is biochemically and spectroscopically indistinguishable from 
cytochrome c produced by the full system I, and we engineer production of cytochrome c by the 
CcmFGH-ind pathway at levels approaching those of the full system I.  Three of the conserved 
histidines in CcmF (TM-His1, TM-His2, and P-His1), as well as the conserved cysteine pairs in 
the thioredox proteins CcmG and CcmH, are required for holocytochrome formation by 
CcmFGH-ind. These findings establish that CcmFH is the holocytochrome c synthetase for 
system I (with thioreduction mediated by CcmG).  We discuss evolutionary and mechanistic 
implications, comparing CcmFGH-ind with the system II cytochrome c synthetase, CcsBA.    
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Results 
CcmFH and CcmG mature cytochrome c in the absence of CcmABCDE 
Conceptually, system I occurs in two steps: i) formation and release of holoCcmE (by 
CcmABCD), and ii) heme delivery to CcmFH (by holoCcmE), the putative site of 
holocytochrome c formation (hence, the “cytochrome c synthetase”).  Studies in our lab 
(Feissner et al., 2006a; Goldman et al., 1997; Richard-Fogal and Kranz, 2010; Richard-Fogal et 
al., 2009) and others (Christensen et al., 2007; Ren and Thony-Meyer, 2001) have addressed step 
one, analyzing intermediates during formation of holoCcmE (such as the stable CcmCDE 
complex), and the ATP-dependent release of holoCcmE.  However, less is known about the 
second step.  To study the two steps independently, we engineered the IPTG-inducible pGEX 
with the genes encoding step one of the pathway, ccmABCDE, and an arabinose-inducible 
pBAD-based plasmid with the genes encoding step two, ccmFGH.  Heme staining of BPER cell 
extracts revealed that expression of all Ccm proteins with the arabinose-inducible chromosmally-
integrated cytochrome c4 (San Francisco et al., 2011), led to robust production of 
holocytochrome c4 (Fig 1A, lane 5).  Note that, typically, only heme that is covalently bound 
remains with the cytochrome c after denaturing SDS-PAGE, and this heme is readily detectable 
by heme stain (Feissner et al., 2003).  Surprisingly, we noticed that cells containing only 
CcmFGH (i.e., lacking ccmABCDE), also produced holocytochrome c4 (Fig 1A, lane 4).  Thus, 
it appeared that holocytochrome formation could proceed in the absence of CcmABCDE, albeit 
at levels less than one-tenth those when CcmABCDE were present, under these conditions.  We 
confirmed chromosomal deletion of the ccmA-H operon in our E. coli ∆ccm strains (Feissner et 
al., 2006b; San Francisco et al., 2011) by genomic PCR (Fig S1).   
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The holocytochrome c synthetase activity of CcmFGH-ind is not limited to the di-heme 
cytochrome c4, but also extends to the mono-heme cytochrome c2 (Fig 1B and C, lane 4).  The 
cytochrome c2 plasmid used here has an in-frame C-terminal fusion to E. coli alkaline 
phosphatase (Pho), expressed from an IPTG-inducible promoter (Beckman et al., 1992).  We 
conclude that CcmFGH, in the absence of other Ccm components, can attach heme to two 
unrelated (other than the Cys-Xxx-Xxx-Cys-His motif) cytochrome c substrates.  Furthermore, 
since alkaline phosphatase is secreted to the periplasm, covalent heme attachment to the 
cytochrome c2:Pho fusion protein must occur in the periplasm (i.e., where CcmFGH function).   
Properties of cytochrome c produced by CcmFGH-ind  
We wanted to further characterize the di-heme holocytochrome c4 produced by 
CcmFGH-ind.  To confirm proper periplasmic secretion (and cleavage of the periplasmic signal 
sequence), and to analyze the spectral properties of the cytochrome c produced by CcmFGH-ind, 
we grew 1L cultures and purified hexahistidine-tagged holocytochrome c4 from the soluble 
fraction (Fig 2A-C).  The full-length 24 kDa holocytochrome c4 and the proteolyzed 12 kDa 
holocytochrome c4’ were detectable by Coomassie blue staining of SDS-PAGE (Fig 2A, lane 8 
“E1”).  Note that it is common for endogeneous proteolysis of the 24 kDa cytochrome to occur, 
yielding two 12 kDa mono-heme forms (Feissner et al., 2006b); however, only the C-terminal of 
these products is purified (along with the full-length 24 kDa protein) since the hexahistidine tag 
is at the C-terminus of the protein.  The purified 24 and 12 kDa forms contained covalent heme 
(Fig 2B, lane 8), and reacted with cytochrome c4 antisera (Fig 2C, lane 8).  The UV-Vis 
absorption spectrum (Fig 2D, red line) and reduced pyridine hemochrome (Fig 2D, inset, red 
line) of the purified cytochrome c4 are consistent with two covalent attachments between the 
thiols of cytochrome c (in Cys-Xxx-Xxx-Cys-His) and the vinyls of heme.  The spectral features 
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of cytochrome c4 produced by CcmFGH-ind (e.g., 552-nm absorption maximum in the spectrum 
of the reduced sample, and 550-nm absorption maximum in the reduced pyridine hemochrome 
spectrum) are indistinguishable from those of the cytochrome c4 produced when all system I 
proteins are present (CcmABCDEFGH; Fig 2D, blue line; Fig 2D, inset, blue line).  Mass 
spectral analysis of cytochrome c4 purified from cells expressing CcmFGH-ind or the full 
system I identified species of the expected molecular weights in each preparation (i.e., within 2 
Daltons of the published molecular weights for the full-length holocytochrome c4 and 
proteolyzed holocytochrome c4’ (Feissner et al., 2006b); Fig S2).  This further confirmed 
covalent attachment of heme and proper cleavage of the periplasmic secretion signal (Fig S2B).  
In these large-scale cultures, yields of holocytochrome c via CcmFGH-ind were approximately 
one-sixth those of the full system I.   
Engineering optimal holocytochrome c production by CcmFGH-ind 
 To engineer increased cytochrome c maturation in the absence of CcmABCDE, we 
piloted the following strategies: i) increasing the concentration of inducer (arabinose; “↑ arab” 
condition), ii) raising intracellular heme levels by addition of the heme biosynthetic precursor α-
aminolevulinic acid (ALA; “ALA” condition), iii) decreasing oxygen tension by reduced shaking 
during growth (“↓ rpm” condition), and iv) engineering the cytochrome c4 gene for increased 
expression (by gene dosage) from a single pBAD-based vector, downstream of ccmF:His6GH 
(“p-c4” condition).  Addition of ALA and increasing cytochrome c4 gene dosage led to the 
largest increases in yields of holocytochrome c (Fig 3A, lanes 4 and 6, respectively; Fig 3B, red 
and orange lines; quantified in Fig 3C).  Additively, with each of the four modifications together, 
levels of holocytochrome c4 produced by CcmFGH-ind increased approximately 6-fold (up to 
0.3 mg per L culture), similar to yields of holocytochrome c4 when CcmABCDE are present (Fig 
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3A, compare lanes 7 and 9; Fig 3B, compare light blue and brown lines; quantified in Fig 3C).  
In cells carrying CcmABCDE in the absence of CcmFGH, no holocytochrome c formation was 
detected (Fig 3A, lane 8).  In the presence of CcmABCDE and CcmFGH (i.e., full system I) and 
each of the four modifications described above, yields of cytochrome c4 were approximately 1 
mg per L culture (Fig 3A, lane 10; Fig 3B, top blue line; quantified in Fig 3C).  Analysis of 
membrane fractions by immunoblot confirmed the presence of CcmF and CcmH, respectively 
(except in the strain carrying only pGEX CcmABCDE; Fig 3D and 3E, lane 8), and the absence 
of CcmE (except for those cells carrying pGEX CcmABCDE; Fig 3F).  These results 
demonstrate that, under optimized conditions, CcmFGH-ind is a robust synthetase capable of 
producing substantial levels of periplasmic holocytochrome c.     
The role of conserved histidines in CcmF in CcmFGH-ind 
 CcmF contains four conserved histidine residues: TM-His1 and TM-His2 in 
transmembrane domains 5 and 12, respectively, and P-His1 and P-His2, located in periplasmic 
loops flanking the WWD domain (see Fig 4A).  P-His1 and P-His2 are proposed to ligate heme 
from holoCcmE when it is bound in the WWD domain, en route to covalent attachment to 
apocytochrome c; TM-His1 and TM-His2 are ligands to the stable heme b (San Francisco et al., 
2011), which may play a role in reducing the holoCcmE heme (bound in the WWD domain) 
prior to covalent attachment.  In the context of the full system I, each of the four histidines is 
essential for holocytochrome c formation (Richard-Fogal et al., 2009; San Francisco et al., 
2011).  To test whether holocytochrome c formation via CcmFGH-ind required these four 
histidines, we engineered substitutions at each residue (in pRGK388) and assayed for heme 
attachment to cytochrome c4.  Substitutions at TM-His1, TM-His2, and P-His1 abolished 
holocytochrome formation to undetectable levels, indicating that these residues are absolutely 
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required for heme attachment to cytochrome c via the CcmABCDE-independent pathway (Fig 
5A, lanes 3, 4, and 6; quantified in Fig 5B).  Substitution of P-His2 with glycine supported 
holocytochrome formation at approximately 20 % levels of WT (Fig 5A, lane 5; quantified in Fig 
5B).  This contrasts with the absolute requirement for P-His2 in the context of the full system I 
(i.e., in the presence of CcmABCDE), and may be suggestive of a holoCcmE-specific role for P-
His2 in cytochrome c formation (see Discussion).   
To test whether other substitutions could support holocytochrome formation at P-His1 or 
P-His2, we engineered alanine, cysteine, methionine, or tyrosine substitutions at P-His1 or P-
His2.  While no P-His1 substitution supported holocytochrome c formation (Fig 5C, upper 
panel), we discovered that P-His2Cys supported cytochrome c assembly at approximately 60 % 
WT levels (Fig 5C, lower panel, lane 4; quantified in Fig 5D).  P-His2Ala was similar to 
substitution with glycine (20 % function relative to WT; Fig 5C, lower panel, lane 3; quantified 
in Fig 5D) while methione and tyrosine substitutions were 3 % and 10 % WT levels, respectively 
(Fig 5C, lower panel, lanes 5 and 6; quantified in Fig 5D).  The inability for any engineered 
substitution at P-His1 to support holocytochrome formation indicates that this residue cannot 
vary from the natural histidine, similar to results with full system I.   
Conserved cysteines in CcmG and CcmH are required for CcmFGH-ind 
 CcmG and CcmH each contain a conserved pair of thioredox-active cysteines that are 
required for cytochrome c synthesis in the context of the full system I (Fabianek et al., 1998; 
Fabianek et al., 1999; Robertson et al., 2008).  To test whether holocytochrome c formation by 
CcmFGH-ind required these thioredoxin functions, we engineered serine substitutions at the 
conserved cysteine pairs in CcmG or CcmH and assayed for cytochrome c formation.  Similar to 
the full system I, in the absence of the conserved cysteine pair in either CcmG or CcmH, no 
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holocytochrome formation was observed (Fig 6A, lanes 3 and 4; quantified in Fig 6B).  Thus, the 
redox-active cysteine pairs of CcmG and CcmH are required for holocytochrome c formation via 
CcmFGH-ind.        
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Discussion 
CcmF has been referred to as the “cytochrome c heme lyase” or the “cytochrome c 
synthetase” in nearly every review on system I in the last decade (e.g., (Hamel et al., 2009; 
Kranz et al., 2009; Mavridou et al., 2013; Sanders et al., 2010; Sawyer and Barker, 2012)).  
However, direct experimental evidence demonstrating this activity for CcmF has been lacking.  
Here, we demonstrate that holocytochrome c formation can occur completely (and robustly) in 
the absence of the CcmABCDE components of the system I pathway, thus establishing that the 
cytochrome c synthetase activity of system I inheres in CcmFH (and CcmG).  We suspect that 
the synthetase activity of CcmFH (with CcmG) has gone unnoticed thus far due to challenges in 
expressing these membrane proteins and engineering conditions for optimal biogenesis.  Only of 
late have we been able to express and purify CcmF in sufficient quantities to begin biochemical 
characterization of this protein (Richard-Fogal et al., 2009; San Francisco et al., 2011).  Indeed, 
the discovery that CcmF contained a stable heme b (coordinated by TM-His1 and TM-His2) was 
made only recently (Richard-Fogal et al., 2009).  Thus, we attribute our observation of this 
“new” CcmFGH-ind synthetase activity to our recent ability to successfully modulate expression 
of stable, functional CcmFH and CcmG in E. coli, and control the expression of substrate 
cytochromes c (e.g., the diheme cytochrome c4 and monoheme cytochrome c2 used here).   
Requirements for CcmFGH-ind versus the full system I 
Many of the requirements for cytochrome c assembly by the full system I extend to 
CcmFGH-ind.  In system I, the thio-active proteins CcmG and CcmH each contain a conserved 
pair of cysteines that are required for holocytochrome formation (Fabianek et al., 1998; Fabianek 
et al., 1999; Robertson et al., 2008). CcmG and CcmH are involved in maintaining the thiols of 
the apocytochrome (at Cys-Xxx-Xxx-Cys-His) in the reduced state, which is a requirement for 
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thioether formation with the heme vinyls.  The conserved cysteines in CcmG (which are reduced 
by the membrane protein DsbD) likely function to reduce the thiols of CcmH (Meyer et al., 
2005; Monika et al., 1997; Setterdahl et al., 2000; Turkarslan et al., 2008).  CcmH also has a 
direct apocytochrome binding function (Di Matteo et al., 2007; Di Silvio et al., 2013; Meyer et 
al., 2005; Verissimo et al., 2011), and it is proposed that, via interaction with CcmF, CcmH 
physically positions the apocytochrome (with reduced cysteine thiols) for covalent heme 
attachment (Meyer et al., 2005; Verissimo et al., 2011).  We discovered that mutation of either 
of the cysteine pairs in CcmG or CcmH abolished holocytochrome formation by CcmFGH-ind 
(Fig 6).  The requirement for the conserved redox-active cysteine pairs in CcmG and CcmH 
demonstrates that the CcmFGH-ind pathway is “intact” with regard to handling of the 
apocytochrome.  This suggests that the lower cytochrome c maturation activity of CcmFGH-ind 
(relative to full system I) is likely due to less efficient heme delivery (i.e., the absence of the 
holoCcmE “heme reservoir” (Feissner et al., 2006b); see below).  This finding also highlights the 
significant evolutionary advantage of the full system I.   
Holocytochrome c formation by the full system I requires conserved histidines in CcmF: 
mutation of any of the four (Fig 4A) renders the system non-functional (Ren et al., 2002; 
Richard-Fogal et al., 2009; San Francisco et al., 2011).  We have shown experimentally that TM-
His1 and TM-His2 are ligands to the b-heme (San Francisco et al., 2011), while P-His1 and P-
His2 are proposed to ligate the incoming heme from holoCcmE when it is bound in the WWD 
domain (Kranz et al., 2009; Richard-Fogal et al., 2009; San Francisco et al., 2011).  For 
CcmFGH-ind, we found that TM-His1, TM-His2, and P-His1 were each indispensable for 
holocytochrome formation.  However, CcmFGH-ind was only partially dependent on P-His2 
(Ala or Gly substitutions at this position retained approximately 20 % activity, and Cys, 60 %, 
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relative to WT).  Since these same substitutions show no activity in the context of the full system 
I, we propose that P-His2 may have a function that is specific to the system I heme chaperone, 
holoCcmE.  The lack of a requirement for P-His2 likely reflects the fundamentally different 
mechanism of heme trafficking to the WWD domain in CcmFGH-ind.  Below, we suggest two 
possible trafficking routes for the endogeneous heme that is attached to cytochrome c by 
CcmFGH-ind.     
Similarities between CcmFGH-ind and CcsBA: evolutionary insights 
The assignment of the synthetase (heme lyase) activity of system I to CcmF has been 
based in part on its topological similarity to the cytochrome c synthetase of system II, CcsBA 
(see Fig 4).  System II is present in many gram positive (and other) bacteria, cyanobacteria, and 
the chloroplasts of plants and algae (Ahuja et al., 2009; Simon and Hederstedt, 2011; Xie and 
Merchant, 1998).  CcsBA, when expressed heterologously in E. coli ∆ccm is sufficient for 
assembly of cytochrome c (Feissner et al., 2006b; Frawley and Kranz, 2009; Kern et al., 2010; 
Richard-Fogal et al., 2012); thus, it is the system II holocytochrome c synthetase.  CcsBA is 
proposed to traffick heme across the cytoplasmic membrane, in addition to facilitating thioether 
formation between the heme and apocytochrome (Frawley and Kranz, 2009; Hamel et al., 2003; 
Kranz et al., 2009; Merchant, 2009).  Thus, it is a heme transporter and a holocytochrome c 
synthetase.  The membrane topologies of CcmF and CcsBA are strikingly similar (see Fig 4): 
each contains four completely conserved His residues (two in transmembrane domains, here 
called TM-His1 and TM-His2; and two in extra-cytoplasmic loops, here called P-His1 and P-
His2) and the conserved WWD domain, a hydrophobic, extra-cytoplasmic feature that has been 
shown (in the system I protein CcmC) to interact directly with heme (Richard-Fogal and Kranz, 
2010).  Additionally, both CcsBA (Frawley and Kranz, 2009) and CcmF (Richard-Fogal et al., 
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2009) bind a non-covalent heme b (see Fig 4).  However, in CcsBA, this heme b is ultimately 
attached to cytochrome c, whereas the stable heme b in CcmF (in the context of the full system I) 
may play a role in reducing heme bound in the WWD domain (from holoCcmE).   
The marked similarities between CcmF and CcsBA, coupled with the finding here that 
CcmF (together with CcmH and CcmG) is a cytochrome c synthetase, raise several interesting 
questions.  First, how is heme trafficked to the site of thioether formation with the 
apocytochrome (presumably, at the CcmF WWD domain with axial ligation by P-His1) in 
CcmFGH-ind synthesis?  We envision two possible scenarios: i) heme enters the WWD domain 
of CcmF directly from the cytoplasmic membrane outer leaflet, possibly, (where it is 
subsequently reduced by the transmembrane heme b), or ii) similar to the proposed mechanism 
for CcsBA, the transmembrane heme b may be channeled to the external WWD domain for 
attachment to the apocytochrome.  While experiments addressing these hypotheses will be 
challenging, the possibility that the CcmFGH-ind synthetase may be CcsBA-like (with respect to 
the channeling of heme from the transmembrane binding site to the WWD domain) is intriguing 
from an evolutionary perspective.   
The complex phylogenetic distribution of systems I and II suggest significant lateral 
transfer (Goldman and Kranz, 1998), making it difficult to discern clear evolutionary patterns.  
We have shown previously that system I can mature cytochromes c at 5-fold lower heme 
concentrations than can system II (Richard-Fogal et al., 2007), and that holoCcmE can function 
as a “heme reservoir” (i.e., when heme synthesis is completely inhibited) (Feissner et al., 2006a).  
On the basis of these results, we have speculated that the holoCcmE reservoir aspect of system I 
may have evolved for cytochrome c synthesis under conditions of iron (or heme) scarcity.  The 
ability to use heme at very low levels, and as a reservoir when no iron is present, represents a 
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possible selection advantage.  Since the CcmFGH-ind synthetase lacks the holoCcmE reservoir, 
it might be considered a “prototype” of an intermediate, or a “transition,” on the evolutionary 
path from system II to the full system I.  CcmFGH-ind synthesis thus provides a unique 
opportunity to directly compare holocytochrome c formation (under low heme conditions) by 
system I with and without the holoCcmE reservoir.   
CcmFGH-ind: a viable candidate for in vitro reconstitution  
 One of the remaining challenges in the field of cytochrome c biogenesis is in vitro 
reconstitution of each of the systems for holocytochrome formation.  Reconstitution of the 
synthetase reactions would be especially informative, as they are common to all three major 
pathways.  To date, system II has been a more attractive candidate for in vitro reconstitution than 
system I, since it consists of a single protein complex.  Our findings here demonstrate that the 
system I synthetase (CcmFGH-ind) is now a viable candidate for in vitro reconstitution as well.  
The CcmFGH-ind synthetase activity reported here thus represents a significant advance for the 
field, in terms of the proof of its function, the unique evolutionary and mechanistic insights it 
provides, and the potential for in vitro reconstitution.    
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Experimental Procedures 
Bacterial Growth Conditions.  Unless otherwise noted, Escherichia coli strains (Table S1) were 
grown at 37
o
C by shaking at 230 rpm in Luria-Bertani broth (LB; Difco) supplemented with the 
appropriate antibiotics (Sigma-Aldrich) and other media additives at the following 
concentrations: carbenicillin, 50 µg mL
-1
; chloramphenicol, 20 µg mL
-1
; gentamicin, 10 µg mL
-1
; 
kanamycin, 20 µg mL
-1
; IPTG (Gold Biotechnology), 1 mM; arabinose (Gold Biotechnology), 
0.2 % (wt/vol); ALA (Sigma-Aldrich), 50 µg ml
-1
.    
Protein Expression and Purification.  E. coli ∆ccm strains RK103 (Feissner et al., 2006b) or 
RK111 (∆ccm carrying the arabinose-inducible chromosomal integrate of the cyt c4:His6 gene) 
(San Francisco et al., 2011) (Table S1) were used for expression.  Starter cultures were 
inoculated from a single colony and grown overnight in 10 mL of LB with the appropriate 
antibiotics.  1 L of LB was inoculated with the 10 mL starter culture and grown to an OD600 of 
1.8, then induced with IPTG and/or arabinose for 14-16 hr.  Cells were harvested at 5,000 x g 
and frozen at -80
o
C.  Cell pellets were thawed and resuspended in PBS (100 mM NaCl, 7.5 mM 
Na2HPO4, 2 mM NaH2PO4, pH 7) and treated with 1 mM PMSF (Sigma-Aldrich) and 100 µg ml
-
1
 egg white lysozyme (Sigma-Aldrich) for 30 min while shaking on ice.  Cells were disrupted by 
repeated sonication for 30 sec bursts on a Branson 250 sonicator (50% duty, 8 output) until 
clearing of the suspension was observed.  Crude sonicate was centrifuged at 24,000 x g for 20 
min to clear cell debris, and the soluble and membrane fractions were separated by centrifugation 
at 100,000 x g for 45 min.  Soluble fractions (L; load) were passed over TALON resin per the 
manufacturer’s recommendations and washed in 1 x modified TALON buffer with increasing 
concentrations of imidazole (wash 1 (W1), 0 mM imidazole; wash 2 (W2), 2 mM imidazole; 
wash 3 (W3), 5 mM imidazole).  Bound hexahistidine-tagged protein was eluted in 1 x modified 
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TALON buffer containing 150 mM imidazole (E; elution).  Total protein concentration was 
determined using the Nanodrop 1000 spectrophotometer (Thermo Scientific).  For growth by 
shaking at 120 rpm (“↓ rpm” condition), starter cultures were initiated from a single colony and 
grown overnight in 100 mL of LB with the appropriate antibiotics.  1 L of LB was inoculated 
with the 100 mL starter culture and grown to an OD600 of 1.8, then induced with IPTG and/or 
arabinose for 14-16 hr.  For the “↑ arabinose” condition, expression was induced with 0.4 % 
arabinose rather than 0.2 %.  For the “ALA” condition, 50 µg mL-1 ALA was added to culture at 
the time of induction.  For analysis of crude membrane fractions, membrane pellets (isolated by 
centrifugation at 100,000 x g) were solubilized in a modified 1x TALON (Clontech) buffer (50 
mM Tris-HCL, pH 7; 300 mM NaCl) with 1 % (wt/vol) dodecyl maltoside (DDM, Anatrace) by 
agitation on ice for 1 hr, and then centrifuged at 24,000 x g for 20 min to remove unsolubilized 
material.   
Heme stains and other methods.  Heme stains and immunoblots were performed as described 
previously (Feissner et al., 2003; Feissner et al., 2006b).  Proteins were separated by 12.5 % 
SDS-PAGE and transferred to Hybond C nitrocellulose membranes (GE Healthcare).  For 
immunoblots, anti-CcmF antibodies were used at a dilution of 1:10000, anti-CcmE antibodies at 
1:10000, anti-cytochrome c4 antibodies at 1:10000, and anti-CcmH antibodies at 1:5000.  
Protein A peroxidase (Sigma-Aldrich) was used as the secondary label.  The chemiluminescent 
signal for heme stains was developed using the SuperSignal Femto kit (Thermo Scientific) or, for 
immunoblots, the Immobilon Western kit (Millipore), and detected with an LAS-1000 Plus 
detection system (Fujifilm-GE Healthcare).  The abundance of holocytochrome c4 was 
determined by pyridine extraction as described in (Berry and Trumpower, 1987), or by 
densitometry analysis of the chemiluminescent signal from heme staining using the Science Lab 
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99-Image Gauge version 3.4 software (Fujifilm-GE Healthcare) as described in (Richard-Fogal 
et al., 2007).  Protein purity was assessed by Coomassie Blue staining of SDS-PAGE.   
UV/Vis absorption spectroscopy.  UV-visible absorption spectra were recorded with a Shimadzu 
UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described previously 
(Frawley and Kranz, 2009).  All spectra were recorded in the same buffer (modified 1x TALON 
buffer) in which the proteins were purified.  Chemically reduced spectra were generated by 
addition of sodium dithionite (sodium hydrosulfite).   
Construction of plasmids.  All oligonucleotide primer sequences, plasmids, and strains are given 
in Table S1.  The single pBAD-based plasmid containing ccmF:His6GH and cyt c4:His6 was 
constructed by PCR amplification of the cyt c4:His6 gene (and the upstream RBS) from 
pRGK332 (Feissner et al., 2006b) and insertion of the resulting fragment into the single PstI site 
downstream of ccmF:His6GH in pRGK388 (Richard-Fogal et al., 2009) to create pRGK448.  
The resulting plasmids were screened by restriction digest to confirm correct orientation of the 
insert, and then sequenced.  All substitutions in pRGK388 (i.e., CcmG (Cys80Ser/Cys83Ser), 
CcmH (Cys43Ser/Cys46Ser), CcmF(His261Gly), and CcmF(His491Ala)) were engineered using 
the QuikChange I Site-Directed Mutagenesis Kit (Agilent Technologies) per the manufacturer’s 
recommendations. All oligonucleotides were synthesized by Sigma-Aldrich.  Each of the final 
constructs was sequenced to verify the mutation(s).   
Proteomics analysis.  Proteomics analyses were carried out by the Washington University 
Resource for Biomedical and Bio-organic Mass Spectrometry Facility.  Briefly, TALON-purified 
holocytochrome c4:His6 samples (produced by the full system I or by CcmFGH-ind) were 
loaded onto an Agilent 2.1 X 15 mm C8 Zorbax Cartridge-Column and eluted using a 9.5 min 
gradient with a flow rate of 200 µL/min.  A positive ion mass spectrum was acquired using a 
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Bruker Maxis Q-ToF mass spectrometer equipped with an electrospray ionization source.  
Protein molecular ions were identified with multiple charge states and deconvoluted to identify 
the molecular weight(s) of the main species.     
Genomic PCR.  E. coli strains (WT E. coli K-12 MG1655; ∆ccm (RK103); ∆ccm cyt c4:His6 
chromosomal integrate (RK111); and RK111 carrying pBAD ccmF:His6GH) were streaked onto 
LB plates containing the appropriate antibiotics and incubated at 37 C overnight.  Single colonies 
were resuspended in 100 µL H2O by vortexing, placed at 90 C for 10 min to lyse cells, and 
centrifuged at 16 000 x g for 5 min to remove cell debris.  1 µL of the supernatant (containing 
cellular DNA) was used as the template in each of four PCRs with the following primer sets: A) 
delCcmF-right + delCcmH-left, B) delCcmC-right + delCcmF-left, C) delCcmB-right + 
delCcmE-left, D) menBflank-right + menBflank-left.  Oligonucleotide primer sequences are 
given in Table S1.  PCRs were performed using GoTaq Green Master Mix (Promega) for 25 
cycles, per the manufacturer’s recommendations.  PCR products were visualized by ethidium 
bromide staining of agarose gels (0.8 %).    
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Figures 
Fig 1. CcmFGH attaches heme to cytochrome c in the absence of CcmABCDE.   
(A) Heme staining of BPER cell extracts showing synthesis of 24-kDa holocytochrome c4:His6 
as a function of expression of separate Ccm components, as indicated.  (B) Heme staining and 
(C) anti-cytochrome c2 immunoblot of BPER cell extracts showing synthesis of 106-kDa 
holocytochrome c2:Pho by CcmFGH as a function of induction with IPTG and/or arabinose.  
One hundred µg total protein was loaded in each lane.  MW, molecular weight standards (lanes 
1).   
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Fig 2. Characterization of cytochrome c produced by CcmFGH-ind.   
(A) Coomassie blue staining of purified cytochrome c4:His6 showing full length 24-kDa 
holocytochrome c4 and proteolyzed 12-kDa holocytochrome c4’.  (B) Heme staining of purified 
cytochrome c4 showing 24-kDa and 12-kDa forms.  (C) Anti-cytochrome c4 immunoblot 
showing 24-kDa and 12-kDa holocytochrome c4. For (A)-(C), abbreviations are M, molecular 
weight standards; S, soluble fraction; FT, flow through; W1, wash 1; W2, wash 2; W3, wash 3; 
W4, wash 4; E1, elution 1; E2, elution 2; E3, elution 3.  (D) UV-Vis absorption spectra of 
purified, sodium dithionite-reduced holocytochrome c4 produced by the full system I (blue line) 
or in the absence of CcmABCDE (red line).  (Inset) Sodium dithionite-reduced pyridine 
hemochrome spectrum of purified holocytochrome c4 produced by the full system I (blue line) or 
in the absence of CcmABCDE (red line) from 500-600 nm.  Absorption maxima are indicated.  
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Fig 3. Optimization of holocytochrome c4 produced by CcmFGH-ind.   
(A) Heme staining of TALON-purified proteins showing relative levels of holocytochrome c4 
synthesized for each indicated condition.  “↑ arab,” increase in arabinose from 0.2 % to 0.4 %; 
“ALA,” addition of ALA to 50 µg mL-1; “↓ rpm,” decrease in shaking during growth from 230 
rpm to 120 rpm; “p-c4,” single plasmid system with cytochrome c4 engineered into pBAD 
CcmFGH; “***,” each of the four additives/conditions together. (B) Sodium dithionite-reduced 
pyridine hemochrome spectra of TALON-purified proteins for each condition, from 500-600 nm.  
Absorption maxima are indicated.  (C) Quantification of yields of holocytochrome c4 (based on 
550 nm. absorption in reduced pyridine hemochrome) for each condition from three independent 
experiments.  Error bars denote standard deviation.  ND, none detected.  (D) Anti-CcmF 
immunoblot of DDM-solubilized membrane fractions showing 54-kDa CcmF.  (E) Anti-CcmH 
immunoblot of DDM-solubilized membrane fractions showing 37-kDa CcmH.  (F) Anti-CcmE 
immunoblot of DDM-solubilized membrane fractions showing 20-kDa CcmE.  Labels are as in 
(A).  
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Fig 4.  Topologies of CcmF and CcsBA.   
Topology of the system I CcmF protein from Escherichia coli (A) and the system II CcsBA 
fusion protein from Helicobacter hepaticus (B).  Possible histidine axial ligands to heme are 
starred, and are designated P-His1, P-His2, TM-His1, and TM-His2.  The highly conserved 
WWD domain and the hydrophobic patches are shaded.  Completely conserved amino acids 
(red) were identified by individual protein alignments using CcmF or the CcsB and CcsA ORFs 
from selected organisms, as described in (Kranz et al., 2009).  Diagram is modified from (Kranz 
et al., 2009).   
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Fig 5. Role of conserved His residues in CcmF in CcmFGH-ind.   
(A) Heme staining of purified holocytochrome c4 assembled by WT and site-directed variants of 
CcmF. (B) Quantification of the results of heme staining (24 kDa holocytochrome c4) from 
purified fractions from three independent experiments.  (C) Heme staining of purified 
holocytochrome c4 assembled by WT and the indicated site-directed variants at CcmF P-His1 
(upper panel) or P-His2 (lower panel).  (D) Quantification of the results of heme staining from 
purified fractions from three independent experiments.  For (B) and (D), synthesis of 
holocytochrome c4 is relative to WT, which has been set at 100 %.  Error bars denote standard 
deviation. ND, none detected.  
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Fig 6. Conserved cysteines in CcmG and CcmH are required for CcmFGH-ind.   
(A) Heme staining of purified holocytochrome c4 assembled by WT and the indicated site-
directed variants at CcmG and CcmH.  “Gmut” is a Cys80Ser/Cys83Ser double mutant, and 
“Hmut” is a Cys43Ser/Cys46Ser double mutant.  (B) Quantification of the results of heme 
staining (24 kDa holocytochrome c4) from purified fractions from three independent 
experiments. Synthesis of holocytochrome c4 is relative to WT, which has been set at 100 %.  
ND, none detected.   
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Supplementary Material 
Fig S1. Confirmation of ∆ccm by genomic PCR.   
Ethidium bromide staining of the products from 4 separate PCRs using the indicated genomic 
DNA templates.  Primer sets A, B, and C anneal to different regions of the ccm operon (panel C), 
and control primer set D anneals to regions flanking E. coli menB.  For WT E. coli, all PCRs 
yielded products of the expected sizes (panel A, lanes 1-4).  No products corresponding to the 
ccm operon were detected for any of the ∆ccm strains (panels A and B), with the exception of 
primer set A for strain ∆ccm c4:His6 int + pBAD CcmF:His6GH, as expected since this strain 
carries the ccmFGH genes on a plasmid.  PCRs using control primer set D yielded products of 
the expected size for each strain.  This confirms that our ∆ccm strains lack the endogeneous 
genes for cytochrome c synthesis; therefore, holocytochrome c formation in these strains is 
completely dependent on plasmid-based expression of the ccm genes.  Lanes 5 and 10 in (A) and 
(B) contain MW markers; bp indicates base pairs.   
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Fig S2. Mass spectral analysis of holocytochrome c4:His6. 
Mass spectral analysis of holocytochrome c4:His6 produced by CcmFGH in the presence (A) or 
absence (B) of CcmABCDE.  After deconvolution of the positive ion mass spectra, two species 
were identified from each sample with the indicated molecular weights (each was within 2 
Daltons of the reported average masses for full length holocytochrome c4:His6 and proteolyzed 
holocytochrome c4:His6’, respectively).  (C) Amino acid sequence of the Bordetella pertussis 
cytochrome c4:His6.  The signal sequence is underlined and heme attachment sites (Cys-Xxx-
Xxx-Cys-His) are in bold.  Arrows indicate the periplasmic signal cleavage site and the site of 
endogeneous proteolysis giving rise to holocytochrome c4:His6’.  The presence of identical 
molecular weight species in preparations of holocytochrome c4:His6 produced by full system I 
and by CcmFGH-ind confirms proper cleavage of the cytochrome c4 periplasmic secretion 
sequence, and covalent attachment of heme.    
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Table S1. Strains, plasmids, and oligonucleotide primers 
Strain Description Reference 
RK103 MG1655 ∆ccm (Feissner et al., 2006) 
RK111 MG1655 ∆ccm cyt c4:His6 chromosomal integrate (San Francisco et al., 2011) 
  
Plasmid Description Reference 
-- pUCA6 cyt c2:Pho (Beckman et al., 1992) 
pRGK332 pBAD cyt c4:His6 (Feissner et al., 2006) 
pRGK388 pBAD ccmF:His6GH (Richard-Fogal et al., 2009) 
pRGK402 pGEX ccmABCDE (San Francisco et al., 2011) 
pRGK434 pBAD ccmF(His173Ala):His6GH (San Francisco et al., submitted) 
pRGK435 pBAD ccmF(His173Gly):His6GH (San Francisco et al., submitted) 
pRGK436 pBAD ccmF(His173Cys):His6GH (San Francisco et al., submitted) 
pRGK437 pBAD ccmF(His173Met):His6GH (San Francisco et al., submitted) 
pRGK438 pBAD ccmF(His173Tyr):His6GH (San Francisco et al., submitted) 
pRGK439 pBAD ccmF(His303Ala):His6GH (San Francisco et al., submitted) 
pRGK440 pBAD ccmF(His303Gly):His6GH (San Francisco et al., submitted) 
pRGK441 pBAD ccmF(His303Cys):His6GH (San Francisco et al., submitted) 
pRGK442 pBAD ccmF(His303Met):His6GH (San Francisco et al., submitted) 
pRGK443 pBAD ccmF(His303Tyr):His6GH (San Francisco et al., submitted) 
pRGK444 pBAD ccmF(His261Gly):His6GH This work 
pRGK445 pBAD ccmF(His491Ala):His6GH This work 
pRGK446 pBAD ccmF:His6G(Cys80Ser/Cys83Ser)H This work 
pRGK447 pBAD ccmF:His6GH(Cys43Ser/Cys46Ser) This work 
pRGK448 pBAD ccmF:His6GH—cyt c4:His6 This work 
 
Primer Sequence (5’-3’) Purpose 
C4:His_PstI_RBS_Fwd GATCTGCAGAGGAGGAATATCATATGAAGCGTGTGCTGTCCCGG pRGK448 
C4:His_PstI_Rev GATCTGCAGTCAGTGGTGGTGGTGGTGGTG pRGK448 
ccmG_C80A/C83A_Fwd CTGGGCGACCTGGGCTCCGACCGCCCGTGCGGAACAT pRGK446 
ccmG_C80A/C83A_Rev ATGTTCCGCACGGGCGGTCGGAGCCCAGGTCGCCCAG pRGK446 
ccmH_C43A/C46A_Fwd CTCACTGAAGAACTGCGCGCCCCGAAAGCCCAGAACAACAGCATTGC pRGK447 
ccmH_C43A/C46A_Rev GCAATGCTGTTGTTCTGGGCTTTCGGGGCGCGCAGTTCTTCAGTGAG pRGK447 
ccmF_H261G_Fwd GGACTGCGCTGATGGGCTCACTGGCGGTCA pRGK444 
ccmF_H261G_Rev TGACCGCCAGTGAGCCCATCAGCGCAGTCC pRGK444 
ccmF_H491A_Fwd GGGATGGTGGCGGCTGCCCTTGGGCTGGC pRGK445 
ccmF_H491A_Rev GCCAGCCCAAGGGCAGCCGCCACCATCCC pRGK445 
A.Fwd (delCcmF_right) GCCGGAGGCCATATGAAGCGCAAAGTATTGTTA gPCR 
A.Rev (delCcmH_left) GCGCCAATAAAAAGCTTATTGTGCGGCCTCCTT gPCR 
B.Fwd (delCcmC_right) AAGAGGCCGCATATGACCCCTGCATTTGCTTCC gPCR 
B.Rev (delCcmF_left) CCGAATTCTGGCATCATATGGCTGGGTCCTTAT gPCR 
C.Fwd (delCcmB_right) GGTATCGAACATATGAGGAAAACACTGCATCAACT gPCR 
C.Rev (delCcmC_left) AGTGTTTTCCACATATGTTCGATACCAGACTCG gPCR 
D.Fwd (menBflank_right) CGCAGGCAAACATACAGCCC gPCR 
D.Rev (menBflank_left) CGGACATAACGCGCATCGG gPCR 
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Abstract 
Proper functioning of the mitochondrion requires the orchestrated assembly of respiratory 
complexes with their cofactors.  Cytochromes c, essential electron carriers in mitochondria and 
critical components of the apoptotic pathway, contain a heme cofactor covalently attached to the 
protein at a conserved CXXCH motif.  While it has been known for over two decades that heme 
attachment requires the mitochondrial protein holocytochrome c synthase (HCCS), the 
mechanism has remained unknown.  We purified the membrane-bound human HCCS with 
endogenous heme, and in complex with its cognate human apocytochrome c.   Spectroscopic 
analyses of HCCS alone and complexes of HCCS with site-directed variants of cytochrome c 
revealed the fundamental steps of heme attachment and maturation.  A conserved histidine in 
HCCS (His154) provided the key ligand to the heme iron.  Formation of the HCCS:heme 
complex served as the platform for interaction with the apocytochrome c.  Heme was the central 
molecule mediating contact between HCCS and apocytochrome c.  A conserved histidine in 
apocytochrome c (His19 of CXXCH) supplied the second axial ligand to heme in the trapped 
HCCS:heme:cytochrome c complex.  We also examined the substrate specificity of human 
HCCS and converted a bacterial cytochrome c into a robust substrate for the HCCS.  The results 
allow us to describe the molecular mechanisms underlying the holocytochrome c synthase 
reaction. 
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Introduction 
Renewed interest in mitochondria stems from recent associations of malfunctioning 
mitochondria with many cancers (1), neurological diseases (2-4), and even reduced life span (5).  
The basis for these associations lies in the respiratory chains that power aerobic life.  Three-
dimensional structures for many respiratory complexes and carriers (6-8) have elucidated the 
detailed mechanisms of electron transport, proton pumping, the reduction of oxygen to water, 
and ATP formation.  Less is known about the biogenesis of these respiratory chain components.  
The synthesis and insertion of cofactors (e.g., heme and metals) into large, multi-subunit 
membrane complexes represents a new frontier in the study of mitochondrial function.  C-type 
cytochromes, among the best-studied players in mitochondrial electron transport (9, 10), are 
redox active heme proteins whose biosynthesis is only just emerging.  Cytochrome c is a soluble 
electron carrier in the intermembrane space (IMS) of mitochondria that functions in electron 
transport between the quinol:cytochrome c oxidoreductase (complex III, or cytochrome bc1) and 
the cytochrome c oxidase (complex IV, or cytochrome a/a3).  In addition to its role in 
mitochondrial respiration, cytochrome c plays a crucial role in apoptotic signaling (11).  A 
second, membrane-bound c-type cytochrome, cytochrome c1, is an integral part of complex III.   
Cytochromes c differ from other cytochromes in that the heme is covalently attached to 
the protein via two thioether linkages between the heme vinyls and two cysteine residues of a 
conserved CysXxxXxxCysHis (CXXCH) heme binding motif.  Two major pathways have been 
identified for the biogenesis of cytochromes c in mitochondria: CCM (cytochrome c maturation) 
(12-15) and CCHL (cytochrome c heme lyase), also called HCCS (holocytochrome c synthase, 
which will be used here) (16, 17).  The CCM system is composed of eight or nine integral 
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membrane proteins and functions in the mitochondrial inner membrane of plants and some 
protozoa, as well as the cytoplasmic membranes of alpha- and gamma-proteobacteria (18).  Most 
mitochondria (e.g., those of fungi, invertebrates, vertebrates, and some protozoa) use HCCS for 
synthesis of cytochrome c.  In fungi, there are two related homologs, HCCS and HCC1S, 
dedicated to maturation of cytochrome c and cytochrome c1, respectively (19, 20), whereas in 
animals a single HCCS enzyme is active toward both cytochrome c and cytochrome c1 (17, 21).  
Additionally, in yeast and other fungi, the FAD-containing protein Cyc2p is required for heme 
attachment to apocytochrome c (22-24).   
The human HCCS has been increasingly implicated in disease.  For example, 
chromosomal mutations in the gene encoding HCCS can lead to a condition called 
microphthalmia with linear skin defects syndrome (MLS; (25, 26)).  Additionally, a role for 
HCCS in apoptosis (separate from that of cytochrome c) has been described in injured motor 
neurons (27).  Despite the identification of HCCS as the gene product responsible for heme 
attachment to cytochrome c in S. cerevisiae over twenty-five years ago (19), the enzyme has 
never been purified or characterized and the mechanism of covalent heme attachment is 
unknown (16, 17).  In yeast, HCCS is nuclear-encoded and is imported directly into the 
mitochondrial IMS from the cytosol via the translocase of the outer membrane (TOM) complex 
(20, 28, 29).  Studies in S. cerevisiae have shown that HCCS is membrane-associated in 
mitochondria and is exposed to the IMS (28-30).  The apparent absence of transmembrane 
helices suggests that membrane association is likely peripheral.  Pioneering studies by Neupert 
and Sherman and colleagues have demonstrated that HCCS also plays an essential role in the 
import of the apocytochrome c from the cytosol to the mitochondrion (30-33).  It is unknown 
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how heme enters the IMS from its site of synthesis in the mitochondrial matrix, although early 
studies showed that reduced heme (Fe
2+
) is necessary for covalent attachment to cytochrome c 
(34, 35).  Preliminary genetic results suggested that heme binding by HCCS occurred at partially 
conserved “Cys-Pro” sequences (36), which serve as heme-regulatory motifs in several other 
proteins.  However, neither of the Cys-Pro sequences in S. cerevisiae HCCS is required for heme 
attachment to cytochrome c (37), and several HCCS proteins lack Cys-Pro sequences entirely.   
Both the mechanism by which HCCS mediates covalent heme attachment to the 
apocytochrome, and the specificity determinants for recognition of heme and the apocytochrome 
c are poorly understood.  Recombinant systems for production of mitochondrial cytochromes c in 
E. coli, developed by Mauk and colleagues (38), have facilitated some progress in this regard 
(e.g., (39-41)) (see SI Appendix, Table S1).  The N-terminal region of the apocytochrome c 
substrate (including the CXXCH motif) is important for recognition by S. cerevisiae HCCS 
(reviewed in (16)), and a few residues in this region have been identified as important for 
holocytochrome c maturation (42, 43).  However, the features of the cytochrome c substrate that 
are recognized by the human HCCS have never been examined.  Here, we report successful 
purification and characterization of the human holocytochrome c synthase from recombinant E. 
coli.  The human HCCS is membrane associated and is purified with endogenous heme 
coordinated by conserved His154.  We define the amino acids in the human cytochrome c that 
are required for holocytochrome c formation by HCCS, and we successfully convert a non-
substrate cytochrome c, cytochrome c2 from the alpha-proteobacterium Rhodobacter capsulatus, 
into a robust substrate for the human HCCS by introducing three sequence alterations.  Finally, 
we report purification of trapped heme-containing complexes between cytochrome c and HCCS, 
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with heme ligands coming from His19 (of the CXXCH motif) in cytochrome c and His154 of 
HCCS.  We show that mutation of either Cys in the conserved CXXCH motif of the cytochrome 
c leads to accumulation of trapped cytochrome c, with a single covalent attachment to the 
remaining cysteine, on the HCCS enzyme.  Our results suggest mechanisms for heme binding, 
interaction with apocytochrome c, thioether formation, and a requirement for release of mature 
holocytochrome c from HCCS.     
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Results 
Purified human HCCS contains heme.   
Despite longstanding interest in HCCS, the enzyme has remained refractile to successful 
purification and biochemical characterization(e.g., (43-45)).  To address this, we engineered the 
cDNA for the human HCCS in three different vectors (pET Blue-2 with an N-terminal His6 tag, 
pTXB1 with a C-terminal Intein fusion, and pGEX with an N-terminal GST fusion) for 
expression and purification in E. coli.  Early attempts at purifying HCCS from cytoplasmic 
fractions were largely unsuccessful for each of the above constructs.  However, upon 
fractionation of E. coli expressing GST-HCCS, we observed that the membrane fraction 
appeared to be enriched for a polypeptide of 57 kDa, the predicted molecular weight for the 
GST-HCCS fusion protein (SI Appendix, Fig S1).  Thus, we directed our efforts towards 
purifying human HCCS from membranes, by solubilization in n-dodecyl β-D-maltopyranoside 
(DDM) (Fig 1A, B, C) or Triton X-100.  Purified full-length GST-HCCS (~57 kDa) and three 
minor proteolytic products each reacted with GST antisera (Fig 1B, lane 9).  Note that soluble 
(cytoplasmic) fractions contained mostly the degraded products and very low levels of full-
length GST-HCCS (Fig 1B, lane 2).  Densitometry analysis indicated that over 98 % of the 
purified, Coomassie-stained protein from the membrane fraction was GST-HCCS.  Analysis by 
LC-MS/MS confirmed that the 57 kDa species was the GST-HCCS fusion protein (SI Appendix, 
Fig S2).  To test the function of human HCCS, it was co-expressed with an arabinose-inducible 
gene encoding the human cytochrome c.  Maturation of the 12 kDa holo-cytochrome c (Fig 1D) 
confirmed that the GST-HCCS fusion protein was active in heme attachment to cytochrome c 
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(see below).  Approximately 3-4 mg of human holocytochrome c was produced per liter of E. 
coli culture.   
Preparations of purified GST-HCCS were tinted red, and heme-staining revealed that 
full-length GST-HCCS contained heme (Fig 1C, lane 9).  Heme proteins exhibit characteristic 
absorptions in the UV and visible regions of the spectrum, referred to as the α, β, and Soret 
bands.  These spectral features can provide information about the identity of the axial ligands, 
and the spin and oxidation states of the heme iron (46).  Purified human HCCS showed a Soret 
peak at 423 nm and three broad shoulders at 540 nm, 570 nm, and 660 nm (Fig 1E, black line).  
Longer wavelength Soret absorptions (like 423 nm) are often characteristic of hexacoordinate, 
reduced heme (Fe
2+
) (46).  Addition of the reducing agent sodium dithionite to purified GST-
HCCS caused no shift in the Soret maximum.  However, the Soret band sharpened (due to loss of 
its lower-wavelength shoulder) and absorbance increased, along with the appearance of small 
peaks at 559 nm and 530 nm (Fig 1E, red line).  These spectral features, in combination with the 
556 nm absorption in the reduced pyridine hemochrome spectrum (Fig 1E, inset) (47), are 
consistent with non-covalent, or b-type, heme.  Since some heme remains with HCCS upon 
SDS-PAGE (Fig 1C), we cannot absolutely rule out the possibility that some heme may be 
covalently bound.  However, our spectral results and the detection of variable amounts of free 
heme in heme stains lead us to favor that heme in HCCS is b-type.  Addition of the oxidizing 
agent ammonium persulfate to purified GST-HCCS caused the Soret band to shift 13 nm to 410 
nm, a wavelength typical of hexacoordinate, oxidized heme (Fe
3+
), and diminished the shoulders 
at 540 nm, 570 nm, and 660 nm (Fig 1E, blue line).  These observations suggest a mixture of 
oxidized heme and hexacoordinate, reduced heme in purified GST-HCCS.     
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To further interrogate the heme-binding environment in HCCS, exogenous imidazole was 
added to purified GST-HCCS and UV-Vis absorption spectra were recorded.  Imidazole is the 
side-chain of histidine, and is often used to probe heme-ligand interactions in vitro (e.g., (48, 
49)).  Upon addition of 100 mM imidazole, the Soret peak shifted from 423 nm to 413 nm (Fig 
1F, purple line).  Subsequent addition of sodium dithionite to GST-HCCS in the presence of 
imidazole (Fig 1F, red line) caused a shift in the Soret from 413 nm to 422 nm, and resulted in 
the appearance of pronounced absorptions at 530 nm and 559 nm.  These spectral features are 
hallmarks of hexacoordinate reduced heme with bis-His axial ligation but are rarely observed in 
hemes with His-Cys, His-Tyr, or His-Met axial ligation (50-52).  These observations are 
consistent with at least one natural histidine axial ligand in HCCS, and an unknown axial ligand 
(possibly a small molecule) that can be replaced by exogenous imidazole.   
His154 is a heme ligand in HCCS.   
There are two histidines (His154 and His211 in human HCCS) conserved in HCCSs from 
a wide variety of organisms (SI Appendix, Fig S3).  Given the established role of His residues as 
axial heme ligands, and our spectroscopic analyses of pure HCCS, we reasoned that one or both 
of these histidines might coordinate heme in HCCS.  We engineered substitutions of each His 
residue and, to test the function of the resulting HCCS variants, co-expressed each with WT 
human cytochrome c in E. coli ∆ccm (Fig 2A, top panel).  HCCS His154 is essential for heme 
attachment; mutation to Ala, Gly, or Tyr completely abolished synthesis of human 
holocytochrome c (Fig 2A, top panel, lanes 1-3).  For His211, substitutions showed only minor 
effects on heme attachment (Fig 2A, top panel, lanes 5-8).   
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To further investigate the function of His154, we tested whether the cytochrome c 
assembly defect of the His154 mutants could be restored by addition of exogenous imidazole to 
E. coli culture.  In vivo chemical complementation by imidazole has been used to correct the 
heme binding function of histidine mutants for recombinant myoglobin (53), and the cytochrome 
c synthetases CcsBA (54) and CcmF (55).  Addition of 10 mM imidazole restored the 
cytochrome c assembly defects of the H154A and H154G HCCS mutants to approximately 40 % 
of WT levels (Fig 2A, bottom panel, lanes 1 and 2) but HCCS H154Y was not corrected (lane 3).  
This is consistent with our previous findings on correction of His mutants in CcmF (55), which 
showed that amino acids with bulkier side chains (like tyrosine) do not accommodate imidazole 
in the heme binding “cavity,” and thus are not functionally complemented.  For the His211 
substitutions in HCCS, imidazole addition had no effect on cytochrome c assembly (Fig 2A, 
bottom panel, lanes 5-8).  To directly test whether His154 was required for binding of heme to 
HCCS, we expressed and purified the non-functional GST-HCCS(H154A) (Fig 2B and C).  
GST-HCCS(H154A) was purified as a stable polypeptide with yields similar to the WT GST-
HCCS, but GST-HCCS(H154A) contained no detectable heme by heme stain (Fig 2D, lane 9) or 
UV-Vis absorption spectroscopy (Fig 2E, orange line).  We conclude that His154 is an axial 
ligand to the heme iron in HCCS.     
Key determinants in human cytochrome c for maturation by the human HCCS.   
 To define the apocytochrome c substrate requirements of the human HCCS, we utilized 
the IPTG-inducible human GST-HCCS and a compatible, arabinose-inducible pBAD plasmid 
carrying the human cytochrome c.  Based on previous studies with S. cerevisiae HCCS (see SI 
Appendix, Table S1) we focused on several conserved residues in the amino-terminus of the H. 
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sapiens cytochrome c (Lys6, Phe11, Cys15, Cys18, and His19; see Fig 3A, bolded residues).  
Throughout our report we refer to the initiation methionine of human cytochrome c as residue 1.  
Cell extracts of recombinant E. coli expressing both human HCCS and cytochrome c were 
assayed for covalent heme attachment (to human cytochrome c) by SDS-PAGE followed by 
heme stain (Fig3B, C) and UV-Vis absorption spectroscopy (Fig 3D).  In the absence of HCCS, 
no holocytochrome c was detected by heme stain (Fig 3B, lane 10) or spectrally (Fig 3D, vector 
control).  Co-expression of human HCCS and cytochrome c resulted in the production of a 12 
kDa holocytochrome c (Fig 3B, lane 11) that showed a UV-Vis absorption spectrum consistent 
with covalent heme attachment, based on the typical α maximum at 550 nm (Fig 3D, WT).  
Replacement of Lys6 with Ala, Arg, or Asp did not impair maturation of human cytochrome c 
(Figs 3B, C, and D).  Substitution of Phe11 with Ala impaired heme attachment to cytochrome c 
by approximately 75 % relative to WT under these conditions (Figs 3B and C).  Human 
cytochrome c1 contains a Tyr residue instead of the Phe at this position (Fig 3A); to test whether 
Tyr could substitute for Phe in human cytochrome c, we engineered a Tyr substitution at Phe11.  
Co-expression of the F11Y variant with human HCCS resulted in levels of heme attachment 
equal to WT cytochrome c (Fig 3B and C), and the peak at 550 nm in the UV-Vis absorption 
spectrum confirmed covalent heme attachment (Fig 3D).  We also engineered substitutions at the 
two Cys residues and the single His residue of the CXXCH motif (Cys15, Cys18, and His19) in 
human cytochrome c.  The C15S and C18A substitutions were matured at approximately 8 % 
and < 3 % of WT levels, respectively (Fig 3B and C).  Substitution of Ala for His19 resulted in 
undetectable levels of cytochrome c (Fig 3B and C).   
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 Our results with regard to the importance of Phe11 differ somewhat from two previous 
studies which showed that an F11A variant of cytochrome c was not detectably matured by S. 
cerevisiae HCCS in the E. coli cytoplasm (42, 43).  This could be due to the broader substrate 
specificity of the human HCCS relative to the S. cerevisiae HCCS.  In S. cerevisiae, there are 
two related homologs, HCCS and HCC1S, that are dedicated to maturation of cytochrome c and 
cytochrome c1, respectively, whereas in humans (and all animals), a single HCCS matures both 
the mitochondrial cytochrome c and cytochrome c1. 
Requirements for recognition of bacterial cytochromes c by the human HCCS.  
 Previous studies have shown that S. cerevisiae HCCS is unable to mature certain 
bacterial cytochromes c (44) despite the structural and functional similarities to the 
mitochondrial cytochrome c (SI Appendix, Fig S4).  Recently, it was shown that a chimeric 
cytochrome c composed of the N-terminal 18 amino acids of yeast cytochrome c followed by the 
C-terminal region of cytochrome c550 from Paracoccus denitrificans (including the CXXCH 
motif from P. denitrificans) could be matured by S. cerevisiae HCCS (43).  Using the R. 
capsulatus cytochrome c2, where the methionine start codon of the human cytochrome c is the 
engineered initiation codon (Fig 4A), holo-cytochrome c2 was not detected above background 
levels upon co-expression with the human HCCS (Fig 4B, lane 1).  A notable difference between 
the N-terminal sequences of R. capsulatus cytochrome c2 and human cytochrome c is the amino 
acid spacing between the conserved Phe (Phe11 in human cytochrome c) and the CXXCH motif 
(refer to boxed region in Fig 4A).  To test whether a three-residue spacing is a requirement for 
recognition by human HCCS, we engineered an Ala insertion between Asn11 and Lys12 (human 
numbering) in R. capsulatus cytochrome c2 and co-expressed it with the human HCCS (in E. coli 
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∆ccm).  Analysis of cell extracts by heme stain showed that cyt c2(Ala-ins) was also not matured 
(Fig 4B, lane 3).   
An additional difference between R. capsulatus cyt c2 and human cytochrome c is the 
local charge in the region preceding the conserved Phe (Fig 4A); specifically, cytochrome c2 
contains two negatively charged Glu residues (Fig 4A, bolded residues).  We engineered E8K 
and E10I substitutions in the WT cyt c2 and the cyt c2(Ala-ins) variant.  Co-expression of cyt 
c2(E8K/E10I/Ala-ins) with the human HCCS led to the production of high levels of a 13 kDa 
species with covalent heme (Fig 4B, lane 6; Fig 4D).  Immunoblotting with cytochrome c2 
antisera confirmed that this covalent heme species was R. capsulatus cytochrome c2 (Fig 4C, 
lane 7).  UV-Vis absorption spectra confirmed covalent heme attachment to cyt 
c2(E8K/E10I/Ala-ins) (Fig 4E).  Approximately 1-2 mg of holocytochrome c2(E8K/E10I/Ala-
ins) was produced per liter of E. coli culture.  By contrast, cyt c2(E8K/E10I), containing its 
natural two-residue spacing between Phe11 and CXXCH, was not matured (Fig 4B, lane 2; Fig 
4D).  We also engineered each single Glu substitution into cyt c2(Ala-ins) to generate cyt 
c2(E8K/Ala-ins) and cyt c2(E10I/Ala-ins), and although both cyt c2(E8K/Ala-ins) and cyt 
c2(E10I/Ala-ins) were matured at higher levels than WT cyt c2 (Fig 4B, lanes 4 and 5; Fig 4D), 
neither was as high as the double substitution.     
While our manuscript was in preparation, a report was published on the conversion of R. 
capsulatus cytochrome c2 into a substrate for S. cerevisiae HCCS (56), with results that are 
consistent with our findings utilizing the human HCCS.  In their study, a Lys insertion was 
engineered (instead of an alanine) and Glu10 was replaced with Leu (instead of Ile).  Our results 
here indicate that positively charged and neutral residues at positions 8 and 10, respectively, and 
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proper spacing between Phe11 and CXXCH, constitute the minimal determinants for maturation 
by human HCCS.  We describe evolutionary implications of these results in Supporting 
Information (see SI Appendix).   
HCCS co-purifies with human cytochrome c.   
To further investigate interactions between HCCS and the substrate cytochrome c, we co-
expressed several of the human cytochrome c variants (F11A, C15S, C18A, H19A) or WT 
cytochrome c with the human HCCS and analyzed the soluble and membrane fractions.  We 
noticed that the detergent-solubilized membrane fractions from cells expressing the C15S or the 
C18A cytochrome c variant (along with HCCS) had higher levels of holocytochrome c than the 
soluble fractions (see SI Appendix, Fig S5C and D, lanes 3, “L” fractions).  Membrane fractions 
from cells expressing the WT, F11A or H19A variants of cytochrome c contained low levels of 
holocytochrome c (see SI Appendix, Fig S5A, B, E, lanes 3, “L” fractions).   
To investigate whether the apparent membrane localization of the cytochrome c variants 
was related to the association of HCCS with the E. coli membrane, we purified GST-HCCS and 
analyzed each preparation for the presence of the human cytochrome c.  In each case, GST-
HCCS was purified from detergent-solubilized membranes as a stable polypeptide with minimal 
degradation (Fig 5A).  In addition to the full-length GST-HCCS fusion protein (~57 kDa) we 
observed in the elution fraction a 12 kDa polypeptide of the molecular weight for cytochrome c 
(SI Appendix, Fig S6A).  Analysis by LC-MS/MS (SI Appendix, Fig S7) and immunoblotting 
with cytochrome c antisera (Fig 5B) confirmed that cytochrome c co-purified with GST-HCCS.  
Table I quantifies the heme and apocytochrome bound in each complex, and summarizes the 
spectral properties of each complex.  Heme staining after SDS-PAGE revealed that the WT 
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cytochrome c and each of the variants contained heme, although at very low levels for the H19A 
variant (Fig 5C).  Covalent heme attachment to the 12 kDa cytochrome c was confirmed by 
retention of the heme through SDS-PAGE after boiling and treatment with 8 M urea (SI 
Appendix, Fig S8).  HCCS complexes with C15S and C18A variants contained approximately 8-
fold more heme than HCCS alone, and the WT, F11A, and H19A complexes contained 
approximately 4-fold more heme (Table 1, column C).  Total heme in each complex was 
proportional to the amount of cytochrome c polypeptide bound in each complex (Table 1, 
column B), suggesting that the interaction of HCCS with heme is stabilized by the presence of 
the cytochrome c acceptor.  To determine the role of heme in formation of the complex between 
HCCS and cytochrome c, we investigated whether HCCS(H154A), which is defective in heme 
binding (see Fig 2), co-purified with any of the cytochrome c variants.  Purified HCCS(H154A) 
(Fig 5D) contained no detectable cytochrome c (Fig 5E) or heme (Fig 5F), just as HCCS(H154A) 
alone had no heme.  The failure of HCCS(H154A) to co-purify with cytochrome c indicates that 
heme binding by HCCS (through His154) is a requirement for interaction with the 
apocytochrome c.   
Spectral analyses of the HCCS:heme:cytochrome c complexes.  
UV-Vis spectra were recorded on each of the purified complexes to gain additional 
insight into the heme:protein interactions within each complex.  In the absence of residue His19 
of apocytochrome c (i.e., the HCCS-H19A complex), the UV-Vis absorption spectrum is 
reminiscent of the spectrum of HCCS alone, with a Soret absorption at 425 nm and broad 
absorptions at 540 nm and 570 nm (Fig 5G, black line).  Addition of the reducing agent sodium 
dithionite to the purified HCCS-H19A complex caused minor changes in the Soret peak and the 
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α-β region of the spectrum (Fig 5G, red line).  To further probe ligand interactions in the HCCS-
H19A complex, we added 100mM imidazole to purified HCCS-H19A and recorded spectra (Fig 
5H, purple line).  The effect of imidazole addition on heme in the HCCS-H19A complex was 
similar to that observed with HCCS alone, with a blue-shift in the Soret band to 418 nm.  Upon 
addition of sodium dithionite to HCCS-H19A in the presence of imidazole, the Soret band 
shifted to 425 nm and pronounced α and β absorptions at 559 nm and 530 nm were observed (Fig 
5H, red line).  These results suggest that in the HCCS:heme:cytochrome c(H19A) complex, 
His154 of HCCS provides one axial ligand and that exogenous imidazole can occupy the second 
axial coordination site.  In contrast, the spectra of each of the other complexes of cytochrome c 
with HCCS (Fig 5I; full spectra are shown in SI Appendix, Fig S9) were markedly different from 
that of HCCS alone, and imidazole caused no change in the spectra of these complexes (SI 
Appendix, Fig S10).  We propose that, in the C15S, C18A, F11A, and WT complexes of 
cytochrome c with HCCS, heme is coordinated by His154 of HCCS and His19 of cytochrome c.    
To analyze the heme environment in each complex (see Table 1, columns G, H, and I), 
we focused on the sodium dithionite-reduced absorptions in the α-β region of the spectrum (500 
nm to 600 nm; see Fig 5I), which are diagnostic for covalent heme attachment and ligand 
interactions with the heme iron (46).  The reduced spectrum of the HCCS-cytochrome c(WT) 
complex exhibited α and β maxima at 555 nm and 523 nm, respectively (Fig 5I, purple line).  
The complex of HCCS with the F11A variant of cytochrome c showed α and β absorptions at 
552 and 524 nm (Fig 5I, orange line).  The HCCS-C15S complex exhibited a unique and rare 
split α maximum (57) at 555-560 nm and a split β peak at 526-535 nm (Fig 5I, blue line).  We 
note that a split α absorption has been observed at room temperature for heme in the CcmCDE 
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complex (58, 59), where, similarly, there is a single covalent attachment to a heme vinyl and bis-
His coordination of the heme iron.  The HCCS-C18A complex exhibited a strong α absorption at 
561 nm and a β peak at 531 nm (Fig 5I, black line).  For the C18A variant, since the α maximum 
was atypical for a c-type heme (i.e., 561 nm absorption; Fig 5I, black line) we confirmed 
covalent attachment of the heme group to the protein by mass spectrometry, where a trypsinized 
peptide corresponding to the heme binding motif of this variant plus covalent heme was detected 
(SI Appendix, Fig S11).   
Thus, for each complex of cytochrome c with HCCS, there are signature absorptions in 
the reduced UV-Vis spectrum that are diagnostic for the specific heme-protein interactions of 
that complex.  We note that the spectra of the complexes of HCCS with WT cytochrome c and 
the C15S variant are markedly different from the spectra that have been reported for released, 
mature WT holocytochrome c (41, 44) and site-directed variants of Cys15 (60, 61), respectively.  
This supports our contention that the spectra of the complexes are indeed reflective of 
interactions with the heme by both the HCCS and the cytochrome c.  We propose that these 
complexes are isolated, trapped intermediates on the path to full maturation and release of the 
human cytochrome c by the human HCCS.     
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Discussion 
Our results are discussed in the context of four distinct steps in the synthesis of 
holocytochrome c by the human HCCS: heme binding, apocytochrome c substrate recognition, 
thioether formation, and release of holocytochrome c (Fig 6A).  We also address longstanding 
questions on the mechanisms of heme binding by HCCS and the roles of individual residues in 
both HCCS and the apocytochrome c substrate.  A major conclusion is that heme is the central 
molecule mediating interaction between HCCS and apocytochrome c.   
Step 1. Heme binding by HCCS.   
The human HCCS is purified from membrane fractions as a full-length GST fusion 
protein with endogenous heme.  Given that the function of HCCS is to covalently attach heme to 
apocytochrome c, heme binding by this enzyme has long been suspected (34, 36, 62) but has 
never been shown directly.  Spectral studies provided insight into the HCCS heme-binding 
environment, suggesting that one ligand to the heme iron was a histidine and that the second 
axial coordination site was occupied by an unknown ligand that could be replaced by exogenous 
imidazole in vitro.  Various approaches were used to demonstrate that residue His154 in HCCS 
was an axial ligand to the heme in HCCS (Fig 2).  First, HCCS(H154A) did not purify with 
heme.  Additionally, HCCS(H154A) was not functional in holocytochrome c synthesis, but 
activity was corrected in vivo by addition of exogenous imidazole.  Finally, HCCS(H154A) did 
not form ternary complexes with heme and cytochrome c (Fig 5).  We therefore conclude that it 
is the heme-bound form of HCCS to which apocytochrome c binds (see step 2).   
Step 2. Recognition of apocytochrome c by HCCS:heme.   
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We undertook two approaches to define the substrate determinants in the apocytochrome 
c that the human HCCS requires for formation of a mature holocytochrome c.  The first was to 
identify key residues in the N-terminus of the cognate human apocytochrome c that were 
required for holocytochrome formation, and the second was to convert a non-substrate bacterial 
cytochrome c (R. capsulatus cytochrome c2) into a substrate for the human HCCS.  For the 
human apocytochrome c, residues Phe11, Cys15, Cys18, and His19 were important (although to 
differing degrees) for optimal holocytochrome c maturation (Fig 3C).  Maturation of cytochrome 
c2 by HCCS required insertion of an Ala residue between Phe11 and Cys15 and substitution of 
Glu residues 8 and 10 (Fig 4).  Predicted structures of the cytochrome c2 N-terminus demonstrate 
that the Ala insertion significantly repositions Phe11 and the two Glu residues (SI Appendix, 
compare Fig S12A to B); therefore, both amino acid spacing and charge (SI Appendix, compare 
Fig S12A to C) are critical for heme attachment by HCCS.  Fig 6B shows the predicted structure 
of the first twenty residues in the human apocytochrome c, with each of the critical determinants 
highlighted.   
We gained remarkable insight into HCCS substrate recognition when we discovered that 
each human cytochrome c variant (F11A, C15S, C18A, H19A) co-purified with HCCS (Fig 5 
and Table 1).  Each of the HCCS:heme:cytochrome c complexes comprised a unique heme 
environment (Fig 5F), suggesting that each variant complex represented a distinct, intermediate 
in maturation.  Thus, these variants are not defective in step 2 (recognition by and binding to 
HCCS:heme) but are defective in a later step in maturation, as described below.  Our results are 
consistent with prior genetic studies in yeast, where a class of mutant apocytochromes c 
(including variants at Cys15, Cys18, and His19) were found to be competent for mitochondrial 
 192 
 
import (in an HCCS-dependent manner), and therefore were still recognized by HCCS, but were 
not matured into holocytochromes c (63).   
Fig 6C diagrams the central role of heme in the formation of the complex of HCCS (blue) 
with the apocytochrome c N-terminus (PEP-FOLD generated structure, green).  Each complex of 
HCCS with apocytochrome c (including HCCS-H19A) contained more total heme than HCCS 
alone (Table 1, column C).  This indicates that apocytochrome c binding stabilizes heme in the 
HCCS:heme:cytochrome c ternary complex (Fig 6A, step 2).  His19 of the apocytochrome 
CXXCH supplies the 2
nd
 axial ligand to heme iron in the complex with HCCS, and HCCS 
His154 provides the first (Fig 6C).  This is suggested by spectral analyses of the 
HCCS:heme:cytochrome c(H19A) complex compared to those of the complexes with WT and 
other cytochrome c variants.  That the HCCS:heme:cytochrome c(H19A) complex contained 
more total heme than HCCS alone further indicates that other residues in apocytochrome c (in 
addition to His19) likely interact with heme.  The spectral features and biochemical 
characterization of these ternary complexes also inform us of the later steps in holocytochrome c 
synthesis.   
Step 3. Formation of thioether bonds.   
Each of the complexes of cytochrome c with HCCS contained at least WT-levels of 
covalent 12 kDa heme, with the exception of the H19A variant (Table 1, column D).  While 
heme in the complex with HCCS was still stabilized by binding of cytochrome c(H19A) (Table 
1, column C), thioether formation was very low for this variant.  We conclude that His19 of 
CXXCH in the apocytochrome c is essential for efficient thioether formation.  We propose that 
coordination of the heme iron by His19 in the HCCS:heme:cytochrome c complex positions the 
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two cysteines for stereospecific ligation to reduced (Fe
2+
) heme, preparing it for thioether bond 
formation.  This is consistent with the effect of exogenous imidazole on the heme environment in 
the HCCS:heme:cytochrome c(H19A) complex, as described in results (Fig 5H and I).  The 
essential role of His19 in step 3 is further supported by the complete absence of released 
holocytochrome c(His19) (Table 1, column E; Fig 3B and C).      
Holocytochromes C15S and C18A were bound to HCCS at steady-state levels two-fold 
higher than the WT holocytochrome c (Table 1, columns B and D).  Since the levels of mature 
holocytochrome c were very low relative to WT (8 % for C15S and < 3 % for C18A), it appears 
that these variants are trapped in HCCS, unable to undergo release.  Thus, covalent bond 
formation at both cysteines appears to be required for efficient release from HCCS.  
Interestingly, Wang and colleagues (1996) observed a class of mutant apocytochromes c 
(including variants in the Cys residues of CXXCH) whose expression inhibited the maturation of 
normal cytochrome c when co-expressed in S. cerevisiae.  They speculated that this class of 
variant apocytochromes might be forming “dead-end” complexes with HCCS.  Here, we show 
that the Cys variant apocytochromes are indeed bound in non-productive complexes with HCCS, 
consistent with the “dominant” cytochrome c variants observed in the aforementioned study.  It 
is striking that the ratio of released to “trapped” WT cytochrome c is one hundred times higher 
(than the C18A variant), highlighting the consequences of thioether formation for full release and 
maturation.  Additionally, that both the C15S and C18A single-cysteine complexes contained 
covalent heme suggests that there may not be a preferred order for thioether formation.   
Step 4. Release of holocytochrome c from the complex.   
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In addition to the requirement for formation of two thioether bonds (step 3), optimal 
production of mature holocytochrome c requires a mechanism for release from HCCS (Fig 6A).  
A number of studies on mitochondrial import of apocytochrome c in whole yeast cells (30, 33, 
63) and in isolated yeast mitochondria (31, 64) have concluded that apocytochrome residues 
important for heme attachment may only represent a subset of residues involved in mitochondrial 
import.  Thus, there are likely multiple residues in the apocytochrome (in addition to Phe11, 
Cys15, Cys18, and His19) that mediate interaction with HCCS:heme.  We propose that a 
dedicated release mechanism (step 4) is essential for the cognate human holocytochrome c 
because of multiple, stable interactions between HCCS:heme and the apocytochrome that are 
related to HCCS-mediated import of the apocytochrome c into the mitochondrion.   
Binding of the human HCCS to its cognate cytochrome c in the ternary complex is 
surprisingly stable, as demonstrated by the fact that the HCCS:heme:cytochrome c complex can 
be purified (in the oxidized state) and maintained in vitro.  We speculate that, in the cell, the 
proper milieu (e.g., reducing environment) promotes folding of the WT holocytochrome c, which 
provides the energy to release heme (and the holocytochrome) from the HCCS active site.  
Although we have not addressed the mechanisms in step 4 directly in our study, a rich history 
exists on the analysis of holocytochrome c folding in vitro, which is useful to consider here.  For 
example, reduced cytochrome c (Fe
2+
) shows a notable difference in folding relative to oxidized 
cytochrome c (Fe
3+
), exhibiting greater stability towards denaturation (65).  Even the binding of 
small axial ligands like carbon monoxide, which can replace the natural methionine axial ligand, 
has significant impacts on the folding and unfolding processes (66).  Thus, the importance of 
reduced heme (Fe
2+
) both for thioether formation and holocytochrome c release might be 
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considered for HCCS-mediated cytochrome c maturation.  Possible factors involved in this 
reduction in mitochondria have been described (24).  Release of holocytochrome c from the 
ternary complex clearly demands that HCCS axial ligand His154 be discharged from the heme 
iron (Fig 6C), which may be facilitated by interaction of the heme with other residues in the 
cytochrome c during folding.  Although the second axial coordination site in mature 
holocytochrome c is occupied by Met81 (Fig 6D), there is ample evidence that this Met residue 
can be replaced and still yield mature cytochrome c (67).  Therefore, other residues in 
cytochrome c may play a role, during folding, in displacing HCCS His154 from the heme.  
Besides a molecular understanding of the mechanisms underlying HCCS function, our study 
provides the foundation for future analyses of other key residues in the human HCCS and the 
cytochrome c, and the framework for delineating the steps in which those residues are involved.    
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Materials and Methods 
Bacterial Growth Conditions.  Escherichia coli strains (SI Appendix, Table S2) were grown at 
37
o
C in Luria-Bertani broth (LB; Difco) supplemented with the appropriate antibiotics (Sigma-
Aldrich) and other media additives at the following concentrations, unless otherwise noted: 
carbenicillin, 50 µg ml
-1
; chloramphenicol, 20 µg ml
-1
; isopropyl-β-D-thiogalactopyranoside 
(IPTG, Gold Biotechnology), 0.1 mM; arabinose (Gold Biotechnology), 0.2 % (w/v).   
Protein Expression and Purification.  For HCCS expression (with or without co-expression of 
cytochrome c), E. coli ∆ccm strain RK103 (68) or RK112 (69) was used.   Starter cultures were 
initiated from a single colony and grown overnight at 37
o
C with shaking at 200 rpm in 100 mL 
of LB with the appropriate antibiotics.  1 L of LB was inoculated to 10 % and was grown with 
shaking at 120 rpm for 1 hr (OD600 < 1.0), at which point the culture was induced with 0.1 mM 
IPTG for pET Blue-2, pTXBI, or pGEX-based expression for 5 hr.  For co-expression of pBAD-
based cytochrome c, the culture was induced with 0.2 % arabinose (w/v) 3 hr after inoculation (2 
hr after induction of HCCS expression) and grown 3 additional hr.  Cells were harvested at 5,000 
x g for 10 min and frozen at -80
o
C overnight.  Cell pellets were thawed and resuspended in 
phosphate-buffered saline (100 mM NaCl, 7.5 mM Na2HPO4, 2 mM NaH2PO4) and treated with 
phenylmethanylsulfonylfluoride (PMSF, Sigma-Aldrich; 1 mM) and egg white lysozyme 
(Sigma-Aldrich; 100 µg ml
-1
) for 30 min while shaking on ice.  Cells were disrupted by repeated 
sonication for 30 sec bursts with a Branson 250 sonicator (50% duty, 60% output) until clearing 
of the suspension was observed.  Crude sonicate was centrifuged at 24,000 x g for 15 min to 
clear cell debris, and membranes were isolated by centrifugation at 100,000 x g for 45 min.  
Membrane pellets were solubilized in a modified 1 x glutathione S-transferase (GST) buffer (150 
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mM NaCl, 50 mM Tris, pH 8; Pierce) with 1 % (w/v) n-dodecyl maltopyranoside (DDM, 
Anatrace) or Triton X-100 (Sigma-Aldrich) on ice for 1 hour.  Detergent-solubilized membranes 
were centrifuged at 24,000 x g for 15 min to remove unsolubilized material.  Solubilized 
membranes (L; load) were passed over glutathione agarose (Pierce) per the manufacturer’s 
recommendations and washed in 1 x modified GST buffer with 0.02 % (w/v) DDM or Triton X-
100.  Bound GST-tagged protein was eluted in 1 x modified GST buffer containing 0.02 % (w/v) 
DDM or Triton X-100 and 20 mM reduced glutathione (E; elution).  The purified protein was 
concentrated and subjected to buffer exchange in an Amicon Ultra Centrifugal Filter 30,000 
MWCO (Millipore) after purification (called “EC”; concentrated elution).  Total protein 
concentration was determined using the Bradford Reagent (Sigma-Aldrich) per the 
manufacturer’s instructions and samples were measured with a PowerWave XS2 Microplate 
Spectrophotometer (BioTek).   
Cytochrome Reporter and Imidazole Complementation Assays. Human holocytochrome c and R. 
capsulatus holocytochrome c2 production were assayed in RK103 (68) harboring pGEX:GST-
HCCS and one of the following pBAD-based plasmids (human cytochrome c: K6A, K6R, K6D, 
F11A, C15S, C18A, H19A, WT; R. capsulatus cytochrome c2: c2(WT), c2(Ala-ins), c2(E8K/Ala-
ins), c2(E10I/Ala-ins), c2(E8K/E10I), c2(E8K/E10I/Ala-ins); see Table S2).  Cultures were grown 
at 37
o
C with shaking at 200 rpm in 5 mL LB with appropriate antibiotics for 3 hr and induced for 
an additional 3 hr with 0.8 % arabinose (w/v) and 1 mM IPTG.  Cells were harvested by 
centrifugation at 10,000 x g and the cell pellet was resuspended in 200 µL of BPER (Thermo 
Scientific) to lyse cells and extract protein.  Total protein concentration was determined using the 
Nanodrop 1000 spectrophotometer (Thermo Scientific) and 100 µg was analyzed by SDS-PAGE 
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followed by heme stain.  Imidazole complementation assays were performed in the same way 
with the exception that 10 mM imidazole (pH 7) was added to culture prior to inoculation. 
Heme stains and other methods.  Heme stains and immunoblots were performed as described in 
(70).  BPER fractions were mixed 1:1 (v/v) with loading dye without reducing agents and boiled 
for 5 min and were separated by 12.5 % SDS-PAGE and transferred to Hybond C nitrocellulose 
membranes (GE Healthcare).  Purified proteins (unboiled) were mixed 1:1 (v/v) with loading dye 
without reducing agents prior to separation by 12.5 % SDS-PAGE and transfer to nitrocellulose.  
Antiserum to human cytochrome c (Santa Cruz) was used at a dilution of 1:5000.  Anti-GST 
antibody (Sigma-Aldrich) was used at a dilution of 1:10000.  Protein A peroxidase (Sigma-
Aldrich) was used as the secondary label.  The chemiluminescent signal for heme stains and anti-
cytochrome c immunoblots was developed with the SuperSignal Femto kit (Thermo Scientific), 
or the Immobilon Western kit (Millipore) for anti-GST immunoblots.  Chemiluminescent signal 
was detected with the LAS-1000 Plus detection system (Fujifilm-GE Healthcare) or the 
ImageQuant LAS-4000 Mini detection system (Fujifilm-GE Healthcare).  Heme concentration in 
purified preparations was determined by pyridine extraction as described in (47), heme stain as 
described in (71), or quantification of the indicated UV-Vis spectral absorptions.  The relative 
abundances of purified GST-HCCS and co-purified human cytochrome c were quantified by 
densitometry analysis of the chemiluminescent signal from anti-GST and anti-cytochrome c 
immunoblots, respectively, and normalized to WT levels.  Protein purity was assessed by 
Coomassie Blue staining of SDS-PAGE. 
UV/Vis absorption spectroscopy.  UV-Visible absorption spectra were recorded with a Shimadzu 
UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described in (54).  All 
 199 
 
spectra were recorded in same buffer in which the proteins were purified: 150 mM NaCl, 50 mM 
Tris pH 8, 0.02 % (wt/vol) DDM or Triton X-100.  Chemical reduction and oxidation of samples 
was achieved by addition of several grains of sodium ditihionite (sodium hydrosulfite) or 
ammonium persulfate, respectively.  To analyze the effect of imidazole on the electronic 
spectrum, small quantities of a concentrated imidazole solution (1 M, pH 7) were added to 
purified protein and spectra were recorded.     
Three-dimensional models.  Three-dimensional models of the N-terminus of human cytochrome 
c and the cytochrome c2 variants from Rhodobacter capsulatus were generated by PEP-FOLD, 
an online resource for de novo three-dimensional peptide structure prediction (72, 73)  
(http://bioserv.rpbs.univ-paris-diderot.fr/PEP-FOLD).  Each of the peptides shown represents the 
lowest energy conformation of the five structures generated by PEP-FOLD.  X-ray crystal 
structures for E. caballus cytochrome c (pdb HRC1) and R. capsulatus cytochrome c2 (pdb 1c2r) 
were obtained from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do).   
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Figures 
Fig 1. Purified HCCS is a heme protein.   
(A) Coomassie blue stain of purified GST-tagged HCCS showing 57 kDa full-length GST-
HCCS.  (B) anti-GST immunoblot of purified GST-tagged HCCS showing 57 kDa full-length 
GST-HCCS, 44 kDa GST-HCCS**, 32 kDa GST-HCCS*, and 29 kDa GST.  (C) Heme stain of 
purified 57 kDa full-length GST-HCCS.  For (A), (B), and (C) abbreviations are: CS, crude 
sonicate; S, soluble fraction; L, load (DDM-solubilized membranes); FT, flow through; W1, 
wash 1; W2, wash 2; W3, wash3; E, elution; EC, concentrated elution; M, molecular weight 
standards.  (D) Heme stain of cytoplasmic extracts (BPER) showing synthesis of the human 
holocytochrome c as a function of HCCS expression and arabinose concentration.  12 kDa 
holocytochrome c is indicated by arrows.  100 µg of total protein was loaded in each lane. For 
(C) and (D), pre-stained molecular weight standards were overlaid in red onto the heme stains.  
(E) UV-visible absorption spectra of purified GST-HCCS (black line), reduced with sodium 
dithionite (red line), or oxidized with ammonium persulfate (blue line).  Inset, sodium dithionite-
reduced pyridine hemochrome spectrum of purified GST-HCCS from 500 nm to 600 nm.  (F) 
UV-visible absorption spectra of purified GST-HCCS (black line), in the presence of imidazole 
(purple line), and in the presence of imidazole reduced with sodium dithionite (red line).  For (E) 
and (F), the region from 500 nm to 700 nm has been multiplied by a factor of three.  Absorption 
maxima are indicated by arrows.      
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Fig 2. HCCS His154 is a heme ligand.   
(A) Heme stain of cell extracts (BPER) showing covalent 12 kDa holocytochrome c assembled 
by WT and site-directed mutants of HCCS in the E. coli cytoplasm in the absence (top panel) or 
presence (bottom panel) of 10 mM imidazole added to culture.  His154 was changed to Ala (lane 
1), Gly (lane 2), or Tyr (lane 3); His211 was changed to Ala (lane 5), Gly (lane 6), Tyr (lane 7), 
or Cys (lane 8).  Additional labels: WT, wild type; VC, vector control, M, molecular weight 
standards.  (B) Coomassie blue stain showing purified 57 kDa full-length GST-tagged 
HCCS(H154A).  (C) anti-GST immunoblot showing 57 kDa full-length GST-tagged 
HCCS(H154A), 44 and 32 kDa degradation products, and 29 kDa GST.  (D) Heme stain of 
purified 57 kDa full-length GST-HCCS.  For (B), (C), and (D) abbreviations are as follows: CS, 
crude sonicate; S, soluble fraction; L, load (DDM-solubilized membranes); FT, flow through; 
W1, wash 1; W2, wash 2; W3, wash3; E, elution; EC, concentrated elution; M, molecular weight 
standards.  For (A) and (D), pre-stained molecular weight standards were overlaid in red onto the 
heme stains.  (E) UV-visible absorption spectra of purified GST-HCCS(H154A) (orange line), 
shown with the spectrum of purified GST-HCCS(WT) (black line). 
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Fig 3. Maturation determinants in human cytochrome c.   
(A) Amino acid sequence alignment of the region encompassing the heme attachment site 
(CXXCH) for the indicated cytochromes c and c1.  The amino acids mutated in this work are 
bolded and indicated by arrows; numbering begins at the N-terminal Met in H. sapiens 
cytochrome c.  (B) Representative heme stain of BPER extracts showing synthesis of 12 kDa 
WT holocytochrome c and the indicated cytochrome c variants by the human HCCS; WT, wild 
type; VC, vector control, M, molecular weight standards. 100 µg of total protein was loaded in 
each lane.  Pre-stained molecular weight standards were overlaid in red onto the heme stain.  (C) 
Quantification of the results of heme staining of BPER extracts from three independent 
experiments.  Percent heme attachment for each variant is relative to synthesis of WT 
cytochrome c, which has been set at 100 %.  Error bars denote standard deviation.  (D) UV-Vis 
absorption spectra of BPER extracts from cells expressing HCCS along with the indicated 
cytochrome c variant.    
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Fig 4. Sequence requirements for maturation of bacterial cytochrome c2.  
 (A) Amino acid sequence alignment of the N-terminal region (including CXXCH) for the 
indicated cytochromes c and cytochrome c2 variants.  The amino acids mutated in this work are 
bolded and indicated by arrows.  The boxed region corresponds to the location of the Ala 
insertion; numbering refers to the H. sapiens cytochrome c N-terminal Met.  (B) Representative 
heme stain and (C) anti-cytochrome c2 immunoblot of BPER extracts showing synthesis of the 
indicated 12 kDa cytochrome c2 variants; M, molecular weight standards. 100 µg of total protein 
was loaded in each lane.  Pre-stained molecular weight standards were overlaid in red onto the 
heme stain.  (D) Quantification of the results of heme staining of BPER extracts from three 
independent experiments.  Percent heme attachment for each indicated variant is relative to 
synthesis of cytochrome c2(E8K/E10I/Ala-ins), which has been set at 100 %.  Error bars denote 
standard deviation.  (E) UV-Vis absorption spectra of whole cell extracts expressing HCCS and 
the indicated cytochrome c2 variant.  Absorption maxima are indicated by arrows.    
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Fig 5. Cytochrome c co-purifies with HCCS.   
(A) Anti-GST immunoblot showing full-length 57 kDa GST-HCCS, (B) anti-cytochrome c 
immunoblot showing 12 kDa cytochrome c, and (C) heme stain showing 12 kDa 
holocytochrome c, from elution fractions of co-purifications of each cytochrome c variant with 
GST-HCCS(WT).  (D) Anti-GST immunoblot showing full-length 57 kDa GST-HCCS, (E) anti-
cytochrome c immunoblot, and (F) heme stain, from elution fractions of co-purifications of each 
cytochrome c variant with GST-HCCS(H154A).  For (A)-(F), 5 µg of purified total protein was 
loaded in each lane.  See Fig S6 for full panels.  For (C) and (F), pre-stained molecular weight 
standards were overlaid in red onto the heme stains. (G) UV-visible absorption spectra of GST-
HCCS co-purified with cytochrome c(H19A) (black line) and reduced with sodium dithionite 
(red line). (H) UV-visible absorption spectra of GST-HCCS co-purified with cytochrome 
c(H19A) (black line), in the presence of imidazole (purple line), and in the presence of imidazole 
reduced with sodium dithionite (red line).  The region from 500 nm to 700 nm has been 
multiplied by a factor of three.  (I) The α-β region showing the characteristic sodium dithionite-
reduced UV-visible absorption spectrum for each indicated cytochrome c variant co-purified 
with GST-HCCS.  Spectra have been offset for clarity.  Absorption maxima are indicated by 
arrows.     
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Fig 6. Steps in the maturation of cytochrome c by human HCCS.   
(A) Diagram depicting the 4 steps in holocytochrome c maturation by HCCS (discussed in text).  
(B) PEP-FOLD generated model of the N-terminal 20 amino acid helix in human cytochrome c 
before interaction with HCCS.  Amino acids important for maturation are indicated by arrows.  
Selected oxygen atoms are shown in red, nitrogens in blue, sulfurs in yellow, the heme 
macrocyle is in pink, and the Fe atom at the heme center is orange.  (C) The 
HCCS:heme:cytochrome c complex (modeled with heme, pink) before thioether formation.  
Heme is coordinated by His19 of apocytochrome c (PEP-FOLD ribbon diagram, green, as in B) 
and His154 of HCCS (overlaid cartoon, blue).  Amino acids and heme vinyls important for 
maturation are indicated by arrows.  (D) The N-terminal 20 amino acids from the X-ray crystal 
structure of mature, released E. caballus holocytochrome c (pdb HRC1).  Amino acids important 
for maturation are indicated by arrows.  Heme is coordinated by His19, as in the complex with 
HCCS, and cytochrome c Met81, which replaces HCCS His154 in the folded, released 
holocytochrome c.  PyMOL was used for displays in B, C, and D.  Amino acid numbering refers 
to the H. sapiens cytochrome c N-terminal Met, as shown in Fig 3A (because the initiation Met 
is processed off, pdb HRC1 refers to Lys8 as Lys7, His19 as His18, Met81 as Met80, etc).   
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Table 1. Characterization of the complexes of HCCS with cytochrome c 
 A B C D E F G H I 
 
GST-
HCCS 
levels1 
CYCS 
bound (in 
complex)1 
Total 
heme (in 
complex)2 
Covalent 
12 kDa 
heme (in 
complex)3 
Released 
holo-cyt 
c3 
Reduced α 
band 
absorption4 
2nd heme 
axial 
ligand5 
1st heme 
axial 
ligand5 
Thioether 
bond 
formation5 
HCCS 
alone 
1.01 ± 
0.04 
-- 0.27 ± 0.09 -- -- 559 
HCCS 
His154 
Unknown None 
HCCS + 
cyt 
c(WT) 
1 1 1 1 1 555 
HCCS 
His154 
cyt c His19 
Cys15-2-
vinyl 
Cys18-4-
vinyl 
HCCS + 
cyt 
c(F11A) 
1.03 ± 
0.14 
0.94 ± 0.14 0.83 ± 0.13 1.02 ± 0.02 
0.25 ± 
0.05 
552 
HCCS 
His154 
cyt c His19 
Cys15-2-
vinyl 
Cys18-4-
vinyl 
HCCS + 
cyt 
c(C15S) 
1.00 ± 
0.11 
2.07 ± 0.10 1.84 ± 0.01 2.22 ± 0.24 
0.08 ± 
0.03 
555/560 split 
HCCS 
His154 
cyt c His19 
Cys18-4-
vinyl 
HCCS + 
cyt 
c(C18A) 
0.98 ± 
0.16 
1.97 ± 0.07 1.93 ± 0.08 2.24 ± 0.36 
0.03 ± 
0.01 
561 
HCCS 
His154 
cyt c His19 
Cys15-2-
vinyl 
HCCS + 
cyt 
c(H19A) 
1.00 ± 
0.15 
0.83 ± 0.02 0.89 ± 0.01 0.25 ± 0.10 
Not 
detected 
559 
HCCS 
His154 
Unknown 
Cys15-2-
vinyl 
Cys18-4-
vinyl 
Mature 
cyt c 
(WT) 
-- -- -- -- -- 550 Met80 His19 
Cys15-2-
vinyl 
Cys18-4-
vinyl 
 
Each value is relative to the complex of HCCS with WT cytochrome c, which has been set at 1, and is based on at least three separate 
experiments.   
1 The amount of GST-HCCS and CYCS protein in each complex was calculated by densitometry analysis of the chemiluminescent signal from 
anti-GST and anti-cytochrome c immunoblots, respectively.     
2 Total heme in each complex was calculated from the Soret absorption in the UV-Vis absorption spectrum and adjusted for total protein 
concentration.   
3 Covalent 12 kDa heme in each complex and released holocytochrome c in BPER fractions were calculated by densitometry analysis of the 
chemiluminescent signal from heme stains.   
4 The reduced α absorption (nm.) for each complex is from the UV-Vis absorption spectrum in the presence of sodium dithionite.   
5 The axial ligands to the heme in each complex and thioether formation between the Cys residues in the cytochrome c and the heme vinyls are 
based on experimental data shown here.   
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Supporting Materials and Methods 
Construction of strains and plasmids.  All oligonucleotide primer sequences, plasmids, and 
strains are given in Supplemental Table 2.  E. coli strains TB1 and HB101 were used as host 
strains for cloning.  To generate N-terminal hexahistidine-tagged HCCS, the human HCCS gene 
was PCR amplified from a cDNA clone (Origene) as described previously (1), digested, and 
ligated into the NcoI and HindIII sites in pET Blue-2 (EMD Biosciences) to generate pRGK402.  
To generate N-terminal GST-tagged HCCS, the human HCCS gene was PCR amplified from 
pRGK402, digested and ligated into the EcoRI and XhoI sites in pGEX 4T-1 (GE Healthcare) to 
generate pRGK403.  To generate C-terminal Intein-tagged HCCS, the human HCCS gene was 
PCR amplified from pRGK402, digested, and ligated into the NdeI and SapI sites in pTXB21 
(NEB) to generate pRGK404.  The human cytochrome c gene (CYCS) was PCR amplified from 
cDNA clone MGC12367 (ATCC), digested, and ligated into the EcoRI and PstI sites in 
pRGK330 (2) to generate pRGK405.  The cytochrome c2 gene from Rhodobacter capsulatus 
(CYCA) was PCR amplified from pRGK389 (1), with an engineered initiation codon to exclude 
the native periplasmic signal sequence as depicted in Figure 4, digested, and ligated into the 
NcoI and XbaI sites of pRGK330 (2) to generate pRGK406.   All nucleotide substitutions and 
insertions were engineered using the QuikChange I Site-Directed Mutagenesis Kit (Agilent 
Technologies) per the manufacturer’s recommendations, and oligonucleotides were synthesized 
by Sigma-Aldrich.  Each of the final constructs was sequenced to verify the mutation(s).   
Proteomics analysis. Identification of GST-HCCS and co-purified cytochrome c was achieved 
by ESI-MS by the Donald Danforth Plant Science Center Proteomics and Mass Spectrometry 
Facility.  Briefly, Coomassie-blue stained bands corresponding to 57 kDa GST-HCCS and the 
co-purified 12 kDa cytochrome c for the WT, C15S, and C18A variants were excised, washed 
 221 
and digested with trypsin overnight.  Tryptic peptides were run on a 1hr gradient LC-MS/MS 
using an LTQ-Orbitrap.  The data was searched using Scaffold (for GST-HCCS) or Mascot (for 
the cytochrome c variants) against a custom database including the sequences provided for each 
of the cytochrome c variants and the following variable modifications: deamidation on Asn and 
Glu, pyroglutamate formation, glutathione and heme on Cys, and Met oxidation.  To confirm 
covalent heme attachment to the C18A variant of cytochrome c, the 12 kDa band corresponding 
to cytochrome c was excised, washed, and digested with trypsin overnight as described in (3).  
Digested samples were subjected to matrix-assisted laser desorption ionization time-of-flight 
(MALDI-TOF) using an IonSpec ProMALDI FT-MS 7.4 T mass spectrophotometer by the 
Washington University in St. Louis NCRR Mass Spectrometry Facility.  
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Supporting Figure Legends 
Figure S1. Full-length GST-HCCS localizes largely to the membrane.  Anti-GST immunoblot 
showing cleared sonicate (CS), soluble (S) and DDM-solubilized membrane (M) fractions from 
E. coli cells expressing N-terminal GST-tagged HCCS.  Note the increase in full-length 57 kDa 
GST-HCCS in the DDM-solubilized membrane fraction (M, lane 3) relative to the soluble 
fraction (S, lane 2).   
 
Figure S2.  Identification of purified human HCCS by mass spectrometry.  The results of LC-
MS/MS on trypsin-digested, full-length 57 kDa GST-HCCS.  23 unique peptides were identified 
corresponding to human HCCS covering 57 % of the HCCS protein sequence.  The sequence of 
each unique peptide along with the modification and the mass (in Daltons) is given.   
 
Figure S3.  Multiple sequence alignment of HCCS and HCC1S genes from Homo sapiens, 
Saccharomyces cerevisiae, Mus musculus, Caenorhabditis elegans, Drosophila melanogaster, 
Plasmodium falciparum, Dictyostelium discoideum, Volvox carteri, Chlamydomonas reinhardtii, 
and Neurospora crassa.  Two histidine residues (boxed, arrows), His154 and His211 in the 
human HCCS, are completely conserved.   
 
Figure S4.  The X-ray crystal structures of (A) E. caballus cytochrome c (pbd HRC1) and (B) R. 
capsulatus cytochrome c2 (pdb 1c2r) exhibit similar three-dimensional folding (4).  Selected 
oxygen atoms are shown in red, nitrogens in blue, sulfurs in yellow, the heme macrocyle is in 
pink, and the Fe atom at the heme center is orange.  Note the similar three-dimensional 
localization of the indicated residues (arrows) with respect to the heme group in the two 
structures.  With the exception of R. capsulatus cytochrome c2 Met95, amino acid designations 
in (A) and (B) refer to the H. sapiens cytochrome c N-terminal Met, as in Fig 3 and 4A (even 
though the initiation Met is cleaved off).  PyMOL was used for displays.   
 
Figure S5.  Human cytochrome c variants co-purify with GST-HCCS.  Heme stains showing the 
co-purification of each cytochrome c variant (WT, F11A, C15S, C18A, and H19A) with GST-
HCCS.  CS, cleared sonicate; S, soluble fraction; L, load (detergent-solubilized membranes); 
W1-W3, wash 1-wash 3; E, elution; M, molecular weight standards.  In all cases, 12 kDa 
cytochrome c co-purified with HCCS (E, lanes 7).  12 kDa holocytochrome c is indicated by 
arrows.  Note the abundance of holocytochrome c in the detergent-solubilized membrane 
fractions (L, lanes 3) and in the subsequent purified elution fractions (E, lanes 7) for the C15S 
and C18A variants relative to that in the soluble fractions (S, lanes 2).  Relative levels of 
holocytochrome c bound to HCCS are shown in Fig 5A and quantified in Table 1.   
 
Figure S6.  Analysis of GST-HCCS and co-purified human cytochrome c.  (A) Coomassie stain 
showing concentrated elution fractions for each of the complexes of HCCS with cytochrome c.  
Full-length 57kDa GST-HCCS and the co-purified 12 kDa cytochrome c variants are indicated 
by arrows.  Note the abundance of the C15S and C18A variants relative to the WT, F11A, and 
H19A variants, quantified in Table 1.  (B) Coomassie stain, (C) anti-GST immunoblot, and (D) 
heme stain showing a representative co-purification of a cytochrome c variant (C18A) with GST-
HCCS.  Note the absence of the 12 kDa cytochrome c in the wash fractions of the heme stain 
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(panel D, lanes 5-7), indicative of a stable interaction between the co-purified cytochrome c and 
HCCS. 
 
Figure S7.  Identification of co-purified cytochrome c by mass spectrometry.  The results of LC-
MS/MS identifying WT, C15S, and C18A variants of cytochrome c co-purified with GST-
HCCS.  These data confirmed that the 12 kDa species co-purified with HCCS were variants of 
human cytochrome c.  The sequence of each unique peptide along with the modification and the 
mass (in Daltons) is given.   
 
Figure S8.  Heme is stably attached (covalent) to the co-purified cytochrome c.  Anti-GST 
immunoblot, anti-cytochrome c immunoblot, and heme stain of purified elution fractions for 
each cytochrome c variant co-purified with HCCS(WT) comparing unboiled samples (lanes 2-7) 
to those boiled and treated with 8 M urea (lanes 9-14).  The full-length 57 kDa GST-HCCS and 
12 kDa cytochrome c (apo- and holo- forms) are indicated by arrows.  Boiling and treatment 
with 8 M urea did not remove the heme from the co-purified cytochrome c variants, suggesting 
that heme binding to cytochrome c in the complex with HCCS is covalent.   
 
Figure S9.  Spectroscopic analyses of the indicated HCCS:heme:cytochrome c complexes.  UV-
Vis absorption spectra (360 nm-700 nm) for the complexes of HCCS with (A) WT, (B) F11A, 
(C) C15S, and (D) C18A cytochrome c variants.  Maxima are indicated by arrows, and the 
region from 500 nm to 700 nm has been multiplied by a factor of three. 
 
Figure S10.  Spectroscopic analyses of the indicated HCCS:heme:cytochrome c complexes in 
the presence of imidazole.  UV-Vis absorption spectra (360 nm-700 nm) for the complexes of 
HCCS with (A) WT, (B) F11A, (C) C15S, and (D) C18A cytochrome c variants in the presence 
of imidazole (100 mM).  Imidazole addition did not alter the spectra of any complex of HCCS 
with cytochrome c, with the exception of the H19A variant (Figure 5B).  Maxima are indicated 
by arrows, and the region from 500 nm to 700 nm has been multiplied by a factor of three. 
 
Figure S11.  Heme is covalently attached to the HCCS-co-purified cytochrome c(C18A) variant.  
The results of MALDI-TOF mass spectrometry on trypsin-digested 12 kDa C18A cytochrome c 
variant co-purified with HCCS.  The peak corresponding to the species with mass of 1617.381 
Daltons was within 0.3 Daltons of the calculated neutral monoisotopic mass predicted for a 
covalent heme-containing peptide of the mutated heme binding motif in the C18A variant of 
cytochrome c (CSQAHTVEK).  The presence of this species indicates that heme is bound 
covalently to the C18A variant of cytochrome c (through Cys15) in the complex with HCCS.   
 
Figure S12.  Predicted structural outcomes of the R. capsulatus cytochrome c2 variants 
engineered in this study.  Comparison of the PEP-FOLD-generated three-dimensional structures 
of the N-termini (19-20 residues) of (A) WT R. capsulatus cytochrome c2 (B) cyt c2(Ala-ins) and 
(C) cyt c2(E8K/E10I/Ala-ins).   Selected oxygen atoms are shown in red, nitrogens in blue, and 
sulfurs in yellow.  Each structure has been oriented such that residue Cys15 is in the same 
position.  Amino acids important for maturation are indicated by arrows.  For clarity, amino acid 
designations refer to the H. sapiens cytochrome c N-terminal Met.  Neither WT cyt c2 nor cyt 
c2(Ala-ins) were detectably matured by human HCCS, while cyt c2(E8K/E10I/Ala-ins) was a 
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robust substrate for the human HCCS.  Note the shift in orientation of E8, E10, and F11 in (B) as 
a result of the insertion of an Ala residue.  Also note that in each case, residue His19 was not part 
of the predicted helix, suggesting that it may have some flexibility, possibly related to its 
function as a ligand to the heme in HCCS.    
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Comment on the evolutionary implications of cytochrome c2 maturation by human HCCS.   
The evolution of the HCCS enzyme occurred after the endosymbiotic event that led to the 
eukaryotic mitochondrion.  This is supported by the fact that the mitochondria of some 
eukaryotes (e.g., all plants and some protozoa) have retained CCM for the synthesis of c-type 
cytochromes.  CCM is utilized by alpha proteobacteria, which are the ancestors of the eukaryotic 
mitochondrion.  CCM is “promiscuous” with regard to substrate specificity, requiring little else 
than the conserved CXXH heme binding motif for recognition and heme attachment.  Most alpha 
proteobacterial cytochromes c (~90 %, or 173 out of 200 analyzed) have a two-residue spacing 
between conserved Phe and the CXXCH motif.  However, for all major groups of alpha 
proteobacteria, there are some cytochromes c with a three-residue spacing, and some that lack 
the Phe altoghether.  Thus, there is not a strictly conserved N-terminal architecture in the alpha 
proteobacterial cytochromes c, which is not unexpected given the flexible substrate requirements 
of CCM (e.g., Phe is not a requirement for CCM recognition and heme attachment).  Indeed, the 
fact that 90 % of the alpha proteobacteria have retained any conservation of N-terminal 
architecture (other than CXXCH) is surprising, and may reflect the importance of the conserved 
Phe, for example, in cytochrome c function(s) post-maturation by CCM.   
By contrast, all eukaryotic mitochondrial cytochromes c, regardless of whether they are 
matured by CCM or HCCS, contain a conserved N-terminal architecture that consists of a three-
residue spacing between conserved Phe (F11) and the CXXCH motif.  Although the conservation 
of this architecture in the CCM-containing mitochondria is surprising, the fact that all HCCS-
containing mitochondria possess cytochromes c with a three-residue spacing supports the idea 
that HCCS evolved with this specific architecture, and it is now “locked” into using it for 
attaching heme to its substrate.  Furthermore, the conservation of N-terminal architecture in 
cytochromes c throughout eukarya suggests that the three-residue spacing may have originated in 
the cytochrome c of the mitochondrial progenitor.  Consequently, the three-residue spacing is 
now embedded as part of the specificity determinants for recognition and maturation by HCCS.  
Animal HCCSs, like the human HCCS studied here, are less discriminatory, recognizing motifs 
within cytochrome c and cytochrome c1 (e.g., such that Tyr11 can replace Phe11).   
It is of note that the organisms from the Euglenozoa phylum, for which no cytochrome c 
assembly system has been discovered, contain cytochromes c with this same conserved N-
terminal architecture (although lacking the first Cys of the heme binding motif).  Allen and 
colleagues (5) have shown that a Euglenozoa (T. brucei) cytochrome c is matured by yeast 
HCCS in E. coli at very low levels (less than 1 % WT), even when the cytochrome has been 
engineered to contain the first Cys of the heme binding motif.  T. brucei cytochrome c has the 
equivalent of Glu8 (as in R. capsulatus cytochrome c2-see Figure 4), which might explain the 
low levels of maturation, but this has not been explored.    
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Figure S1 
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Figure S2 
 
Sequence Modifications Observed Actual Mass Start Stop 
(K)DEDISQKDMYNIIR(I)  580.6139 1,738.82 139 152 
(K)DEDISQKDmYNIIR(I) Oxidation (+16) 585.9449 1,754.81 139 152 
(K)DEDISQKDmYNIIR(I) Oxidation (+16) 878.4138 1,754.81 139 152 
(K)DEDISQKDMYNIIR(I)  870.4168 1,738.82 139 152 
(K)ENLDPSNLMPPPNQTPAPDQPFALSTVREESSIPR(A) 1,282.30 3,843.87 77 111 
(K)ENLDPSNLmPPPNQTPAPDQPFALSTVREESSIPR(A) Oxidation (+16) 1,287.63 3,859.87 77 111 
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVR(E) Oxidation (+16) 1,245.28 3,732.81 70 104 
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVR(E) Oxidation (+16) 934.209 3,732.81 70 104 
(R)GTAAENKENLDPSNLMPPPNQTPAPDQPFALSTVR(E) 1,239.94 3,716.81 70 104 
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVREESSIPR(A) Oxidation (+16) 1,511.40 4,531.19 70 111 
(R)GTAAENKENLDPSNLMPPPNQTPAPDQPFALSTVREESSIPR(A) 1,506.07 4,515.20 70 111 
(R)HDWIINR(C)  477.2509 952.4873 215 221 
(R)IHNQNNEQAWK(E)  691.333 1,380.65 153 163 
(R)IHNQNNEQAWKEILK(W)  622.3253 1,863.95 153 167 
(R)IHNQNNEQAWKEILK(W)  932.985 1,863.96 153 167 
(K)KTYSVPAHQER(A)  439.2316 1,314.67 49 59 
(K)KWVYPSEQmFWNAMLK(K) Oxidation (+16) 1,037.50 2,072.98 117 132 
(K)KWVYPSEQMFWnAMLK(K) Deamidation (+1) 1,029.99 2,057.97 117 132 
(K)KWVYPSEQMFWNAMLKK(G)  729.3695 2,185.09 117 133 
(K)KWVYPSEQMFWNAmLKK(G) Oxidation (+16) 1,101.55 2,201.08 117 133 
(R)SWmGYELPFDR(H) Oxidation (+16) 708.8176 1,415.62 204 214 
(R)SWMGYELPFDR(H)  700.8187 1,399.62 204 214 
(R)SWmGYELPFDR(H) Oxidation (+16) 708.8178 1,415.62 204 214 
(R)SWmGYELPFDRHDWIInR(C) Oxidation (+16), Deamidation (+1) 784.7057 2,351.10 204 221 
(R)SWmGYELPFDRHDWIINR(C) Oxidation (+16) 784.3722 2,350.09 204 221 
(K)TYSVPAHQER(A)  594.2949 1,186.58 50 59 
(K)WKDEDISQK(D)  574.7818 1,147.55 137 145 
(K)WKDEDISQKDmYNIIR(I) Oxidation (+16) 690.6702 2,068.99 137 152 
(K)WKDEDISQKDmYNIIR(I) Oxidation (+16) 518.2537 2,068.99 137 152 
(K)WKDEDISQKDMYNIIR(I)  685.3389 2,052.99 137 152 
(K)WKDEDISQKDMYNIIR(I)  514.256 2,053.00 137 152 
(K)WKDEDISQKDmYNIIR(I) Oxidation (+16) 1,035.50 2,068.99 137 152 
(K)WKDEDISQKDMYNIIR(I)  1,027.50 2,052.99 137 152 
(K)WVYPSEQMFWNAMLK(K)  965.4558 1,928.90 118 132 
(K)WVYPSEQmFWNAmLK(K) Oxidation (+16), Oxidation (+16) 981.4504 1,960.89 118 132 
(K)WVYPSEQmFWNAmLK(K) Oxidation (+16), Oxidation (+16) 654.6355 1,960.88 118 132 
(K)WVYPSEQmFWnAmLK(K) Oxidation (+16), Deamidation (+1), 
Oxidation (+16) 
654.9654 1,961.87 118 132 
(K)WVYPSEQmFWNAMLK(K) Oxidation (+16) 973.4531 1,944.89 118 132 
(K)WVYPSEQmFWNAmLK(K) Oxidation (+16), Oxidation (+16) 654.6367 1,960.89 118 132 
(K)WVYPSEQmFWNAmLK(K) Oxidation (+16), Oxidation (+16) 981.4522 1,960.89 118 132 
(K)WVYPSEQMFWNAmLK(K) Oxidation (+16) 973.4536 1,944.89 118 132 
(K)WVYPSEQMFWNAMLK(K)  643.9739 1,928.90 118 132 
(K)WVYPSEQMFWNAmLK(K) Oxidation (+16) 649.3039 1,944.89 118 132 
(R)YVIDYYDGGEVNK(D)  767.8568 1,533.70 224 236 
(R)YVIDYYDGGEVNKDYQFTILDVRPALDSLSAVWDR(M) 1,024.75 4,094.99 224 258 
(K)WKDEDISQKDMYNIIR(I)  685.3384 2,052.99 137 152 
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVR(E) Oxidation (+16) 934.21 3,732.81 70 104 
(R)IHNQNNEQAWK(E)  461.2256 1,380.65 153 163 
(K)KTYSVPAHQER(A)  439.2311 1,314.67 49 59 
(R)GTAAENKENLDPSNLMPPPNQTPAPDQPFALSTVR(E) 1,239.94 3,716.81 70 104 
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Figure S3 
H_sapiens_HCCS                    ----MGLSPSAPAVAVQASNAS----ASPPSGCPMHEGKMKGCPVNTEPS 42 
S_cerevisiae_HCCS_cyc3p           ----MGWFWAD----QKTTG---------KDIGGAAVSSMSGCPVMH--- 30 
S_cerevisiae_HCC1S_cyt2p          ---MMSSDQQGKCPVDEETKKLWLR--------EHGNEAHPGATAPGNQ- 38 
M_musculus_HCCS                   ----MGASASSPATAVNASNASDGQPASPPSGCPMHKGQRKGCPVTAATS 46 
C_elegans_HCCS                    ----MGSSQSTPKVQDANADAERIRKAQHSMAAAGGGSQ---CPLTPEQR 43 
D_melanogaster_HCCS               ----MGNTAIT-RVQMEATKSVPVDHAKYMSGSGAPPPE---CPMHQKHG 42 
P_falciparum_HCCS                 ----------------MQNLSPACTFNKNEEKIKCPSSTKLGCSDGTKII 34 
P_falciparum_HCC1S                -------------------------------------------------- 
D_discoideum_HCCS                 ----MG---------DDNTNNTSITKSSPTDAMG---------------- 21 
V_carteri_VOLCADRAFT_75232        -------------------------------------------------- 
V_carteri_VOLCADRAFT_105944       ----MGNQQSS----APSSPPAACAA-CADGQPSAKEAP--SCPVNPRHR 39 
C_reinhardtii_XP_001699246.1      -------------------------------------------------- 
C_reinhardtii_XP_001697002.1      ----MGNQQSA----SAPPPATSAAP-CAEAAAAAGAEPPSSCPVNPKYK 41 
N_crassa_OR74A_HCCS_NCU05601      ----MGWFWAD----GNASAAAPVVPPSHKDLAASGAVPPPSCPMHNKTM 42 
N_crassa_OR74A_HCC1S              MAGQAGAGSEDKCPVDHKTRELWLQQAKQAKAAQEAAAAAGGSTAPSPEN 50 
                                                                                     
 
H_sapiens_HCCS                    GPTCEKKTY--------------------SVPAHQERAYEYVECPIRGTA 72 
S_cerevisiae_HCCS_cyc3p           --------------------------------ESSSSSPPSSECPVMQGD 48 
S_cerevisiae_HCC1S_cyt2p          -------------------------------LECSANPQDNDKTPEY--- 54 
M_musculus_HCCS                   DLTSESKAH--------------------TVPAHQDRAYDYVECPVTGAR 76 
C_elegans_HCCS                    AAASGE------------------------------NCGAGGACPVG--- 60 
D_melanogaster_HCCS               DAKSAS-----------------------AVPPHP-KMQAASECPVQ--- 65 
P_falciparum_HCCS                 QH------------------------------------------------ 36 
P_falciparum_HCC1S                -------------------------------------------------- 
D_discoideum_HCCS                 -----------------------------------------GGCPIA--- 27 
V_carteri_VOLCADRAFT_75232        -------------------------------------------------- 
V_carteri_VOLCADRAFT_105944       NP-AVYNVYG-------------------ERINDPNNPQPKSPLQSIQGA 69 
C_reinhardtii_XP_001699246.1      -------------------------------------------------- 
C_reinhardtii_XP_001697002.1      NP-AVYNVYG-------------------QRINDPNSQAKPSPLASITGA 71 
N_crassa_OR74A_HCCS_NCU05601      DALSAHKPVT-------------------PAPEPTPAAAAPSKCPVNHGA 73 
N_crassa_OR74A_HCC1S              AFTTPVVPAPQQPPTQTPIPQPAQQTAVPAALPTSQQQQQSSSSSSWSSW 100 
                                                                                     
 
H_sapiens_HCCS                    AENK----------------------------ENLDPSN-LMPPPNQTPA 93 
S_cerevisiae_HCCS_cyc3p           ND-------------------------------RINPLNNMP-ELAASKQ 66 
S_cerevisiae_HCC1S_cyt2p          ----------------------------------------HTT------- 57 
M_musculus_HCCS                   AKDK----------------------------ESLDPSN-LMPPPNQTPS 97 
C_elegans_HCCS                    -ADK----------------------------ASINPLNNELEHPNQKPA 81 
D_melanogaster_HCCS               -HDN----------------------------SDVNPLN-MMPPANQQPA 85 
P_falciparum_HCCS                 ---------------------------------EINERNMMPEIPNVSLT 53 
P_falciparum_HCC1S                ----------------------------------MNEQ----KKENINIK 12 
D_discoideum_HCCS                 --------------------------------HDINPAN-HMYKPNQNPH 44 
V_carteri_VOLCADRAFT_75232        ----------------------------------MAPPSKLP--PHQQ-- 12 
V_carteri_VOLCADRAFT_105944       DM--------------------------------LDPKNNMPLEPNQLPC 87 
C_reinhardtii_XP_001699246.1      ----------------------------------MAPPDKLP--PHQA-- 12 
C_reinhardtii_XP_001697002.1      DV--------------------------------LDPKNNMPLEPNQLPC 89 
N_crassa_OR74A_HCCS_NCU05601      KDTLAAAAAAVAPKQPQPENHQPAAASEPSFFSKLNPLNYMFSSISQEPA 123 
N_crassa_OR74A_HCC1S              LP------------------------------FMSSSSGSTTTGAAAAAG 120 
                                                                                     
 
H_sapiens_HCCS                    PDQPFALSTVREESSIPRAD-------------------SEKKWVYPSEQ 124 
S_cerevisiae_HCCS_cyc3p           PGQKMDLPVDRTISSIPK-S-----------------PDSNEFWEYPSPQ 98 
S_cerevisiae_HCC1S_cyt2p          ----VDLSQSREVSTIPRTN-------------------SDRNWIYPSEK 84 
M_musculus_HCCS                   PDQPFTLSTSREESSIPRAD-------------------SEKKWVYPSEQ 128 
C_elegans_HCCS                    PDQPFALPTKREKSTIPKAG------------------TETETWTYPSPQ 113 
D_melanogaster_HCCS               ADQPFPLPTDRQTSTIPKVTE----------------DGSVQFWQYPSQQ 119 
P_falciparum_HCCS                 DENDFTFNKKRHVSSIPKNNNE--------------------YWVYPSSQ 83 
P_falciparum_HCC1S                NISNHNNSDGKEKSSIPSKNG---------------------SWYYPSQK 41 
D_discoideum_HCCS                 PDQTKPLSTERITSTIPRTE--------------------KDNWQYPSPQ 74 
V_carteri_VOLCADRAFT_75232        PGHDY--------------------------------------WVYPSEQ 24 
V_carteri_VOLCADRAFT_105944       PGQRKPLSTERVASTIPKGG-----------------TDGT--WLFPSPQ 118 
C_reinhardtii_XP_001699246.1      PGQQN--------------------------------------WVYPSEQ 24 
C_reinhardtii_XP_001697002.1      PGQRKPLSTERVASNIPKGG-----------------TEST--WLFPSPQ 120 
N_crassa_OR74A_HCCS_NCU05601      PNQAIALPTERDPSSIPKGT-----------------GDGN--WEYPSPQ 154 
N_crassa_OR74A_HCC1S              ATPQLNLGEHREISSIPRAATTGPSACPSNAEQETGADTSTGNWVYPSEK 170 
                                                                             * :** : 
 
H_sapiens_HCCS                    MFWNAMLKKGWKWKDEDISQKDMYNIIRIHNQNNEQAWKEILKWEA---- 170 
S_cerevisiae_HCCS_cyc3p           QMYNAMVRKGKIGGSGEVAEDAVESMVQVHNFLNEGCWQEVLEWEK---- 144 
S_cerevisiae_HCC1S_cyt2p          QFYEAMMKKNWD-----PNSDDMKVVVPLHNSINERVWNYIKSWEDKQG- 128 
M_musculus_HCCS                   MFWNAMLRKGWKWKDDDISQKDMYNIIRIHNQNNEQAWKEILKWEA---- 174 
C_elegans_HCCS                    MFWNAMLKKGWRWQDDSLSKSDMENIISIHNANNEEAWREVLKWEN---- 159 
D_melanogaster_HCCS               MFWNAMLRKGWRWKTEDVSQKDMGDIIRIHNANNEQAWQEVLKWEA---- 165 
P_falciparum_HCCS                 QFYNSLIRKNK-----DIDKNYIDAVVSVHNEVNEESWKQILKYEH---- 124 
P_falciparum_HCC1S                QFYNTTKKKGY-----SFSQEDLNMALKIHNAVNEETWNKIMKKEQ---- 82 
D_discoideum_HCCS                 MFFNAMKKKQYEPKEE-----DMSVVISIHNTVNEKCWEDVLQWEN---- 115 
V_carteri_VOLCADRAFT_75232        MFYNAMKRK-----GWDPQTEDMRNVVAIHNSVNERAWREVMAWER---- 65 
V_carteri_VOLCADRAFT_105944       MVFNALRRKGK---GDDVTEDDMDGFIAAHNSMNEATWQRVMLWES---- 161 
C_reinhardtii_XP_001699246.1      MFYNAMKRK-----GWDPQAEDMRSVVGIHNTVNEQAWHQVLAWER---- 65 
C_reinhardtii_XP_001697002.1      MVFNALKRKGK---GDDVTEDDMDGFIAAHNSMNEATWQRVAQWEM---- 163 
N_crassa_OR74A_HCCS_NCU05601      QMYNALLRKG----YTDTDITAVESMVAVHNFLNEGAWNEIVEWERRFGK 200 
N_crassa_OR74A_HCC1S              QFYEAMKRKGHDG----ASAADMKTVVPIHNAVNERAWAEILRWEKPFT- 215 
                                   .:::  :*             :   :  **  **  *  :   *      
 
H_sapiens_HCCS                    ------------------------LHAAECPCGPSLIRFGGKAKEYSPRA 196 
S_cerevisiae_HCCS_cyc3p           ------------------------PHTDESHVQPKLLKFMGKPGVLSPRA 170 
His154 
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S_cerevisiae_HCC1S_cyt2p          ------------------------GEACG---GIKLTNFKGDSKKLTPRA 151 
M_musculus_HCCS                   ------------------------LHAHECPCGPSLVRFGGKAREYSPRA 200 
C_elegans_HCCS                    ------------------------LLHPECAE-PKLKSFKGDAKNLSPRA 184 
D_melanogaster_HCCS               ------------------------LHAKECGN-PRLKSFGGKAKDFSPRA 190 
P_falciparum_HCCS                 -------------------------MHKRSCTDVTLHRFLGKFDDLSIKA 149 
P_falciparum_HCC1S                -------------------------KYFDICKEQKLIKFVGYPTKLSIKA 107 
D_discoideum_HCCS                 ------------------------DYKDVCPN-PKLKKFKGKATDFSPKA 140 
V_carteri_VOLCADRAFT_75232        ------------------------LHCEECP-NPRLKRFQGRPSDLSPKA 90 
V_carteri_VOLCADRAFT_105944       ------------------------LHRPECD-YPTLLRFQGKPHDLSPLA 186 
C_reinhardtii_XP_001699246.1      ------------------------LHCDECA-TPRLKRFQGRPSDLSPKA 90 
C_reinhardtii_XP_001697002.1      ------------------------LHRGECD-TPTLLRFQGKPHDLSPLA 188 
N_crassa_OR74A_HCCS_NCU05601      GLMRGWEIMKRGEENAPMMLRRLEAQENDPEPQPTLIRFQGRPKDMTPKA 250 
N_crassa_OR74A_HCC1S              ------------------------GEACGCAEGPKLQSFMGESKRMTPKA 241 
                                                                     *  * *     :  * 
 
H_sapiens_HCCS                    RIR-SWMGYEL--------PFDRHDWIINRCG----------TEVRYVID 227 
S_cerevisiae_HCCS_cyc3p           RWM-HLCGLLFPSHFSQELPFDRHDWIVLRGERKAEQQPPTFKEVRYVLD 219 
S_cerevisiae_HCC1S_cyt2p          WFRSRILHLAK--------PFDRHDWQIDRCG----------KTVDYVID 183 
M_musculus_HCCS                   RIR-SWMGYEL--------PFDRHDWIINRCG----------TEVRYVID 231 
C_elegans_HCCS                    RFRNLFLGYDL--------PFDRHDWIVDRCGT---------KQVQYVID 217 
D_melanogaster_HCCS               RFR-SWLGYEL--------PFDRHDWIVDRCG----------KDVRYVID 221 
P_falciparum_HCCS                 RFRSIFSSMGR--------PFDRHDWYVNRCG----------TQVKYILD 181 
P_falciparum_HCC1S                FMLTLIG-YNK--------PFDRHEWYIDRCG----------NTIKYIID 138 
D_discoideum_HCCS                 KFLNTFLGYKL--------PFDRHDWIVDRNG----------KEVRYVID 172 
V_carteri_VOLCADRAFT_75232        RLL-NFVGFGL--------PFDRHDWVVDR----------CGREVRYVID 121 
V_carteri_VOLCADRAFT_105944       WIR-NLLGGPA--------PFDRHDWIVDR----------CGREVRYVID 217 
C_reinhardtii_XP_001699246.1      RLL-NFVGFGL--------PFDRHDWVVDR----------CGKEVRYIID 121 
C_reinhardtii_XP_001697002.1      WVR-HMLGGPA--------PFDRHDWVIDR----------CGKEVRYIID 219 
N_crassa_OR74A_HCCS_NCU05601      ALL-QVLGRIN-SKYATEPPFDRHDWYVSRDENGQK------KEVRYVID 292 
N_crassa_OR74A_HCC1S              RLNT-LLGYTA--------PFDRHDWIVDRCG----------TRVDYVID 272 
                                                     *****:* : *              : *::* 
 
H_sapiens_HCCS                    YYDGGEVN-KD-YQFTI-LDVRPALDSLSAVWDRMKVAWWRWTS------ 268 
S_cerevisiae_HCCS_cyc3p           FYGGPDDEN---GMPTFHVDVRPALDSLDNAKDRMTRFLD---RMISGPS 263 
S_cerevisiae_HCC1S_cyt2p          FYSTDLNDANSQQQPLIYLDVRPKLNSFEGFRLRFWKSLGF--------- 224 
M_musculus_HCCS                   YYDGGEVN-KE-YQFTI-LDVRPAFDSFSAVWDRMKVAWWRWTS------ 272 
C_elegans_HCCS                    YYDGGAVDPSS-KLFTI-LDVRPAVNDIGNIWDRMVVAYWRFKFETLG-F 264 
D_melanogaster_HCCS               YYDGGLVD-KD-YRFAL-LDVRPAMDSVDNVWDRMRVAYMRWKYELFEKF 268 
P_falciparum_HCCS                 YYN-DESINDD---KNIYIDVRPAMNSFSNVWDRLRYPFYEFYFKYVKKD 227 
P_falciparum_HCC1S                YYDGKKEKNSA---VSIYIDARPQLN-HQNAIDNVKIIYIKICRFLNN-- 182 
D_discoideum_HCCS                 FYEGRINKDSG-KSIGIYIDVRPAIDDFSSLKDRVLHFFK---------- 211 
V_carteri_VOLCADRAFT_75232        FYNGAPQPGQA-APVAFFLDVRPALDSVEAVWDRIRMQVAWVVSGRWMER 170 
V_carteri_VOLCADRAFT_105944       FYFYDDKAG---TPEAFEIVARPAVDSLESALDRVKMNIYIKFAEWGLPC 264 
C_reinhardtii_XP_001699246.1      FYNGAPQPGQS-AAAAFFLDVRPALDSVEAAWDRLRMQ-------WW--- 160 
C_reinhardtii_XP_001697002.1      FYFFDDKAG---TPQAFEIVARPAVDSVEAALDRVKMNIYLKFAEWGLPC 266 
N_crassa_OR74A_HCCS_NCU05601      FYSAPPEPT---GEPVFYLDVRPAVT-VTGACERLLRWGG---DVWWKAS 335 
N_crassa_OR74A_HCC1S              FYAGRNNDRAGAGKLNFYLDVRPKLNTWEGVKMRALRFVGMN-------- 314 
                                  :*              : : .** .        .                 
 
H_sapiens_HCCS                    ----------------------------- 
S_cerevisiae_HCCS_cyc3p           -----SSSSAP------------------ 269 
S_cerevisiae_HCC1S_cyt2p          ----------------------------- 
M_musculus_HCCS                   ----------------------------- 
C_elegans_HCCS                    TPSLPIPPTEGHNVNH------------- 280 
D_melanogaster_HCCS               GSADGGKVTAGSD---------------- 281 
P_falciparum_HCCS                 ELFK------------------------- 231 
P_falciparum_HCC1S                -LF-------------------------- 184 
D_discoideum_HCCS                 ----------------------------- 
V_carteri_VOLCADRAFT_75232        ----------------------------- 
V_carteri_VOLCADRAFT_105944       PITGHSGTVVAKQQQQQQQVAQPSGAGSS 293 
C_reinhardtii_XP_001699246.1      ----------------------------- 
C_reinhardtii_XP_001697002.1      PITGQAGAVAQAAAAAG---GQQAASGSS 292 
N_crassa_OR74A_HCCS_NCU05601      -----GGEVRERERSK------------- 346 
N_crassa_OR74A_HCC1S              ----------------------------- 
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Figure S4 
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Figure S5 
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Figure S6 
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Figure S7 
Peptide sequence: WT cytochrome c Seq. m/z (obs) Mr (expt) Mr (calc) 
KIFIMK 9-14 390.2439 778.4732 778.4775 
KIFIMK 9-14 390.2445 778.4745 778.4775 
KIFIMK + ox (M) 9-14 398.2412 794.4678 794.4724 
HKTGPNLHGLFGR 27-39 359.1977 1432.7615 1432.7688 
HKTGPNLHGLFGR + deam (NQ) 27-39 359.4485 1433.7649 1433.7528 
TGPNLHGLFGR 29-39 584.8093 1167.6040 1167.6149 
TGPNLHGLFGRK 29-40 432.9085 1295.7036 1295.7099 
TGPNLHGLFGRK + deam (NQ) 29-40 433.2413 1296.7020 1296.6939 
KTGQAPGYSYTAANK 40-54 778.8813 1555.7480 1555.7630 
KTGQAPGYSYTAANKNK 40-56 600.3039 1797.8899 1797.9009 
KTGQAPGYSYTAANKNK + deam (NQ) 40-56 600.6311 1798.8716 1798.8849 
TGQAPGYSYTAANK 41-54 714.8368 1427.6589 1427.6681 
TGQAPGYSYTAANKNK 41-56 557.6061 1669.7966 1669.8060 
GIIWGEDTLMEYLENPK + ox (M) 57-73 1012.4795 2022.9444 2022.9608 
GIIWGEDTLMEYLENPK + ox (M); deam (NQ) 57-73 1012.9840 2023.9534 2023.9448 
KYIPGTK 74-80 403.7397 805.4648 805.4698 
MIFVGIK 81-87 404.2414 806.4681 806.4724 
MIFVGIK + ox (M) 81-87 412.2377 822.4608 822.4673 
MIFVGIKK 81-88 468.2883 934.5620 934.5674 
MIFVGIKK + ox (M) 81-88 476.2863 950.5580 950.5623 
EERADLIAYLK 90-100 660.8589 1319.7032 1319.7085 
EERADLIAYLKK 90-101 483.6068 1447.7985 1447.8034 
ADLIAYLK 93-100 453.7657 905.5169 905.5222 
ADLIAYLKK 93-101 345.5434 1033.6084 1033.6171 
MGDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKAANKNKGHWGEDTLMEYLE
NPKKYIPGTKMIFVGIKKKEKATNE 76 % protein sequence coverage 
Peptide sequence: C18A cytochrome c Seq. m/z (obs) Mr (expt) Mr (calc) 
KIFIMK 9-14 390.2448 778.4750 778.4775 
KIFIMK + ox (M) 9-14 398.2414 794.4683 794.4724 
KIFIMKCSQAHTVEK 9-23 441.4909 1761.9345 1761.9270 
CSQAHTVEK 15-23 501.7349 1001.4552 1001.4600 
HKTGPNLHGLFGR 27-39 359.1978 1432.7622 1432.7688 
HKTGPNLHGLFGR + deam (NQ) 27-39 359.4484 1433.7644 1433.7528 
TGPNLHGLFGR 29-39 584.8106 1167.6066 1167.6149 
TGPNLHGLFGR + deam (NQ) 29-39 585.3031 1168.5917 1168.5989 
TGPNLHGLFGRK 29-40 432.9061 1295.6964 1295.7099 
TGPNLHGLFGRKTGQAPGYSYTAANK 29-54 677.3450 2705.3510 2705.3674 
TGPNLHGLFGRKTGQAPGYSYTAANK + deam (NQ) 29-54 677.5961 2706.3554 2706.3514 
KTGQAPGYSYTAANK 40-54 778.8821 1555.7497 1555.7630 
KTGQAPGYSYTAANK + deam (NQ) 40-54 519.9261 1556.7563 1556.7471 
KTGQAPGYSYTAANKNK 40-56 600.3038 1797.8895 1797.9009 
KTGQAPGYSYTAANKNK + deam (NQ) 40-56 600.6306 1798.8700 1798.8849 
TGQAPGYSYTAANK 41-54 714.8366 1427.6586 1427.6681 
TGQAPGYSYTAANKNK 41-56 557.6059 1669.7958 1669.8060 
NKGIIWGEDTLMEYLENPK + ox (M) 55-73 756.0371 2265.0895 2265.0987 
NKGIIWGEDTLMEYLENPKK 55-74 793.4031 2377.1873 2377.1987 
NKGIIWGEDTLMEYLENPKK + ox (M) 55-74 798.7358 2393.1854 2393.1936 
NKGIIWGEDTLMEYLENPKK + ox (M); deam (NQ) 55-74 599.5536 2394.1851 2394.1777 
GIIWGEDTLMEYLENPK 57-73 1004.4884 2006.9622 2006.9659 
GIIWGEDTLMEYLENPK + ox (M) 57-73 1012.4834 2022.9522 2022.9608 
GIIWGEDTLMEYLENPKK 57-74 712.6916 2135.0529 2135.0609 
GIIWGEDTLMEYLENPKK + ox (M) 57-74 1076.5340 2151.0534 2151.0558 
GIIWGEDTLMEYLENPKK + ox (M); deam (NQ) 57-74 718.3563 2152.0471 2152.0398 
GIIWGEDTLMEYLENPKKYIPGTK + ox (M) 57-80 937.8090 2810.4051 2810.4200 
KYIPGTK 74-80 403.7396 805.4647 805.4698 
MIFVGIK 81-87 404.2420 806.4695 806.4724 
MIFVGIK + ox (M) 81-87 412.2395 822.4645 822.4673 
MIFVGIKK 81-88 468.2863 934.5581 934.5674 
MIFVGIKK + ox (M) 81-88 476.2867 950.5588 950.5623 
KEERADLIAYLK 89-100 724.9061 1447.7976 1447.8034 
EERADLIAYLK 90-100 660.8576 1319.7006 1319.7085 
EERADLIAYLKK 90-101 483.6065 1447.7977 1447.8034 
ADLIAYLK 93-100 453.7653 905.5161 905.5222 
ADLIAYLKK 93-101 517.8129 1033.6113 1033.6171 
ADLIAYLKKATNE 93-105 725.3977 1448.7809 1448.7874 
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MGDVEKGKKIFIMKCSQAHTVEKGGKHKTGPNLHGLFGRKAANKNKGHWGEDTLMEYLE
NPKKYIPGTKMIFVGIKKKEKATNE 89 % sequence coverage 
Peptide sequence: C15S cytochrome c Seq. m/z (obs) Mr (expt) Mr (calc) 
KIFIMK 9-14 390.2450 778.4754 778.4775 
KIFIMK + ox (M) 9-14 398.2414 794.4683 794.4724 
SSQCHTVEK 15-23 509.7303 1017.4461 1017.4549 
HKTGPNLHGLFGR 27-39 359.1981 1432.7633 1432.7688 
HKTGPNLHGLFGR + deam (NQ) 27-39 478.9312 1433.7719 1433.7528 
HKTGPNLHGLFGRK 27-40 391.2221 1560.8593 1560.8637 
TGPNLHGLFGR 29-39 584.8117 1167.6089 1167.6149 
TGPNLHGLFGRK 29-40 432.9092 1295.7058 1295.7099 
TGPNLHGLFGRK + deam (NQ) 29-40 433.2384 1296.6933 1296.6939 
TGPNLHGLFGRKTGQAPGYSYTAANK 29-54 677.3450 2705.3510 2705.3674 
KTGQAPGYSYTAANK 40-54 778.8844 1555.7542 1555.7630 
KTGQAPGYSYTAANKNK 40-56 600.3039 1797.8898 1797.9009 
KTGQAPGYSYTAANKNK + deam (NQ) 40-56 600.6327 1798.8762 1798.8849 
TGQAPGYSYTAANK 41-54 714.8344 1427.6543 1427.6681 
GIIWGEDTLMEYLENPK + ox (M) 57-73 1012.4833 2022.9520 2022.9608 
KYIPGTK 74-80 403.7400 805.4654 805.4698 
MIFVGIK + ox (M) 81-87 412.2379 822.4612 822.4673 
MIFVGIKK 81-88 468.2899 934.5652 934.5674 
MIFVGIKK + ox (M) 81-88 476.2862 950.5579 950.5623 
EERADLIAYLK 90-100 660.8595 1319.7044 1319.7085 
EERADLIAYLKK 90-101 483.6070 1447.7993 1447.8034 
ADLIAYLK 93-100 453.7666 905.5187 905.5222 
ADLIAYLKK 93-101 517.8122 1033.6099 1033.6171 
ADLIAYLKK 93-101 517.8149 1033.6152 1033.6171 
ADLIAYLKKATNE 93-105 483.9343 1448.7811 1448.7874 
ADLIAYLKKATNE + deam (NQ) 93-105 484.2661 1449.7766 1449.7715 
MGDVEKGKKIFIMKSSQCHTVEKGGKHKTGPNLHGLFGRKAANKNKGHWGEDTLMEYLE
NPKKYIPGTKMIFVGIKKKEKATNE 88 % sequence coverage 
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Figure S8 
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Figure S9 
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Figure S10 
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Figure S11 
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Figure S12 
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Table S1. Published studies on maturation of cytochrome c by HCCS 
Reference Compartment HCCS Cytochrome c Results 
Verissimo et al. 
(2012) Biochem 
Biophys Res Comm 
E. coli cytoplasm S. cerevisiae  S. cerevisiae iso-
2-cyt c 
 R. capsulatus cyt 
c2 
 Iso-2-cyt c/cyt c2 
chimera 
 Cyt c2-insK11 
 Cyt c2-E9L 
 Cyt c2-insK11 + 
E9L 
 Cyt c2-insK11 + 
N12T 
 R. capsulatus cyt c2 not 
matured 
 Iso-2-cyt c/cyt c2 chimera (and 
truncated chimera) fully 
matured 
 Cyt c2-insK11 matured at low 
level 
 Cyt c2-insK11 + E9L matured 
at high levels 
 Cyt c2-E9L not matured 
 Cyt c2-insK11 + N12T not 
matured 
Stevens et al. (2011) 
FEBS Lett 
E. coli cytoplasm S. cerevisiae  E. caballus cyt c 
 S. cerevisiae iso-
1-cyt c 
 P. denitrificans 
cyt c550 
 Iso-1-cyt c/cyt 
c550 chimera 
 G6A, F10A in E. caballus not 
matured 
 F15A (but not G11A) in S. 
cerevisiae not matured 
 D2A, E4A, K7A, K5A, K8A 
matured at WT levels 
 P. denitrificans cyt c550 not 
matured 
 Chimera with S. cerevisiae N-
term up to but not including 
CXXCH fused to P. 
denitrificans cyt c550 matured 
at WT levels 
Kleingardner and 
Bren (2011) 
Metallomics 
E. coli cytoplasm S. cerevisiae  E. caballus cyt c 
 E. caballus cyt c 
1x-ins 
 E. caballus cyt c 
3x-ins 
 E. caballus cyt c 
G13 ins 
 E. caballus F10A 
 E. caballus cyt c 1x-ins not 
matured 
 Cyt c 3x-ins matured at 1/3 
levels 
 Cyt c G13 ins matured at 1/3 
levels but spectrally 
heterogeneous 
 Cyt c F10A not matured at 
detectable levels 
Fulop et al. (2009) 
FEBS J 
E. coli cytoplasm S. cerevisiae  T. brucei cyt c 
WT (AAQCH) 
 T. brucei cyt 
c(CAQCH) 
 S. cerevisiae iso-
1-cyt c 
 Both T. brucei cyts c matured 
at very low levels; 0.25 % the 
level of S. cerevisiae iso-1-cyt 
c 
Rosell and Mauk 
(2002) Biochem 
E. coli cytoplasm S. cerevisiae  S. cerevisiae iso-
1-cyt c(C14S) 
 S. cerevisiae iso-
1-cyt c(C17S) 
 Iso-1-cyt c(C14S) matured at 
1/10 levels of WT; spectrally 
distinct from WT 
 Iso-1-cyt c(C17S) expression 
20-fold lower than C14S 
variant; apparently did not 
permit enough to conduct 
analysis 
Silkstone et al. 
(2002) Biophysical 
Chem 
E. coli cytoplasm S. cerevisiae  S. cerevisiae iso-
1 cyt 
c(M80D/E/S/A) 
 
 S. cerevisiae iso-1 cyt c Met80 
variants were matured 
efficiently 
Rumbley et al. 
(2002) 
Biochemistry 
E. coli cytoplasm S. cerevisiae  E. caballus cyt 
c(E5G) 
 E. caballus cyt 
c(K9G) 
 E. caballus cyt 
c(V12G) 
 E. caballus cyt c E5G, K9G, 
V12G variants all matured, but 
with increasing proximity to 
CXXCH, level of mis-attached 
heme increased (attributed to 
interference with formation of 
N-terminal helix) 
 Starting E. caballus cyt c 
construct carried H26N, H33N 
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mutations 
Sanders et al. 
(2001) Mol Micro 
E. coli cytoplasm S. cerevisiae  S. cerevisiae iso-
2-cyt c/P. 
denitrificans cyt 
c550 chimera 
 Chimera (with N-term and 
CXXCH from iso-2-cyt c) 
matured 
Sanders and Lill 
(2000) BBA 
E. coli cytoplasm S. cerevisiae  S. cerevisiae iso-
1-cyt c 
 S. cerevisiae iso-
2-cyt c 
 P. denitrificans 
cyt c 
 Synechocystis sp. 
PCC 6803 cyt 
c553 
 S. cerevisiae iso-1 and iso-2 cyt 
c matured at high levels 
 P. denitrificans and 
Synechocystis cyt c not matured 
at detectable levels 
Corvest et al. 
(2010) Genetics 
Whole S. cerevisiae 
cells 
S. cerevisiae  S. cerevisiae cyt 
c1(CA[/P/T/H/L/
S]CH) 
 Cyt c1(CAPCH) depends on 
HCCS and Cyc2p for 
maturation; HCC1S maturation 
achieved by overexpression of  
HCC1S or substitution of P 
with H/L/S/T 
Bernard et al. 
(2003) JBC 
Whole S. cerevisiae 
cells 
Plasmid S. 
cerevisiae 
HCCS and 
HCC1S 
 
Plasmid H. 
sapiens HCCS 
 
Plasmid M. 
musculus 
HCCS 
 S. cerevisiae cyt 
c 
 S. cerevisiae cyt 
c1 WT (CAACH) 
 S. cerevisiae cyt 
c1(CAPCH) 
 S. cerevisiae cyt 
c1(CADCH) 
 S. cerevisiae HCC1S cannot 
mature cyt c 
 S. cerevisiae, H. sapiens, and 
M. musculus HCCS can 
complement HCC1S deletion 
for respiratory growth (i.e., 
they are active towards both cyt 
c an cyt c1) 
 S. cerevisiae HCCS can mature 
CAPCH and CADCH mutants 
of cyt c1 
Wang et al. (1996) 
JBC 
Whole S. cerevisiae 
cells 
Chromosomal + 
plasmid S. 
cerevisiae 
 S. cerevisiae iso-
2-cyt 
c([S/A]XX[S/A]
H) 
 S. cerevisiae iso-
2-cyt c(F19A) 
 S. cerevisiae iso-
2-cyt c(H27A) 
 S. cerevisiae iso-
2-cyt c(∆Ala1-
Lys14) 
 S. cerevisiae iso-
2-cyt c(∆Gly15-
Leu18) 
 Iso-2-cyt c(S/AXXS/AH) 
variants not matured, but 
imported into mitochondria 
(when HCCS was 
overexpressed on plasmid) 
 Iso-2-cyt c(F19A) not matured; 
10 % mitochondrial import 
 Iso-2-cyt c(H27A)not matured; 
40 % associated with 
mitochondria but only 10 % 
internalized into mitochondria 
 Iso-2-cyt c(∆Ala1-Lys14) 
matured at low levels (10 %) 
 Iso-2-cyt c(∆Gly15-Leu18) not 
matured; 10 % mitochondrial 
import 
Fumo et al. (1995) 
Gene 
Whole S. cerevisiae 
cells 
Chromosomal 
S. cerevisiae 
 S. cerevisiae iso-
1-cyt c(H18A) 
 Iso-1-cyt c(H18A) is 
nonfunctional (did not support 
growth in medium with liquid 
lactate, a nonfermentable 
carbon source) 
 Iso-1-cyt c(H18A) was not 
detected spectrally in intact 
cells 
 In targeted random mutagenesis 
experiment, only His was found 
as a.a. 18 
 Iso-1-cyt c(H18R) integrated 
chromosomally not support 
growth in lactate medium and 
holo-cyt c(H18R) was not 
detected in low temperature 
difference spectroscopy 
Tanaka et al. Whole S. cerevisiae Chromosomal  H. sapiens cyt  H. sapiens cyt c(C14A) 
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(1990) J Biochem cells S. cerevisiae c(C14A) efficiently matured and 
complemented CYC1 
deficiency in yeast on lactate 
medium 
Sorrell et al. (1989) 
JACS 
Whole S. cerevisiae 
cells 
Chromosomal 
S. cerevisiae 
 S. cerevisiae iso-
2-cyt c(H18R) 
 Iso-2-cyt c(H18R) on a plasmid 
weakly complemented yeast 
strain lacking cytochrome c on 
glycerol or lactate media 
 Less than 1 mg/10 L culture 
were purified; spectrally 
identical to WT iso-2-cyt c 
 Iso-2-cyt c(H18R) has slower 
rate of electron transfer than 
WT 
Tong and 
Margoliash (1998) 
JBC 
Purified S. cerevisiae 
mitochondria “in 
vitro” 
Chromosomal + 
plasmid S. 
cerevisiae 
 D. melanogaster 
cyt c(C14S) 
 D. melanogaster 
cyt c(C17S) 
 D. melanogaster 
cyt 
c(C14S/C17S) 
 D. melanogaster cyt c(C14S) 
matured, but at lower levels 
than WT 
 D. melanogaster cyt c(C17S) 
was matured at “trace” amounts 
 D. melanogaster cyt 
c(C14S/C17S) was 
undetectable 
Veloso et al. (1983) 
JBC 
Purified S. cerevisiae 
mitochondria 
“in vitro” 
Chromosomal 
S. cerevisiae 
 N-terminal 25 
residues of E. 
caballus cyt c 
 Heme was attached to E. 
caballus cyt c(N-term 25) at 25 
% levels of full apocytochrome 
c 
 No maturation when Gly 
replaced Cys in CXXCH 
Catalogue of published studies on the effects of cytochrome c mutations on maturation by 
HCCS.  Studies are organized according to the biological compartment in which the study was 
conducted (i.e., E. coli cytoplasm, whole S. cerevisiae cells, or isolated S. cerevisiae 
mitochondria) and then in reverse chronological order.  Full citations for each of the studies 
above are provided in the references section of the main text.   
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Table S2. Oligonucleotide primers, plasmids, and strains used in this research. 
Oligonucleotide Sequence (5’-3’) 
Plasmid 
Constructed 
CYCS_K6A_Fwd ATGGGTGATGTTGAGGCGGGCAAGAAGATTTTTATTATGAAGTG pRGK412 
CYCS_K6A_Rev CACTTCATAATAAAAATCTTCTTGCCCGCCTCAACATCACCCAT pRGK412 
CYCS_K6R_Fwd ATGGGTGATGTTGAGCGCGGCAAGAAGATTTTTATTATGAAGTG pRGK413 
CYCS_K6R_Rev CACTTCATAATAAAAATCTTCTTGCCGCGCTCAACATCACCCAT pRGK413 
CYCS_K6D_Fwd ATGGGTGATGTTGAGGACGGCAAGAAGATTTTTATTATGAAGTG pRGK414 
CYCS_K6D_Rev CACTTCATAATAAAAATCTTCTTGCCGTCCTCAACATCACCCAT pRGK414 
CYCS_F11A_Fwd GAGAAAGGCAAGAAGATTGCGATTATGAAGTGTTCCCAGTGCC pRGK415 
CYCS_F11A_Rev GGCACTGGGAACACTTCATAATCGCAATCTTCTTGCCTTTCTC pRGK415 
CYCS_F11Y_Fwd GTTGAGAAAGGCAAGAAGATTTATATTATGAAGTGTTCCCAGTGC pRGK416 
CYCS_F11Y_Rev GCACTGGGAACACTTCATAATATAAATCTTCTTGCCTTTCTCAAC pRGK416 
CYCS_C15S_Fwd GATTTTTATTATGAAGAGCTCCCAGTGCCACACCGTTGAAAAGGG pRGK417 
CYCS_C15S_Rev CCCTTTTCAACGGTGTGGCACTGGGAGCTCTTCATAATAAAAATC pRGK417 
CYCS_C18A_Fwd ATGAAGTGTTCCCAGGCGCACCGTTGAAAAGGGAGG pRGK418 
CYCS_C18A_Rev CCTCCCTTTTCAACGGTGCGCCTGGGAACACTTCAT pRGK418 
CYCS_H19A_Fwd TATTATGAAGTGTTCCCAGTGCGCGACCGTTGAAAAGGG AGGCAA pRGK419 
CYCS_H19A_Rev TTGCCTCCCTTTTCAACGGTCGCGCACTGGGAACACTTCATAATA pRGK419 
HCCS_H154A_Fwd GTATAATATCATTAGAATTGCCAATCAGAATAACGAGCAGGC pRGK420 
HCCS_H154A_Rev GCCTGCTCGTTATTCTGATTGGCAATTCTAATGATATTATAC pRGK420 
HCCS_H154G_Fwd CATTAGAATTGGCAATCAGAATAACGAGCAGGCTTGGAAGG pRGK421 
HCCS_H154G_Rev CCTTCCAAGCCTGCTCGTTATTCTGATTGCCAATTCTAATG pRGK421 
HCCS_H154Y_Fwd CATTAGAATTTACAATCAGAATAACGAGCAGGC pRGK422 
HCCS_H154Y_Rev GCCTGCTCGTTATTCTGATTGTAAATTCTAATG pRGK422 
HCCS_H211A_Fwd GAGTTGCCTTTTGATAGGGCGGATTGGATCATAAACCGTTGC pRGK423 
HCCS_H211A_Rev GCAACGGTTTATGATCCAATCCGCCCTATCAAAAGGCAACTC pRGK423 
HCCS_H211G_Fwd GAGTTGCCTTTTGATAGGGGCGATTGGATCATAAACCGTTGC pRGK424 
HCCS_H211G_Rev GCAACGGTTTATGATCCAATCGCCCCTATCAAAAGGCAACTC pRGK424 
HCCS_H211Y_Fwd GGTATGAGTTGCCTTTTGATAGGTATGATTGGATCATAAACCG pRGK425 
HCCS_H211Y_Rev CGGTTTATGATCCAATCATACCTATCAAAAGGCAACTCATACC pRGK425 
HCCS_H211C_Fwd GAGTTGCCTTTTGATAGGTGCGATTGGATCATAAACCGTTG pRGK426 
HCCS_H211C_Rev CAACGGTTTATGATCCAATCGCACCTATCAAAAGGCAACTC pRGK426 
pTXB1_HCCS_Nde1_Fwd GGTGGTCATATGGGTTTGTCTCCATCTGC pRGK404 
pTXB1_HCCS_SapI_Rev GGTGGTTGCTCTTCCGCATTTCGAGGTCCAACGCCACCAAGCAGC pRGK404 
pBAD_CYTC2_Nco1_Fwd GACTCCATGGGCGACGCCGCGAAGGGCG pRGK406 
pBAD_CYTC2_XbaI_Rev CTTCTAGATTATTTCACGACCGAGGCCAG pRGK406 
CYTC2_Ala-ins_Fwd GGGCGAAAAAGAATTCAACGCCAAGTGCAAGACCTGCCA pRGK407 
CYTC2_Ala-ins_Rev TGGCAGGTCTTGCACTTGGCGTTGAATTCTTTTTCGCCC pRGK407 
CYTC2_E8K_E10I_Fwd (Ala-ins) GCGACGCCGCGAAGGGCAAAAAAATATTCAACGCCAAGTGCA pRGK408 
CYTC2_E8K_E10I_Rev (Ala-ins) TGCACTTGGCGTTGAATATTTTTTTGCCCTTCGCGGCGTCGC pRGK408 
CYTC2_E8K_E10I_Fwd GGCGACGCCGCGAAGGGCAAAAAAATATTCAACAAGTGCAAGAC pRGK409 
CYT_C2_E8K_E10I_Rev GTCTTGCACTTGTTGAATATTTTTTTGCCCTTCGCGGCGTCGCC pRGK409 
CYT_C2_E8K_Fwd (Ala-ins) GACGCCGCGAAGGGCAAAAAAGAATTCAACGC pRGK410 
CYTC2_E8K_Rev (Ala-ins) GCGTTGAATTCTTTTTTGCCCTTCGCGGCGTC pRGK410 
CYTC2_E10I_Fwd (Ala-ins) CGCCGCGAAGGGCGAAAAAATATTCAACGCCAAGTGC pRGK411 
CYTC2_E10I_Rev (Ala-ins) GCACTTGGCGTTGAATATTTTTTCGCCCTTCGCGGCG pRGK411 
pGEX_HCCS_MfeI_Fwd CTCAATTGATGGGTTTGTCTCCATCTGC pRGK403 
pET-Blue2-Down_Rev GTTAAATTGCTAACGCAGTCA pRGK403 
pBAD_CYCS_EcoRI_Fwd GCGGAATTCGCCATGGGTGATGTTGAG pRGK405 
pBAD_CYCS_PstI_Rev GAGCTGCAGTTACTCATTAGTAGC pRGK405 
pET-Blue-2_HCCS_NcoI_Fwd CCAGCCATGGGTCATCATCATCATCATCACGGTTTGTCTCCATCTGCTCC pRGK402 
pET-Blue-2_HCCS_HindIII_Rev CGAAGCTTGTGCATAGTTTTACGAGGTCCAAC pRGK402 
 
Plasmid Description Reference 
pRGK330 pBAD24-based plasmid for arabinose inducible expression 
Feissner et al. 
2006 
pRGK389 Template for R. capsulatus cytochrome c2 
Richard-Fogal 
et al. 2012 
pRGK402 Expression of N-terminal hexahistidine-tagged HCCS (pET Blue2) This work 
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pRGK403 Expression of N-terminal GST-tagged HCCS (pGEX 4T-1) This work 
pRGK404 Expression of C-terminal Intein-tagged HCCS (pTXB1) This work 
pRGK405 Expression of human cytochrome c (pBAD) This work 
pRGK406 Expression of cytoplasmic R. capsulatus cytochrome c2 (pBAD) This work 
pRGK407 pBAD cyt c2(Ala-ins) This work 
pRGK408 pBAD cyt c2(E8K/E10I/Ala-ins) This work 
pRGK409 pBAD cyt c2(E8K/E10I) This work 
pRGK410 pBAD cyt c2(E8K/Ala-ins) This work 
pRGK411 pBAD cyt c2(E10I/Ala-ins) This work 
pRGK412 pBAD CYCS(K6A) This work 
pRGK413 pBAD CYCS(K6R) This work 
pRGK414 pBAD CYCS(K6D) This work 
pRGK415 pBAD CYCS(F11A) This work 
pRGK416 pBAD CYCS(F11Y) This work 
pRGK417 pBAD CYCS(C15S) This work 
pRGK418 pBAD CYCS(C18A) This work 
pRGK419 pBAD CYCS(H19A) This work 
pRGK420 pGEX HCCS(H154A) This work 
pRGK421 pGEX HCCS(H154G) This work 
pRGK422 pGEX HCCS(H154Y) This work 
pRGK423 pGEX HCCS(H211A) This work 
pRGK424 pGEX HCCS(H211G) This work 
pRGK425 pGEX HCCS(H211Y) This work 
pRGK426 pGEX HCCS(H211C) This work 
 
Strain Description Reference 
RK103 ∆ccm E. coli strain MG1655 deleted for all ccm genes 
Feissner et al. 
2006  
RK112 ∆ccm E. coli strain BL21 (DE3) deleted for all ccm genes 
Richard-Fogal 
et al. 2012 
 
 245 
Supporting Information References 
(1) Richard-Fogal, C. L., San Francisco, B., Frawley, E. R., and Kranz, R. G. (2012) Thiol 
redox requirements and substrate specificities of recombinant cytochrome c assembly systems II 
and III. Biochim Biophys Acta 1817, 911-9. 
(2) Feissner, R. E., Richard-Fogal, C. L., Frawley, E. R., Loughman, J. A., Earley, K. W., 
and Kranz, R. G. (2006) Recombinant cytochromes c biogenesis systems I and II and analysis of 
haem delivery pathways in Escherichia coli. Mol Microbiol 60, 563-77. 
(3) Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V., and Mann, M. (2006) In-gel 
digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1, 2856-
60. 
(4) Sogabe, S., Ezoe, T., Kasai, N., Saeda, M., Uno, A., Miki, M., and Miki, K. (1994) 
Structural similarity of cytochrome c2 from Rhodopseudomonas viridis to mitochondrial 
cytochromes c revealed by its crystal structure at 2.7 A resolution. FEBS Lett 345, 5-8. 
(5) Fulop, V., Sam, K. A., Ferguson, S. J., Ginger, M. L., and Allen, J. W. (2009) Structure 
of a trypanosomatid mitochondrial cytochrome c with heme attached via only one thioether bond 
and implications for the substrate recognition requirements of heme lyase. Febs J 276, 2822-32. 
 
 246 
 
Chapter 6: Summary and Future Investigations 
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Summary 
The studies in this dissertation explore the structure(s) and function(s) of the system I 
cytochrome c synthetase, CcmF (Fig 1), and the cytochrome c synthase for system III, HCCS.  
The transmembrane b-heme binding site within CcmF was defined and spectroscopically 
characterized, the requirements for formation of the CcmF-holoCcmE complex were determined, 
and CcmFH (along with CcmG) was shown to be a cytochrome c synthetase independent of 
CcmABCDE.  For system III, interactions between HCCS and heme, and HCCS and cytochrome 
c, were characterized, allowing us to propose mechanisms for heme binding, interaction with 
apocytochrome c, thioether formation, and release of mature holocytochrome c from HCCS (Fig 
2).   
Characterization of the b-heme binding site in CcmF 
 Purification of CcmF revealed a stoichiometric and stable heme b, present in the absence 
of the other Ccm components, and heme-binding was shown to depend on a conserved 
transmembrane histidine (TM-His1) [1].  In Chapter 2 [2], a second conserved transmembrane 
histidine (TM-His2) is shown to be required for binding the heme b (Fig 1).  Exogeneous 
imidazole is used to correct the cytochrome c assembly defects of mutations at TM-His1 and 
TM-His2, providing further support for a ligand-type function for these histidines.  Resonance 
Raman spectroscopy is used to confirm the presence of a 6-coordinate, low-spin heme species in 
CcmF with bis-His coordination.  It is shown that replacement of TM-His1 with cysteine (a 
residue that can substitute as an axial ligand) supports holocytochrome c formation at 70 % WT 
levels, and purified CcmF TM-His1Cys contains heme b with unique spectral characteristics.  
The stable heme b is shown to be conserved in CcmF proteins from a diverse set of prokaryotes 
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(including Thermophilus thermophilus and Desulfovibrio vulgaris).  Finally, the midpoint 
potential of the CcmF b-heme is determined.  These results constitute a thorough characterization 
of the transmembrane binding site for the CcmF heme b (coordinated by TM-His1 and TM-His2) 
and suggest a possible mechanism by which heme (from holoCcmE) becomes reduced (to Fe
2+
), 
which is required for covalent attachment to the apocytochrome (Fig 1). 
Requirements for formation of the CcmF-holoCcmE complex 
 Despite the wide assumption in the field that formation of a CcmF-holoCcmE complex is 
an intermediate during cytochrome c biogenesis, experimental evidence in support of this was 
lacking.  In chapter 3, it is shown that CcmF and holoCcmE form a complex in the absence of 
CcmH.  This complex requires conserved CcmF P-His1 and P-His2 (Fig 1).  Exogeneous 
imidazole is used to correct the cytochrome c assembly defects of substitutions at P-His1 and P-
His2, suggesting that these WWD-flanking histidines are axial ligands to heme from holoCcmE 
when it is bound in the CcmF WWD domain.  For complex formation to occur, holoCcmE must 
be released from CcmABCD, and it is shown that the apo-form of CcmE interacts with CcmF at 
20-fold lower levels than holoCcmE.  These results establish the requirements for formation of 
the holoCcmE-CcmF complex, an interaction at the heart of heme trafficking in system I 
cytochrome biogenesis, and suggest a role for CcmH in mediating interaction between CcmF and 
holoCcmE.   
CcmFH (with CcmG) is the system I cytochrome c synthetase 
 Unlike the synthases for systems II and III (which, when expressed heterologously in E. 
coli ∆ccm, are sufficient for holocytochrome c formation [3,4]), the synthetase activity of 
CcmFH had not been directly demonstrated.  In chapter 4, it is shown that CcmFH (and the 
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periplasmic thioredoxin CcmG) can attach heme covalently to cytochromes c2 and c4 in E. coli 
∆ccm, independent of CcmABCDE.  This activity, termed CcmFGH-ind, is sufficient for robust 
production of holocytochrome c with spectral and biochemical characteristics indistinguishable 
from those of the holocytochrome c produced by the full system I.  It is shown that CcmFGH-ind 
requires three conserved histidines in CcmF (TM-His1, TM-His2, and P-His2) as well as the 
conserved cysteine pairs in the thioredoxins CcmG and CcmH.  These findings establish that 
CcmFH (together with CcmG) is the cytochrome c synthetase for system I, and provide unique 
mechanistic and evolutionary insights into cytochrome c biogenesis, as discussed in chapter 4.   
HCCS forms a complex with heme and cytochrome c 
 Despite the identification of the yeast HCCS over twenty-five years ago [5], progress in 
understanding the mechanism(s) of HCCS function had been limited by difficulties in purifying 
the protein [6].  In Chapter 5 [7], the first biochemical work on an HCCS protein (the HCCS 
from humans) is described.  HCCS, expressed in recombinant E. coli as an N-terminal fusion to 
glutathione S-transferase, purifies with a heme b that is coordinated by a conserved histidine 
(His154, see Fig 2).  When co-expressed with its cognate human apocytochrome, HCCS is 
shown to form a complex with heme and cytochrome c, with axial ligands supplied by conserved 
His154 of HCCS and His19 (of Cys-Xxx-Xxx-Cys-His) of the cytochrome c.  It is shown that 
the minimal requirements for covalent heme attachment to the apocytochrome are present in the 
apocytochrome N-terminus (and include, but are not limited to, Cys-Xxx-Xxx-Cys-His), and a 
non-substrate cytochrome (bacterial cytochrome c2) is converted into a robust substrate for the 
human HCCS by engineering three sequence alterations.  Trapped, intermediate complexes 
between HCCS and site-directed variants of cytochrome c are characterized.  These data allow us 
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to delineate four steps in the long-sought mechanism of mitochondrial cytochrome c assembly by 
HCCS, and are diagrammed in Fig 2.     
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Future studies on system I 
The structure of the b-heme binding site in CcmF has been investigated, but the role of 
the b-heme in cytochrome c biogenesis remains hypothetical.  Many of the requirements for 
formation of the holoCcmE-CcmF complex have been identified, but a direct role for the WWD 
domain in this interaction has not been described.  Only a limited spectral characterization of the 
holoCcmE-CcmF complex has been undertaken, and knowledge of the role that CcmH plays in 
mediating complex formation between holoCcmE and CcmF is based only on the inability to trap 
holoCcmE when CcmH is present.  Some of the molecular details of cytochrome c biogenesis by 
CcmFGH-ind are still unknown; in particular, the origin of the heme that is attached to 
cytochrome c and the role of the CcmF WWD domain in holoCcmE-independent assembly.   
Determining the midpoint potentials of all heme-bound intermediates 
 Initial attempts at determining the redox potential of the CcmF b-heme by potentiometric 
methods were severely constrained by the large yields of protein that were required.  Critically, 
the technique described in this thesis (an adaptation of the Massey method [8] that was refined in 
the laboratory of Emma Raven [9]; see chapter 2) requires yields that we are routinely able to 
achieve with our membrane proteins.  Thus, determining the midpoint potentials for each of the 
heme carriers in system I (as well as system II, for which yields of holo-protein are similar, and 
the cytochrome c:heme:HCCS complexes of system III) is a feasible goal.   
Heme trafficking during cytochrome c biogenesis (for systems I, II, and III) involves 
multiple changes in coordination of the heme, and the midpoint potential is very sensitive to 
changes in axial ligation [10].  Furthermore, it is likely that many of the heme-protein 
intermediates (e.g., the holoCcmE-CcmF complex, or the complex of HCCS with cytochrome c) 
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have defined redox requirements that must be satisfied for heme trafficking and/or covalent 
attachment to proceed.  Therefore, establishing the midpoint potentials of the heme-protein 
complexes would inform our understanding of the mechanistic requirements for the heme 
reactions in cytochrome c biogenesis.     
The role of the CcmF WWD domain 
 The conserved WWD domain [11] is a hydrophobic, extra-cytoplasmic feature that is the 
hallmark of the heme-handling protein (HHP) superfamily [12], which includes CcmC, CcmF, 
and CcsBA.  In CcmC, the Kranz lab has shown that the WWD domain is directly involved in 
binding heme (in holoCcmE): mutation of conserved residues in the WWD domain caused 
spectral perturbations (and, for some substitutions, heme loss) in the holoCcmCDE complex 
[13].  Two conserved histidines in CcmC that flank the WWD domain (His60 and His184, here 
called P-His1 and P-His2, respectively) were shown to be axial ligands to the heme in the WWD 
domain.  For CcmF, although a direct role for the WWD domain in heme binding has yet to be 
demonstrated, there is strong circumstantial evidence to support its involvement in heme-
binding: i) conserved, WWD domain-flanking histidines P-His1 and P-His2 in CcmF (analogous 
to P-His1 and P-His2 in CcmC) are individually required for cytochrome c assembly by system I, 
ii) the cytochrome c assembly defects of mutations at P-His1 and P-His2 in CcmF can be 
corrected by exogeneous imidazole, suggesting that these residues likely have a ligand-type 
function, and iii) in the absence of either P-His1 or P-His2, holoCcmE forms a complex with 
CcmF at levels 5-fold lower than WT CcmF, and the double P-His1/P-His2 mutant complexes 
with holoCcmE at 10-fold lower levels (see chapter 3).  Because P-His1 and P-His2 are 
positioned adjacent to the WWD domain (as they are in CcmC), the above results strongly 
 253 
 
suggest a role for the CcmF WWD domain in binding heme from holoCcmE.  Nonetheless, 
direct experimental evidence demonstrating this function is still needed.  Most directly (and 
quickly), the hypothesis that the CcmF WWD domain binds holoCcmE could be tested by 
engineering substitutions of conserved residues in the WWD domain and assaying for interaction 
with holoCcmE.  Comparing levels of holoCcmE that co-purify with CcmF carrying WWD 
substitutions with those  of WT CcmF (by heme stain and anti-CcmE immunoblot, as described 
in Chapter 3) would be informative.     
The role of the b-heme in system I 
 The CcmF heme b is required for every activity of CcmF that we have investigated thus 
far.  Holocytochrome c formation in the context of the full system I and by CcmFGH-ind, as well 
as complex formation with holoCcmE, all require the conserved transmembrane histidines (TM-
His1 and TM-His2), for axial coordination of the heme b.  However, the precise role(s) of the 
heme b in each of these functions is largely speculative.  For the interaction of CcmF with 
holoCcmE, we suggest that the transmembrane b-heme establishes a structural feature that is 
required for holoCcmE to bind in the CcmF WWD domain.  This seems likely given that the 
CcmF protein is significantly destabilized in the absence of the heme b, with the protein being 
more susceptible to degradation (yields of full-length protein are typically only a quarter of those 
of WT).   
For the CcmFGH-ind pathway, the role of the heme b is particularly intriguing, since the 
origin of the heme that is ultimately attached to the cytochrome c (in the absence of 
CcmABCDE) is currently unknown.  As discussed in chapter 4, it is possible that, in CcmFGH-
ind, the heme b is channeled from the transmembrane binding site to the external WWD domain 
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for covalent attachment, as in system II cytochrome c synthesis, by CcsBA [14,15].  The 
evolutionary insights that could be gained from studies comparing cytochrome c assembly by 
CcmFGH-ind to the full system I under low-iron conditions, for example, are fascinating.   
For cytochrome c assembly via the full system I, we have hypothesized that the b-heme 
may be involved in reducing the heme in holoCcmE, prior to covalent attachment to the 
apocytochrome [1,2,16].  Recall that reduced heme (Fe
2+
) is required for thioether formation 
between the heme vinyls and apocytochrome thiols [17,18].  Additionally, reduction of heme in 
holoCcmE would favor discharge of the covalent bond to His130 [16]; thus, this role for the 
heme b provides a mechanism for releasing (apo)CcmE as well as preparing heme for covalent 
attachment to the apocytochrome.  Clarifying the role(s) that the CcmF heme b plays in each of 
these activities will be challenging, but the information gained would greatly advance our 
understanding of CcmF function.  These studies may require reconstitution, in vitro, using 
purified holoCcmE, CcmFH and apocytochrome.   
The role of CcmH in mediating complex formation between holoCcmE and CcmF 
 We discovered that in the absence of CcmH, holoCcmE was trapped in complex with 
CcmF at levels 10-fold higher than when CcmH was present (chapter 3).  This suggests that 
CcmH may play a direct role in mediating complex formation between CcmF and holoCcmE.  In 
cytochrome c biogenesis by system I, it is proposed that holoCcmE delivers heme to the CcmF 
WWD domain (where heme is coordinated by CcmF P-His1 and P-His2), and CcmH 
“chaperones” the apocytochrome and orients the thiols (of Cys-Xxx-Xxx-Cys-His) to facilitate 
covalent attachment to the heme bound in the WWD domain [16,19,20,21,22].  To date, there 
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has been no evidence of a direct interaction between CcmH and holoCcmE (nor has a direct 
interaction between CcmF and the apocytochrome been reported).   
In chapter 3, we briefly discuss two possible mechanisms by which CcmH may modulate 
the interaction between CcmF and holoCcmE: i) in the absence of apocytochrome, CcmH may 
physically occlude the CcmF WWD domain (exerting a “lid-like” function), or ii) CcmH may 
facilitate rapid binding and release of holoCcmE from the CcmF WWD domain, such that a 
stable holoCcmE-CcmF complex is difficult to detect when CcmH is present.  While 
distinguishing between the above scenarios may be difficult, defining a domain within CcmH 
responsible for this apparent activity (modulation of CcmF-holoCcmE complex formation) 
would be valuable for the field.  Candidate domains/residues could be tested directly by 
engineering stable truncations or site-directed mutations in CcmH, and determining the levels of 
holoCcmE that co-purify with CcmF (using the same methods described in chapter 3).  This line 
of investigation benefits from past work that has shown the CcmH protein to be quite amenable 
to engineering approaches, since stable C- and N-terminal truncations, as well as substitutions of 
conserved residues, have been reported [23,24,25,26,27,28].  Here, as above, in vitro 
reconstitution studies would be useful; the Kranz lab has expertise purifying holoCcmE [29] and 
CcmF (alone and in complex with CcmH) [1,2].     
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Future studies on system III 
 Our study on the human HCCS [7] (chapter 5) was the first biochemical analysis of an 
HCCS protein.  This seminal study defined the requirements for covalent heme attachment to 
cytochrome c, characterized complexes between HCCS and cytochrome c, and delineated 
individual steps for cytochrome c maturation by HCCS.  Several intriguing lines of inquiry have 
arisen from these findings, including defining elements in HCCS and the cytochrome c that 
mediate complex formation, and further refining our understanding of the process of 
holocytochrome c release from HCCS.   
Requirements for complex formation with cytochrome c versus heme attachment  
 In chapter 5, we report conversion of a non-substrate cytochrome, the cytochrome c2 
from R. capsulatus, into a robust substrate for HCCS by introducing three alterations to the N-
terminal sequence.  This engineered cytochrome, termed here cytochrome c2(+), thus contains 
the minimal requirements for covalent heme attachment by HCCS.  In chapter 5, we also 
describe purification of HCCS in complex with heme and the human cytochrome c, with heme 
axial ligands supplied by conserved His154 of HCCS and His19 (of Cys-Xxx-Xxx-Cys-His) of 
the apocytochrome.  The cognate human cytochrome c, therefore, includes elements that mediate 
complex formation with HCCS in addition to containing the determinants for covalent heme 
attachment.  Intriguingly, cytochrome c2(+) does not detectably co-purify with HCCS 
(unpublished data), despite being a robust substrate for covalent heme attachment.  This indicates 
that cytochrome c2(+) lacks the elements required for complex formation with HCCS, and, 
further, that these elements are not required for covalent heme attachment.   
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We have speculated that the complex formed between the human HCCS and the human 
cytochrome c in our recombinant E. coli may be related to interactions that occur during 
mitochondrial import of cytochrome c by HCCS (recall that HCCS is required for import of the 
apocytochrome from the cytosol into the mitochondrial intermembrane space 
[18,30,31,32,33,34]).  Determining the specific amino acids that mediate complex formation, 
therefore, could inform our understanding of this process.  To identify the elements in the human 
cytochrome c that mediate complex formation with HCCS, a site-directed mutagenesis approach 
could be taken, initially targeting residues in the human cytochrome c.  The elements found to be 
required for complex formation could subsequently be engineered into the cytochrome c2(+), 
and we could assay for cytochrome c2(+) in purifications of HCCS.  Even low levels of complex 
would be detectable, owing to our high-titer cytochrome c2 antisera.  These studies would 
establish possible side chain interactions that mediate stable complex formation between 
cytochrome c and HCCS.   
Production of novel cytochromes c by HCCS 
 Recently, we have discovered that a variant of the human cytochrome c carrying a 
methionine substitution at conserved His19 (of Cys-Xxx-Xxx-Cys-His) can be matured by 
HCCS at a low level (unpublished data).  To our knowledge, this could turn out to be the first 
example of a cytochrome c with bis-Met coordination of heme (the 6
th
 axial ligand in 
cytochrome c is a methionine residue, Met81).  Therefore, strategies to improve yields of this 
novel cytochrome c, thereby facilitating a thorough analysis of its structural and spectroscopic 
properties, are certainly of a high priority.  A method for improving the cytochrome c yields 
could also open the door for analysis of other novel cytochromes c that may yet be discovered.  
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Mechanistically, maturation of the His19Met cytochrome c is intriguing because it demonstrates 
that methionine can serve as a heme axial ligand in the complex with HCCS, promoting covalent 
attachment and subsequent holocytochrome c release (albeit at a much lower level than the 
native histidine).  As discussed in chapter 5, in the complex of HCCS with the WT human 
cytochrome c, His19 is required for covalent heme attachment to the cysteines [7]; i.e., 
holocytochrome c formation cannot proceed in the absence of a suitable axial ligand.  
Characterization of the complex between HCCS, heme, and the His19Met cytochrome c could 
further elucidate the requirements for holocytochrome c formation by HCCS.   
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Figures 
Fig 1. Topology of the CcmF and CcmH integral membrane proteins from E. coli.   
Possible histidine axial ligands to heme are starred (His173=P-His1; His303=P-His2; 
His261=TM-His1; His491=TM-His2).  The highly conserved WWD domain is shaded as are the 
hydrophobic patches.  Completely conserved amino acids (red) were identified by individual 
protein alignments using CcmF ORFs from selected organisms, as described in (Kranz, Richard-
Fogal et al. 2009).  Diagram is from (Kranz, Richard-Fogal et al. 2009).   
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Fig 2. Steps in the maturation of cytochrome c by human HCCS.   
(A) Diagram depicting the 4 steps in holocytochrome c maturation by HCCS (discussed in text).  
(B) PEP-FOLD generated model of the N-terminal 20 amino acid helix in human cytochrome c 
before interaction with HCCS.  Amino acids important for maturation are indicated by arrows.  
Selected oxygen atoms are shown in red, nitrogens in blue, sulfurs in yellow, the heme 
macrocyle is in pink, and the Fe atom at the heme center is orange.  (C) The 
HCCS:heme:cytochrome c complex (modeled with heme, pink) before thioether formation.  
Heme is coordinated by His19 of apocytochrome c (PEP-FOLD ribbon diagram, green, as in B) 
and His154 of HCCS (overlaid cartoon, blue).  Amino acids and heme vinyls important for 
maturation are indicated by arrows.  (D) The N-terminal 20 amino acids from the X-ray crystal 
structure of mature, released E. caballus holocytochrome c (pdb HRC1).  Amino acids important 
for maturation are indicated by arrows.  Heme is coordinated by His19, as in the complex with 
HCCS, and cytochrome c Met81, which replaces HCCS His154 in the folded, released 
holocytochrome c.  PyMOL was used for displays in B, C, and D.  Amino acid numbering refers 
to the H. sapiens cytochrome c N-terminal Met, as shown in Fig 3A (because the initiation Met 
is processed off, pdb HRC1 refers to Lys8 as Lys7, His19 as His18, Met81 as Met80, etc).   
  
 265 
 
 
 
